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US Food and Drug Administration

FdUDP
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HER2
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M.P.
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NMR
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RNA

Ribonucleic acid
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University of Wollongong
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Abstract
The effectiveness of current anticancer drugs such as nitrogen mustards, 5-fluorouracil
and sunitinib is hampered by dose-limiting side effects. Targeted prodrugs designed to be
selectively activated in hypoxic regions of solid tumours and locally deliver active
cytotoxins are potentially very useful for improving the efficacy and side effect profiles
of anticancer chemotherapeutics. This project investigated rationally designed hypoxiaactivated antitumour amide- and ester-linked kinase inhibitor–cytotoxin prodrug
conjugates. These mutual prodrugs combined an angiogenesis inhibitor, semaxanib
(SU5416), together with a cytotoxin into a single molecule, with the cytotoxin being
either a 4-aminoaniline nitrogen mustard or floxuridine (an FDA-approved
antimetabolite). The compounds contained an arylnitro triggering group designed to
undergo bioreductive activation selectively in hypoxic regions of tumours to the aniline
derivative. Formation of the aniline group then initiates a spontaneous intramolecular
cyclisation reaction to simultaneously eject the two active anticancer drugs.

The first goal of the project was to devise and implement viable synthetic routes towards
semaxanib|4-aminoaniline mutual prodrug 1 and semaxanib|floxuridine mutual prodrug
2. The synthesis of mutual prodrug 1 was optimised and scaled-up based on a previous
small-scale synthesis completed by PhD student Nicholas Kirk. The synthesis of 1 was
accomplished in 6 steps providing 190 mg of 1 prepared in pure form. The synthesis of
mutual prodrug 2 was completed in 7 steps to give a total of 302 mg of pure 2.

Chemical reductions of 1 and 2 confirmed that intramolecular cyclisation occurs
spontaneously after nitro to amine/hydroxylamine conversion. Preliminary cell testing
and reduction potential measurements with 1 and 2 performed by collaborators at the
University of Auckland showed favourable deactivation of the prodrugs relative to their
parent cytotoxins in an aerobic environment. Unfortunately, the compounds were unable
to undergo bioreductive activation under hypoxic conditions, which was attributed to the
low arylnitro one-electron reduction potentials (measured by collaborators using pulse
radiolysis).

Whilst these biological studies were being undertaken, an alternative and more divergent
strategy for future syntheses of mutual prodrugs was investigated. The new strategy
-xxv-
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addressed the key shortcomings in the synthesis of 1 and 2, specifically the low yielding
Knoevenagel condensations. The new route allowed the Knoevenagel reaction to be
performed in higher yield earlier in the synthesis on a simpler allyl ester. Subsequent
pyrrole N-tert-butoxycarbonyl (BOC) protection and deallylation reaction gave an
advanced carboxylic acid common intermediate 32 that could potentially be coupled
directly to diverse cytotoxins containing free amino or alcohol groups. Model ester and
amide couplings reactions were then successfully developed and optimised for future use
with cytotoxins and intermediate 32.

A second series of model prodrugs were designed and synthesised in an attempt to address
the poor bioactivation observed with 1 and 2. These new target compounds were
semaxanib derivatives containing electron withdrawing groups added to the nitroaryl ring
to increase the one-electron reduction potentials. The compound also contained n allyl
ester to serve as a simpler model substitute for ester-linked cytotoxins. From this series,
4 model prodrugs were synthesised containing either fluorine or trifluoromethyl electron
withdrawing groups at various positions around the arylnitro ring. Each compound was
chemically reduced at the arylnitro group and shown to undergo spontaneous
intramolecular cyclisation to the expected indolin-2-one. Pulse radiolysis measurements
showed that addition of the electron withdrawing groups does indeed increase in the oneelectron reduction potentials. In the course of these studies, an interesting side reaction
was discovered involving intramolecular nucleophilic aromatic substitution and
cyclisation of a pyrrole moiety onto an arylnitro group. The compounds produced, novel
pyrroloquinolines, have great scope for future investigations as protein fluorescent tags.
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Chapter 1: Introduction
1.1

A Brief History of Cancer Treatments

Before 1950, cancer treatments were based solely on the surgical removal of solid
tumours. Radiation treatments became common after 1960 following the invention of
linear accelerators but, like surgery, these suffered from an inability to treat metastatic
cancers. The introduction of anticancer chemotherapy can be traced back to the discovery
of nitrogen mustards; the first effective chemical treatments for cancer.1 Nitrogen
mustards were developed in 1942 by Louis Goodman and Alfred Gilman, who were
employed by the United States Department of Defence to investigate the therapeutic
potential of toxins developed as chemical warfare agents.2 Nitrogen mustards are reactive
alkylating agents that exhibit cytotoxic anticancer effects through covalent attachment to
DNA.3

In the 1950s, Mitomycin C was isolated by Japanese microbiologists in fermentation
cultures of Streptomyces caespitosus (Figure 1.1).4 Mitomycin C is a potent DNA
crosslinker that undergoes reductive activation to mitosene, which can successively
N-alkylate two DNA bases leading to crosslinks and cell death.5

Figure 1.1 Chemical structure of Mitomycin C.

Shortly after World War II, a second approach to anticancer chemotherapy was identified
by Sydney Farber, who used folic acid to treat patients with leukaemia. Subsequent
investigations with folate analogues led to aminopterin and eventually amethopterin
(methotrexate, Figure 1.2). These antimetabolites block folate-requiring enzymes to
suppress proliferation of malignant cells.6-7
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Figure 1.2 Chemical structure of methotrexate.

The effectiveness of natural products as cancer treatments was explored by Gordon
Zubrod and led to the discovery of the taxanes in 1964 and camptothecins in 1966 (Figure
1.3). The drug Paclitaxel (Taxol), obtained from the bark of the Pacific Yew tree, was
developed from this work by Bristol Myers Squibb and it was approved for use in 1991
for the treatment of ovarian cancer.8 Taxol belongs to the class known as mitotic
inhibitors; compounds that either inhibit or promote the assembly of microtubules.
Camptothecin, derived from a Chinese ornamental tree, inhibits topoisomerase I, an
enzyme responsible for DNA unwinding and strand passage. Early clinical trials with
camptothecin identified a problem with nephrotoxicity leading to the development of
irinotecan, a less toxic analogue that was granted US Food and Drug Administration
(FDA) approval in 1996 for the treatment of colon cancer.9

Figure 1.3 Chemical structures of paclitaxel, camptothecin and irinotecan.

Anthracyclines are a class of chemotherapy drugs that were first isolated from the
actinobacteria Streptomyces peucetius in the 1960s.10 They were originally investigated
for their antibiotic effects due to their ability to intercalate between base pairs of
DNA/RNA strands. Investigations into their anticancer effects then led to the
development of doxorubicin (Figure 1.4). Doxorubicin interacts with DNA by
intercalation, inhibiting the progression of topoisomerase II and preventing cell
replication.11
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Figure 1.4 Chemical structure of doxorubicin.

Vinca alkaloids are a set of anti-mitotic and anti-microtubule alkaloids that were
originally isolated from the periwinkle plant Catharanthus roseus (basionym Vinca
rosea). Anticancer effects of the class were first identified in the late 1950s after a
drug-screening program.12 Important agents from this class are vinblastine and
vincristine, which were both approved for use in multiple cancer indications during the
1960s (Figure 1.5). These agents exhibit their mechanism of action by binding to tubulin,
stopping cells from separating their chromosomes during the metaphase of cell division
and eventually leading to cell apoptosis.13

Figure 1.5 Chemical structures of vinblastine and vincristine.

Tyrosine-kinase inhibitors, a more recent class of anticancer drugs, were first investigated
in 1988.14 Tyrosine-kinase enzymes are responsible for the activation via phosphorylation
of many proteins involved in signal transduction cascades. In the context of cancer,
epidermal growth factor receptors (EGFR) are one of the main targets as they promote
tumour angiogenesis, growth and metastases. Tyrosine-kinase inhibitors became of
significant interest after the discovery of low molecular weight inhibitors that could
discriminate between EGFR and other tyrosine kinase receptors, including human
epidermal growth factor receptor 2 (HER2) and the insulin receptor.15 Two examples of
drugs from this class are imatinib and lapatinib (Figure 1.6).
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Figure 1.6 Chemical structures of imatinib and lapatinib.

Monoclonal antibodies are a recent class of cancer treatments. These protein-based
therapeutics are antibodies made by identical immune cells that are all clones of a parent
cell, meaning that they bind to the same antigen. Recent advances have been made in the
targeting of specific antigens overexpressed, mutated or selectively expressed in specific
tumour types.16

1.2

Project Summary

New cancer treatments have been steadily moving towards a more personalised approach
that limits side effects and maximises efficacy. It was envisioned at the start of my PhD
project that by combining two chemotherapeutics into a single mutual prodrug, which
was able to be selectively activated within solid tumours to locally release both active
drugs, could alleviate some of the debilitating side effects of current cancer treatment
whilst maximising potential benefits. One way to achieve tumour selective prodrug
activation is through exploitation of the unique micro environment of solid tumours. In
our case, we aimed to exploit the hypoxic microenvironment of solid tumours to trigger
mutual prodrug activation. The following sections rationalise the choice of anticancer
agents for inclusion in the mutual prodrugs and their method of activation.

1.3

Angiogenesis Inhibitors in Cancer Treatment

Angiogenesis is the normal physiological process of new blood vessel growth from a preexisting vasculature. It occurs mainly during growth and development but is also
important during wound healing. As in normal tissues, tumours require an adequate
supply of oxygen and nutrients and an ability to remove waste products.17 When solid
tumours increase in size and density their vascular requirements increase, leading to
pro-angiogenic gene expression driven by increasing tumour hypoxia.18 Tumour
angiogenesis is activated when hypoxic tumour cells release vascular endothelial growth
factors (VEGFs) (Figure 1.7). High levels of VEGF is able to stimulate angiogenesis from
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a dormant, mature vasculature.19 VEGF results first in vasodilation and increased
permeability of capillaries, enabling extravasation of plasma proteins to form a
provisional matrix upon which endothelial cells can migrate and develop new vasculature.

1. Hypoxia induced

2. Stimulation of

3. Tumour growth and

expression of VEGF

angiogenesis by

metastasis

by tumour cells

VEGF

1.

2.

3.

VEGF

Figure 1.7 Tumour growth and metastasis is promoted by angiogenesis driven by
signalling VEGF. (Figure modified from ref. 20).20

Angiogenesis in normal tissues is tightly regulated by a balance between pro- and antiangiogenic signals. When angiogenesis occurs in a tissue, the new vessels rapidly mature
and switch off further angiogenesis. Tumour induced angiogenesis, however, does not
result in new endothelial cell maturation, allowing continued growth of new tumour blood
vessels.21

1.3.1

Semaxanib (SU5416) and Sunitinib (Sutent®)

Semaxanib (SU5416) is a tyrosine-kinase and angiogenesis inhibitor from Sugen Inc.
(acquired by Pfizer in 2003) that reached Phase III clinical trials for the treatment of
advanced colorectal cancer.22 Trials with semaxanib were halted in February 2002 so that
the company could focus efforts on a superior successor compound sunitinib (Sutent®)
(Figure 1.8). Sunitinib was subsequently approved by the FDA for use as a single agent
treatment for renal cell carcinoma and imatinib-resistant gastrointestinal stromal
tumours.23 More recently it was approved for the treatment of pancreatic neuroendocrine
tumours.24
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Figure 1.8 Structures of semaxanib and sunitinib.

1.3.2

Mechanisms of Angiogenesis Inhibition

Sunitinib and semaxanib inhibit angiogenesis by ATP- competitive inhibition of receptor
tyrosine kinases. Semaxanib is a selective inhibitor of the tyrosine kinase activity of the
VEGF-2 receptor,25 while sunitinib shows much broader activity against VEGF-1,
VEGF-2, VEGF-3, Fms-like tyrosine kinase-3 receptor (FLT3), stem cell factor receptor
(KIT), colony-stimulating factor receptor type 1 (CSF-1R) and the glial cell-line-derived
neurotrophic factor receptor (RET).26 VEGF released by hypoxic tumour cells binds to
VEGF receptors (VEGFRs) on the surface of endothelial cells, causing dimerization and
activation of intracellular kinase domains. The activation process requires concurrent
binding of intracellular adenosine triphosphate (ATP). Sunitinib and semaxanib enter
cells by passive diffusion and compete with ATP for the VEGFR ATP-binding site.27
Once sunitinib or semaxanib are bound, VEGF cannot activate its intracellular kinase
domain, leading to inhibition of downstream signalling and ultimately angiogenesis.
Sunitinib also inhibits VEGF-dependent proliferation and migration of endothelial cells
to disrupt capillary tube formation.28

1.4

Mechanism of Nitrogen Mustard Cytotoxicity

Nitrogen mustards form highly reactive aziridinium ions via intramolecular cyclisation
of an amine to expel a leaving group (often chloride) located two carbons atoms away
(Scheme 1.1). The aziridinium ring is highly strained and susceptible to ring opening by
the nucleophilic guanine bases of DNA. This alkylation reaction can be repeated to result
in the formation of interstrand DNA crosslinks.29-30 Alkylation of DNA alone is not in
itself cytotoxic and it is the interstrand crosslinks of double stranded DNA that drives the
cytotoxicity of nitrogen mustards.31-32
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Scheme 1.1 Formation of aziridinium ions by nitrogen mustards leads to reactions with
nucleophiles (Nu), including guanine bases of DNA, resulting in formation of cytotoxic
interstrand DNA crosslinks.

1.5

5-Fluorouracil (5-FU)

5-FU was first synthesised in 1957 and continues to be a mainstay treatment for many
types of cancers. It is approved for use both alone and in combination with other drugs
for the treatment of basal cell carcinoma, breast cancer, colorectal cancer, gastric
adenocarcinoma, pancreatic cancer and squamous cell carcinomas of the head and neck.33
Approximately 2 million patients worldwide are administered 5-FU each year.34

1.5.1

Mechanisms of 5-FU Cytotoxicity

After IV administration, 5-FU rapidly enters cells via the same facilitated transport
mechanism responsible for uracil uptake.35 More than 80% of administered 5-FU is
metabolised in the liver by dihydropyrimidine dehydrogenase (DPD) to inactive
(racemic)

dihydrofluorouracil

(DHFU),

which

is

further

converted

to

α-fluoro-β-ureidopropionic acid and α-fluoro-β-alanine (FBAL) (Scheme 1.2).36 All three
metabolites are inactive and excreted in urine within 24 hours. Approximately 60-90% of
administered 5-FU ends up as FBAL.37

Scheme 1.2 Liver metabolism of 5-FU produces three inactive metabolites;
dihydrofluorouracil (DHFU), α-fluoro-β-ureidopropionic acid and α-fluoro-β-alanine
(FBAL).
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Once inside cells, 5-FU is converted to active metabolites by the same pathways available
to its endogenous counterpart uracil. Active metabolites include fluorodeoxyuridine
monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine
triphosphate (FUTP) (Figure 1.9). The active 5-FU metabolite FUTP is extensively
incorporated into RNA, where it disrupts normal RNA function by inhibiting the
processing of pre-RNA into mature ribosomal RNA. It also disrupts post-transcriptional
modification of transfer RNAs and the activity of small nuclear RNA/protein complexes,
resulting in inhibition of pre-messenger RNA splicing.38-43

Figure 1.9 Active metabolites of 5-FU, fluorodeoxyuridine monophosphate (FdUMP),
fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate (FUTP).

Part of the antitumour mechanism of 5-FU involves inhibition of thymidylate synthase
(TS) (Figure 1.10). TS is crucial for cell survival as it catalyses the reductive methylation
of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP),
with reduced folate 5,10-methylenetetrahydrofolate (CH2THF) acting as a cofactor.
FdUMP produced from 5-FU binds to the nucleotide binding site of TS to form a stable
ternary complex between the enzyme and CH2THF that blocks dUMP binding and
inhibits dTMP synthesis.44-45 Depletion of dTMP results in reduced deoxythymidine
triphosphate (dTTP), which in turn affects levels of deoxyadenosine triphosphate (dATP),
deoxyguanosine triphosphate (dGTP) and deoxycytidine triphosphate (dCTP) through
various feedback mechanisms.46 The resulting imbalance in the dATP/dTTP ratio is
thought to disrupt DNA synthesis and repair, resulting in lethal DNA damage and cell
death.47-48 Deoxynucleotide (dNTP) imbalance also leads to higher concentrations of
deoxyuridine triphosphate (dUTP) within cells.49-50 Both dUTP and the 5-FU metabolite
FdUTP can be misincorporated into DNA and disrupt its function. The concentration of
dUTP is highly dependent on levels of pyrophosphatase (dUTPase), which acts to limit
intracellular accumulation.51-52
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uracil-DNA-glycosylase (UDG) is ineffective in the presence of high FdUTP/dTTP
ratios.53 Misincorporation excision and repair instead leads to further errors in DNA,
eventually breaking the DNA strand and triggering cell death.

Figure 1.10 Fluorodeoxyuridine triphosphate (FdUTP) inhibition of thymidine synthase
(TS) leading to DNA damage and disrupted DNA replication and repair. (Figure modified
from 54).54

1.5.2

Floxuridine

Fluorodeoxyuridine (FUDR), a prodrug form and metabolite of 5-FU, is an FDA
approved drug sold commercially as floxuridine (Scheme 1.3). Floxuridine is more
efficiently metabolized to active species in the liver than 5-FU and is sometimes
administered via the hepatic artery to treat liver metastases of colorectal cancers.55
Meta-analysis of randomised trials indicated that this route is superior in terms of
response rates and survival compared to intravenous administration.56 Floxuridine is
metabolised to either 5-FU (via thymidine phosphorylase, TP) or to the active metabolite
FdUMP (via thymidine kinase, TK).

Scheme 1.3 Metabolism of floxuridine to 5-FU and FdUMP.
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Prodrugs in Anticancer Chemotherapy

Prodrugs are pharmacologically inert molecules that are converted to active drugs in vivo
after undergoing metabolic reactions. They are often used to render drug molecules
inactive until specific enzymes or biological environments within the body convert them
to the active parent. Anticancer prodrugs often contain a non-toxic group covalently
attached to the active agent to enhance stability, solubility or another drug property and/or
enhance selectivity for tumour cells.57

1.6.1

Mutual Prodrugs

Mutual prodrugs are comprised of two or more drugs that are chemically linked such that
they are released from each other simultaneously after some triggering reaction in vivo.58
The drugs can either be connected directly or via a linker. A potential advantage of mutual
prodrugs is that they address issues relating to co-administration of structurally unrelated
molecules and their distribution to the target tissue(s), since they are co-transported as a
single molecule.59

One reported example is the 5-FU|Cytarabine mutual prodrug described by Menger et al.
(1997).60 This prodrug combines (via a succinate linker) 5-FU and cytarabine, a front-line
anticancer agent used mainly in the treatment of leukaemia (Scheme 1.4).61 The mutual
prodrug was designed to undergo amidase-mediated hydrolysis in vivo. The linking of the
two drugs together creates the inactive prodrug. It has been proposed that a “dual-hit”
from a mutual prodrug of this type can be more cytotoxic to tumour cells than the two
individual drugs used in combination. Attachment of the acyl group to the exocyclic
amine also serves to decrease inactivation of cytarabine by cytidine deaminase.62

Scheme 1.4 Metabolic activation of a 5-FU|cytarabine mutual prodrug yields two active
drugs (5-FU and cytarabine) and two “waste” (linker) fragments.60
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Tumour-Selective Activation of Antitumour Prodrugs

A shortcoming of traditional anticancer cytotoxins (such as 5-FU and nitrogen mustards)
is their relatively low selectively for tumour cells over normal tissues. Consequently,
treatments with these agents are hampered by dose-limiting toxic side effects. One
possible solution to this problem is to create prodrugs that selectively reveal the active
drug(s) only in the immediate tumour microenvironment. This can lead to improved
pharmacodynamics and reduced side effects by lowering exposure of normal tissues to
the toxic active agent(s). Prodrugs of this type are often comprised of trigger, linker and
effector units, with the linker unit functioning to release the effector (active drug) after
the triggering moiety undergoes a metabolic reaction selectively within tumours.63

1.7

Antibody-Drug Conjugates

Antibody-drug conjugates (ADC) are a major class of modern, tumour-selective
anticancer prodrugs. The design of an ADC involves linking a highly potent cytotoxin to
a monoclonal antibody via a linker that can be selectively cleaved within tumour cells to
release the active cytotoxin (Figure 1.11).64

Figure 1.11 Antibody drug conjugates comprise a monoclonal antibody, linker and drug.
The mechanism of action involves: 1) specific binding of the antibody to an internalising
antigen, followed by endocytosis; 2) transfer to the lysosome; 3) lysosomal cleavage of
the linker to release the active drug; 4) drug transfer to the cytoplasm/nucleus leading to
cell death and diffusion to neighbouring tumour cells to cause bystander killing effects.
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Ideally, the antibody targets an internalising antigen exclusively expressed on the surface
of tumour cells, leading to tumour-selective drug uptake.65 Linkers are typically
composed of a lysosome-sensitive peptide, which upon endocytosis and fusion with
lysosomes, is cleaved by lysosomal proteases to release the active cytotoxin within
tumour cells.66

1.7.1

Brentuximab vedotin (Adcetris®)

Brentuximab vedotin (Adcetris®) is an FDA-approved ADC used in the treatment of
relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.67
Brentuximab vedotin consists of the chimeric monoclonal antibody brentuximab
(cAC10), a maleimide attachment group, a cathepsin-cleavable linker (valine-citrulline),
a fragmenting spacer and the cytotoxin monomethyl auristan E (MMAE) (Figure 1.12).68
The brentuximab antibody selectively targets the CD30 cell-surface antigen (expressed
by both anaplastic large cell lymphoma and Hodgkin lymphoma) leading to tumour
selective uptake.69 The antitumour activity arises from MMAE, an exquisitely potent
antimitotic.70

Figure 1.12 Structure of the ADC Brentuximab vedotin (Adcetris®).

1.7.2

Trastuzumab emtansine (Kadcyla®)

Trastuzumab emtansine (Kadcyla®) is an FDA-approved ADC for the treatment of
HER2-positive metastatic breast cancer.71 The drug consists of the monoclonal antibody
trastuzumab, a succinimide linker and mertansine, a modified maytasine analogue that
contains a thioether (Figure 1.13). The trastuzumab antibody targets HER2, which is
overexpressed in 20-30% of breast cancers.72 Trastuzumab (Herceptin®) itself was
approved by the FDA for use in HER2-positive metastatic breast cancer in 1998.73
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Trastuzumab binds to the IV domain of the extracellular segment of the HER2 receptor
causing cell arrest in the G1 phase of the cell cycle and reduced cell proliferation.74 After
tumour selective endocytosis and fusion with a lysosome, the (HER2)-trastuzumab-DM1
complex is degraded to release mertansine,75 a potent anti-microtubule agent that triggers
apoptosis.75

Figure 1.13 Structure of trastuzumab emtansine (Kadcyla®).

1.8

Bioreductive Activation of Antitumour Prodrugs

Rapidly dividing solid tumours quickly outgrow their existing blood supply and develop
poorly perfused hypoxic regions.76 The vasculature that develops after tumour
angiogenesis initiated by hypoxia tends to be aberrant and less ordered than in normal
tissues, meaning that pockets of hypoxia remain.77 Tumour cells closest to vessels
consume the majority of available oxygen, whilst those further away are left in a
continuous state of hypoxia. Oxygen partial pressures in hypoxic regions can drop below
2 mm Hg, or 20 times lower than in deoxygenated blood (Figure 1.14). A concomitant
drop in pH occurs due to increased lactic acid production from cells undergoing anaerobic
metabolism.78 Prodrugs that can exploit the uniquely hypoxic regions of solid tumours to
locally release active cytotoxins, especially those capable of diffusing and killing nearby
oxygenated tumour cells (i.e. bystander effects),79 are conceptually a very attractive way
of achieving tumour-selective chemotherapy.80
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Figure 1.14 Oxygen and pH gradients present in solid tumours arising from an aberrant
vasculature. Cells closest to the nearby blood vessels (red) consume all available oxygen
leaving cells furthest away to experience continuous hypoxia (blue).

1.8.1

Enzymatic Activation of Prodrugs by Reductases

Over the last 30 years, many hypoxia-activated prodrugs have been designed to exploit
enzymes for tumour selective prodrug activation. For example, prodrug activation can be
initiated by a one-electron reduction carried out by flavin-dependant oxidoreductases.
The one-electron adducts that are formed can be back-scavenged by molecular oxygen in
normoxic tissues to regenerate the prodrug. In hypoxic tissues, the one-electron adduct
either fragments via a radical dependant mechanism or is further reduced by a stepwise
addition of electrons. Sequencing of the human genome identified ninety annotated
human flavoproteins that are responsible the catalysing redox processes in primary
metabolic pathways, such as the citric acid cycle, β-oxidation and degradation of amino
acids.81 Identification of specific flavoproteins that are the most amenable to tumourspecific activation of prodrugs has proven to be difficult due to the functional redundancy
of this family of proteins.82 Nevertheless, some of the more important bioreductive
enzymes identified include cytochrome p450 oxidoreductase (POR), NAD(P)H quinone
dehydrogenase 1 (NQO1), xanthine oxidase/xanthine dehydrogenase and cytochrome b5
reductase.83
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Quinones as Hypoxia-Activated Prodrugs

Quinones occur in many biologically active molecules, including vitamin K and
doxorubicin. The quinone group has long been of interest in hypoxia activated prodrugs
due to the ease with which it undergoes one-electron reduction, primarily catalysed by
POR, which converts it to a semiquinone radical anion (Scheme 1.5).84 This radical anion
is back-scavenged by molecular oxygen, making it highly suited to hypoxia-activated
prodrugs. One issue with quinones, however, is their propensity to undergo irreversible
two electron reductions to hydroquinones in reactions catalysed by NQO1.

Scheme 1.5 Quinones can undergo an irreversible two-electron reduction in vivo
catalysed by NQO1, or oxygen sensitive reversible one-electron reduction catalysed by
POR.

1.9.1

Apaziquone

Two electron quinone reductions have been explored for the activation of the prodrug
apaziquone (Scheme 1.6), which can be selectively activated by a NQO1 catalysed
two-electron reduction.85 Both the semiquinone radical and hydroquinone adducts can
alkylate DNA.86 Meta-analysis of NQO1 polymorphism C609T demonstrated an
increased risk of multiple types of cancers.87 Levels of NQO1 are significantly higher in
tumours with nodal metastases compared to those without metastasis, resulting in some
tumour selective activation of apaziquone.88 Results from two phase III clinical trials of
apaziquone were reported in 2017 (sponsored by Spectrum Pharmaceuticals and
Allergan) for the treatment of superficial non-muscle invasive bladder cancer in patients
undergoing transurethral resection of bladder tumours. Unfortunately, both trials missed
the primary endpoint of a statistically significant reduction in disease recurrence at two
years following tumour resection and a single dose of apaziquone versus placebo
(NCT00461591 and NCT00598806). In 2017, a new phase III trial with an increased
single dose of apaziquone (8 mg from previous trials of 4 mg) began recruiting with
results to be reported in 2021 (NCT03224182).

-15-

Chapter 1

Geraud N. Sansom

Scheme 1.6 Apaziquone can undergo two-electron reductive activation via NQO1,
resulting in a hydroquinone, or oxygen-sensitive one-electron reduction to the
semiquinone radical by POR. Both adducts are able to damage DNA.

1.10

N-oxides as Hypoxia-Activated DNA Intercalator Prodrugs

Anticancer agents containing N-oxides were described as early as the 1960s.89 The two
main subclasses of N-oxides can act as hypoxia activated prodrugs; i.e. tertiary amine-Noxides and aromatic-N-oxides. Tertiary amine-N-oxides typically rely on loss of targetbinding interactions when in the N-oxide prodrug form. Upon hypoxia-triggered
reduction, the newly revealed amine shows increased affinity for the target. Aromatic-Noxides are reduced in a one-electron process that generates cytotoxic nitroxide radicals,
which cause radical-mediated oxidative DNA strand cleavage.90 Hypoxia-selectivity is
achieved by the initial radical species being back-oxidised by molecular oxygen, thus
limiting toxicity in oxygenated tissues.
1.10.1 Banoxantrone (AQ4N) – A Tertiary Amine-N-oxide
Mitoxantrone is a DNA intercalator that disrupts DNA synthesis and DNA repair in both
cancerous and healthy cells, leading to severe side effects (Scheme 1.7). Mitoxantrone is
also a potent type II topoisomerase inhibitor and can interfere with RNA. At physiological
pH, the alkyl amine groups are protonated and form key interactions with the negatively
charged DNA backbone. The experimental drug banoxantrone (AQ4N) is a prodrug of
mitoxantrone that shows reduced binding to DNA due to the presence of tertiary
amine-N-oxides. AQ4N is unique among hypoxia-activated prodrugs because its
alkyl-N-oxides undergo bioreduction catalysed by nitric oxide synthase in a two-electron
process.91 Reduction of AQ4N is thought to be inhibited by molecular oxygen through
competitive inhibition at the heme iron atom, leading to hypoxia-selective activation.92
AQ4N undergoes two identical bioreduction of its amine N-oxides to first give AQ4M
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(single bioreduction) and finally its active drug AQ4, a potent inhibitor of type II
topoisomerase.93

Scheme 1.7 AQ4N is a prodrug variant of mitoxantrone that masks the alkyl amines as
N-oxides. AQ4N undergoes two-electron bioreductive activation catalysed by nitric oxide
synthase to give the intercalator AQ4. This process is inhibited by molecular oxygen,
giving rise to hypoxia-selective activation.

Encouraging results were seen with AQ4N in two phase I clinical trials, with no
dose-limiting side effects observed.94-95 A phase II trial of AQ4N in combination with
radiotherapy and temozolomide in glioblastoma multiforme (NCT00394628) was
commenced in 2006 but results were not reported.
1.10.2 Tirapazamine (TPZ) – An Aromatic-N-oxide
The most extensively-studied aromatic di-N-oxide hypoxia-activated prodrug is
Tirapazamine (TPZ) (Scheme 1.8).96 TPZ undergoes one-electron reduction by either
POR or nitric oxide synthase to form a TPZ•− radical anion.97-98 The radical anion can
then be back-oxidised by molecular oxygen or protonated to form the TPZ• radical, which
undergoes rearrangement with loss of water to form a benzotriazinyl radical (BTZ•).
Alternatively,

TPZ•

releases

a

hydroxyl

radical

(•OH)

to

produce

1,2,4-benzotriazin-3-amine 1-oxide (SR 4317). Once formed, the BTZ• and hydroxyl
radicals can induce reactive DNA radicals through hydrogen abstraction at the C1′, C4′
or C5′ positions of the deoxyribose sugar backbone.99 Under hypoxic conditions, either
TPZ or SR 4317 can substitute for molecular oxygen in the subsequent oxygenation of
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the C1′, C4′ or C5′ radicals.99 The oxygenated radicals then trigger sequence-independent
DNA strand cleavage and tumour cell death.100

Scheme 1.8 Mechanism of hypoxia-selective activation of TPZ leading to DNA cleavage
and tumour cell death.

TPZ was studied in three phase III clinical trials (NCT00094081, NCT00017459 and
NCT00262821) but the results of only one has been published. In this trial, TPZ was
tested in combination with cisplatin (CIS) and irradiation in cervical carcinoma. TPZ/CIS
therapy was tolerated at the modified starting dose, however, the combination failed to
show superiority over CIS chemoradiotherapy in terms of progression-free survival or
overall survival.101 Although these results were discouraging, it was highlighted that the
clinical trials did not employ biomarkers to identify patients expected to benefit most
from the therapy. One explanation that has been offered for the lack of success of TPZ
and other hypoxia-activated prodrugs in clinical studies is the inadvertent inclusion of
patients whose tumours show low levels of hypoxia. A hypoxia-imaging sub-study within
a larger randomised phase II trial comparing TPZ/CIS plus radiation to CIS plus radiation
for advanced head and neck cancer demonstrated a significant benefit for TPZ, providing
the first clinical evidence that TPZ acts by specifically targeting hypoxic tumour cells.102
The study supported use of [18F]-fluoromisonidazole positron emission tomography
imaging as a means of stratifying patients with hypoxic tumours in future clinical
studies.82

1.11

Metal Complexes as Prodrugs Designed for Bioreductive Activation

Metal complexes have been intensively studied as hypoxia-activated prodrugs.103 Cobalt
is a suitable metal for selective delivery of chemotherapeutics to regions of tumour
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hypoxia owing to the higher lability of reduced Co(II) complexes relative to Co(III). It
was originally proposed that as the reduction potential of Co(III) complexes is usually
between −0.20 to −0.40 V, they could be reduced to Co(II) within hypoxic cancer cells,
with selectivity obtained by the Co(II) complex being back-oxidised by molecular oxygen
within normoxic cells. The complex could break apart in hypoxic tumour cells releasing
attached cytotoxins.104 Pulse radiolysis studies, however, revealed that selectivity was
mostly achieved through competitive binding of oxygen to one-electron reductants in
cells rather than through Co(II)/Co(III) redox cycling.105

1.11.1 Examples of Cobalt(III) Hypoxia Activated Prodrugs
An early example of a cobalt(III) hypoxia-activated prodrug was SN24771 (Figure
1.15).106 When the nitrogen mustard is bound to the cobalt complex it is unable to alkylate
DNA. In cell culture assays, SN24771 showed 5- to 30-fold higher toxicity towards
hypoxic cells versus normoxic cells.80, 106 Although SN24771 showed significant hypoxia
selectivity in vitro, no selectivity was observed in vivo and development of the compound
was abandoned.107 It is thought that the limited stability of the cobalt(III) complex itself
likely contributed to the poor activity in vivo.

In an attempt to improve the kinetic stability of the cobalt(III) oxidation state, complexes
containing tetradentate ligands such as cyclam and cyclen were investigated.108 One
complex contained a potent DNA minor groove alkylator 1-(chloromethyl)-5-hydroxy1H-pyrrolo[3,2-f]quinolin-3(2H)-yl)(5,6,7-trimethoxy-1H-indol-2-yl)methanone (secoCPyI-TMI) bound to cobalt(III), along with the cyclam (Figure 17). The racemic secoCPyI-TMI cobalt complex showed 81 to 212-fold higher cytotoxicity under hypoxic
conditions relative to 20% oxygen in a panel of 10 human tumour cell lines.108

Figure 1.15 Examples of cobalt(III) prodrugs containing nitrogen mustard or
seco-CPyI-TMI cytotoxins as ligands.
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1.11.2 Example of a Copper(II) Hypoxia Activated Prodrug
The limited aqueous solubility of Co(III) complexes and their stability problems led to
exploration of other metals in hypoxia-activated prodrugs. Reduction of a copper(II)
complex containing a cyclen nitrogen mustard derivative to copper(I) was shown to
release the active cytotoxin (Figure 1.16). This complex showed 24-fold selectivity for
hypoxic human tumour cells in vitro and good water solubility.109 Hypoxia-activated
copper complexes are still in early development and are yet to be studied in the clinic.

Figure 1.16 Example of a copper(II) cyclen nitrogen mustard prodrug.

1.12

Nitroaromatics as Hypoxia-Activated Prodrugs

Nitroaromatics as a class of hypoxia activated prodrugs have been extensively studied,
with multiple examples progressing to clinical trials. There are two main subtypes of
nitroaromatic prodrugs; those that rely on differences between electronic properties of the
nitro groups versus the amine/hydroxylamine reduction products and those that involve
fragmentation reactions that occur after nitro reduction.

1.12.1 PR-104
The most widely studied nitroaromatic prodrug of the first type is PR-104 (Scheme 1.9).
This dinitrobenzamide mustard relies on the nitro groups pulling electron density away
from the nitrogen mustard to prevent formation of the DNA-reactive aziridinium ions
(Section 1.4). Bioreductive activation to the hydroxylamine or aniline results in a large
increase in reactivity and cytotoxicity of the nitrogen mustard.110 PR-104 is actually a
pre-prodrug, where it must undergo two separate activation steps before revealing the
active cytotoxin. The sidechain phosphate group increases aqueous solubility but is
quickly metabolised by plasma phosphatases giving the prodrug PR-104A. Selectivity for
cancer cells is achieved by reduction of the nitroaromatic group by one-electron
reductases forming the PR-104A nitro radical anion, which in normoxic cells is
back-scavenged by molecular oxygen to form superoxide. In hypoxic tumour cells,
further reduction delivers the active cytotoxin. Reduction of PR-104A gives PR-104H
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(hydroxylamine) after addition of 4-electrons and PR-104M (amine) after 6-electron
reduction. Using a combination of siRNA transfection and antisense expression it was
determined that the main reductase responsible for the initial reduction is POR, although
other flavoenzymes may also contribute.111

Scheme 1.9 Mechanism of activation of the pre-prodrug PR-104. The major PR-104
metabolite in solid tumour patients was the O-glucuronide metabolite (PR-104G) formed
by glucuronidation of PR-104A.

During

animal

studies,

PR-104

showed

significant

efficacy,

especially

in

AKR1C3-expressing xenografts, where it decreased disease progression and tumour
metastases and prolonged overall mouse survival.112-113 Phase I/II trials with PR-104 were
initiated for relapsed small cell lung cancer (NCT00544674), non-small cell lung cancer
(NCT00862134), hepatocellular carcinoma (NCT00862082) and refractory/relapsed
acute leukemia (NCT01037556). Unfortunately, each trial of PR-104 was discontinued
after PR104 showed significant toxicity, including myelosuppression and gastrointestinal
effects.114 It is thought that the intestinal cytotoxicity occurs through biliary excretion of
the O-glucuronide metabolite (PR-104G), the major PR-104 metabolite identified in solid
tumour patients (Figure 11).115 Once in the gut, β-glucuronidase activity of the gut flora
regenerates PR-104A and bacterial nitroreductases trigger reduction of PR-104A to its
active cytotoxins in the intrinsically hypoxic environment of the intestines.116
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Myelosuppression is thought to occur through effects on hematopoietic stem/progenitor
cells residing within hypoxic bone marrow niches.117

1.12.2 Evofosfamide (TH-302)
Nitroimdazoles (e.g. misonidazole) were originally developed as oxygen mimetics that
could act as radiosensitizers in hypoxic tumour cells to cause oxidative DNA damage in
the presence of ionising radiation.118 The compounds showed limited selective toxicity
towards hypoxic tumour cells in the absence of radiation due to their ability to fragment
into DNA alkylating species.119 This observation led to development of Evofosfamide
(TH-302), a nitroimidazole conjugated to a bromoisophosphoramide mustard (Scheme
1.10).120 Following initial reduction by a one-electron reductase, oxygen back-oxidises
the nitro radical anion to form superoxide. In hypoxic tumour cells, further reduction leads
to the hydroxylamine and amine derivatives, both of which push electrons into the
imidazole

ring

leading

to

fragmentation

and

release

of

an

activated

bromoisophosphoramide mustard.

Scheme 1.10 Mechanism of hypoxia- activation of TH-302.

In vitro studies with TH-302 showed up to 300-fold higher cytotoxicity toward hypoxic
tumour cells versus aerobic cells,121 and initial results of phase I/II studies showed limited
safety concerns.122-123 Treatment of advanced or metastatic pancreatic carcinoma with a
combination of gemcitabine and TH-302 showed significantly improved progression-free
survival compared to gemcitabine alone. These promising results led to two phase III
trials in soft tissue sarcoma (NCT01440088) and pancreatic adenocarcinoma
(NCT01746979). In the soft tissue sarcoma trials, TH-302 in combination with
doxorubicin showed little difference in median progression free survival to doxorubicin
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alone (6.3 months versus 6.0 months).124 The disappointing results of these trials caused
Threshold Pharmaceuticals to halt clinical development of TH-302.

1.12.3 Nitroaromatic Prodrug of a 4-Aminoaniline mustard
In an early example reported by the Denny group, a bioreductively-activated nitrogen
mustard prodrug was conceived that linked a 4-aminoaniline mustard to a
2-(2-nitrophenyl)acetic triggering moiety.125 Hypoxia-selective 6-electron reduction of
the aryl NO2 group in the molecule was designed to trigger a cyclisation reaction that
yielded the active mustard and an indolin-2-one waste fragment (Scheme 1.11). The
presence of the amide bond in the prodrug served to lower the reactivity of the mustard
towards DNA, with nucleophilic reactivity greatly increasing after amide cleavage. In
normoxic tissues, the 1-electron reduction product (nitro radical anion) would be backscavenged by molecular oxygen to regenerate the inert prodrug.

Scheme 1.11 Tumour-selective nitroaromatic prodrug reported by Denny et al.125

1.13

Molecularly Targeted Hypoxia Activated Prodrugs

DNA is the most common target for hypoxia activated prodrugs, such as cytotoxic crosslinking agents. These drugs induce DNA damage in proliferating normal tissues and,
therefore, are associated with high levels of toxicity.126 It was envisioned that selectively
activation triggered by tumour hypoxia would limit off-target toxicity. Diffusion of
activated prodrugs into the surrounding area has been shown to cause bystander damage
to neighbouring cells.127 A more elegant approach is the development of molecularly
targeted hypoxia activated prodrugs, delivering a ligand for protein inhibition which is
more toxic to hypoxic tissues than normal cells.128 The small molecules inhibitors
released by hypoxia activated prodrugs are aimed at exploiting biochemical responses to
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hypoxia by targeting proteins associated with tumourigenesis and survival, leading to
greater selectivity over healthy tissue.129

1.13.1 Nitroaromatic Molecularly Targeted Hypoxia Activated Prodrugs
An early example of a molecularly targeted hypoxia activated prodrugs incorporated a
poly(ADP-ribose)polymerase (PARP) inhibitor, developed by Parveen and co-workers
(Figure 1.17).130 PARP1 has been implicated in the repair of damaged DNA, repairing
single-stranded DNA breaks and therefore, inhibiting PARP was proposed to increase
radiosensitivity. This has led to a series of similarly designed molecularly targeted
hypoxia activated prodrugs such as CH-01 (targeting Chk1/Aurora A, ),131 BCCA621C
(targeting DNA-protein kinase),132 SN29966 (targeting EGFR)133 and TH-4000 (targeting
EGFR).134

Figure 1.17 Molecularly Targeted Hypoxia Activated Prodrugs (bioreductive moiety
shown in green).

The most clinically advanced molecularly targeted hypoxia activated prodrug is TH-4000,
originally developed as a result of a structure activity relationship study of SR29966, which is a
hypoxia activated epidermal growth factor receptor tyrosine kinase inhibitor.135 TH-4000 employs
a 4-nitroimidazole bioreductive group, which under hypoxic conditions, undergoes conjugate
elimination to release the active tyrosine kinase inhibitor TH-4000E (Scheme 1.12).
Fragmentation is proposed via the radical formed after single electron reduction, not requiring
reduction to the corresponding amine or hydroxylamine.

-24-

Chapter 1

Geraud N. Sansom

Scheme 1.12 Mechanism of hypoxia selective activation of TH-4000 to a radical anion
followed by fragmentation to release the tyrosine kinase inhibitor TH-4000E.

Phase I clinical trials of TH-4000 showed TH-4000 was more effective than commonly
used tyrosine kinase inhibitors such as erlotinib against non-small-cell lung carcinoma
xenografts with wild-type and mutant EGFR.136-137 On the basis of these results, TH-4000
was advanced into two parallel phase II clinical trials against EGFR-mutant, T790Mnegative patients with advanced NSCLC (NCT02454842) and metastatic squamous cell
carcinoma of the head and neck or skin (NCT02449681). Unfortunately, both clinical
trials have now been terminated due to a lack of efficacy with results yet to be published.

1.14

Design of Hypoxia-Activated Semaxanib|Cytotoxin Mutual Prodrugs

Many of the concepts presented to this point were integrated into the design of two
prototype hypoxia-activated antitumour mutual prodrugs comprised of semaxanib
(Section 1.3.1) linked to either 4-aminoaniline nitrogen mustard or floxuridine (Section
1.5.2) cytotoxins. The prodrugs were specifically designed to invoke the hypoxiaactivated 2-(2-nitrophenyl)acetic triggering mechanism reported by Denny et al.125
(Section 1.12.3). However, instead of releasing an indoline-2-one as a “waste” fragment,
they would release this moiety as part of the angiogenesis inhibitor semaxanib (Section
1.3.1). The other active drug released from the mutual prodrugs would be either the
4-aminoaniline mustard or floxuridine cytotoxin. The arylnitro group acts as the
triggering moiety, designed to undergo selective reduction to the corresponding aniline
in hypoxic regions of solid tumours. Spontaneous cyclisation analogous to that reported
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by Denny et al would then fragment the prodrugs to reveal the two active drugs (Scheme
1.13(b)).125

The Kelso Research Group at the University of Wollongong (UOW) reported the
synthesis and anti-angiogenic properties of 2-(2-nitrophenyl)acetate derivatives related to
the drug semaxanib (Scheme 1.13(a)).138 It was noted that a hydrogen bond was invariably
present

between

the

pyrrole-NH

and

carbonyl

oxygen

atoms

in

the

2-(2-nitrophenyl)acetic amides and esters (Scheme 1.13(a)), suggesting the scaffold may
be pre-organised and activated for rapid indoline-2-one cyclisation following reduction
to the aniline.138

Scheme 1.13 (a) Anti-angiogenic 2-(2-nitrophenyl)acetate derivatives related to
sunitinib.138 (b) Prototype mutual prodrugs 1 and 2 and their proposed mechanism of
bioreductive activation to selectively release indoline-2-one multi-kinase inhibitor
semaxanib 3 and 4-aminoaniline mustard or floxuridine cytotoxins within hypoxic
regions of tumours.

It is conceivable that clinical use of mutual prodrugs of this type could mitigate side
effects resulting from either or both drugs, while at the same time increasing localised
tumour concentrations of the active agents to improve pharmacodynamics. The mutual
prodrug 2 may also lessen the hepatic metabolism issues associated with 5-FU therapy. It
is speculated that a therapeutically beneficial prodrug activation “viscous cycle” might
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also be established within solid tumours, where continuous administration of the prodrug
over time could create increasingly hypoxic tumours through the anti-angiogenic action
of semaxanib, possibly enhancing prodrug activation and efficacy as a course of treatment
progresses (Figure 1.18).

Figure 1.18 Postulated therapeutically beneficial “viscous cycle” created by hypoxiaactivated semaxanib|cytotoxin mutual prodrugs.

1.15

Project Aims

The primary aims of this thesis work were to develop viable routes for the synthesis of
useable quantities (>100 mg) of the semaxanib|cytotoxin mutual prodrugs 1 and 2. A
second aim was to perform chemical reductions (i.e. NO2→NH2) on the prodrugs to
establish whether the molecules spontaneously cyclise and fragment to yield the two
constituent anticancer drugs. The third aim was to submit the compounds to collaborators
at the University of Auckland for pulse-radiolysis experiments and cell testing to measure
the nitroaromatic reduction potentials and hypoxia-selective cytotoxicity, respectively.
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Chapter 2: Synthesis of Semaxinib|4-Aminoaniline
Mustard 1
2.1

Route Development

The synthesis of semaxinib|4-aminoaniline mustard mutual prodrug 1 had previously
been scoped on small scale in A/Prof. Michael Kelso’s laboratory at UOW by former PhD
student Nicholas Kirk (Scheme 2.1).139 Kirk’s pilot synthesis was used as the foundation
for developing a scale-up synthesis capable of delivering sufficient material for chemical
and biological testing, as well as optimising the yields and procedures for publication.

Scheme 2.1 Pilot synthesis of mutual prodrug 1 developed by former PhD student
Nicholas Kirk.
The first step in Kirk’s synthesis involved coupling 2-(2-nitrophenyl)acetic acid to
p-phenylenediamine to give amide 4. This was followed by bis-alkylation of the aniline
nitrogen with 2-bromoethanol to yield 5. The bis-alcohol 5 was protected with
tert-butyldimethylsilyl (TBS) groups to afford 6. With both alcohols protected, a key
Knoevenagel condensation of N-methylcarbamoyl pyrrole-2-carbaldehyde 7 with 6 gave
(Z)-8.138 Silyl deprotection afforded the bis-alcohol 9 and bis-mesylation followed by
chlorination delivered 1.
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Amide Coupling

The closest literature precedent for the coupling of p-phenylenediamine to 2-(2nitrophenyl)acetic acid came from Denny et al’s work exploring 2-(2-nitrophenyl)acetic
acid|4-aminoaniline mustard prodrugs (Section 1.12.3).125 In their work, the target
nitrogen mustard prodrug was not actually synthesised and a model compound was
prepared instead. Denny et al coupled 2-(2-nitrophenyl)acetic acid to p-anisidine using
diethyl cyanophosphate and 1-methylimidazole (Scheme 2.2). Diethyl cyanophosphate is
an older, toxic amide coupling reagent so alternative reagents were investigated.

Scheme 2.2 Literature precedent for amide coupling of 2-(2-nitrophenyl)acetic acid to
electron rich aryl amines.125

Nicholas Kirk investigated the use of hexafluorophosphate benzotriazole tetramethyl
uronium (HBTU), diisopropylethylamine in dichloromethane for the coupling to obtain
4. The reaction was high yielding (75%) but the workup procedure needed to be optimised
for larger scale. In Kirk’s procedure, upon completion of the reaction the organic layer
was extracted with 1 M HCl and the aqueous layer collected, washed with
dichloromethane, neutralised with 1 M NaOH, filtered and solids recrystallised from hot
ethanol. I found that increasing the concentration of HCl and NaOH to 5 M greatly
simplified the isolation procedure and produced purer 4. Use of 5 M HCl caused the
product to precipitate in the acidic aqueous extract, which could be filtered and
neutralised with 5 M NaOH. The improved reaction and workup procedure was
performed twice on multigram scale (10.1 g and 10.2 g of 2-(2-nitrophenyl)acetic acid),
delivering pure 4 in slightly increased yield (80%, Scheme 2.3). A total of 23.8 g of 4 was
synthesised in the two reactions.
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Scheme 2.3 Amide coupling of 2-(2-nitrophenyl)acetic acid to p-phenylenediamine with
HBTU to give 4.

2.2.1

Spectroscopic Evidence for the Formation of 4

Clear evidence for the formation of 4 was observed by 1H nuclear magnetic resonance
(NMR) spectroscopy in deuterated dimethyl sulfoxide (d6-DMSO) (Figure 2.1). The
appearance of two new 2H doublets at 7.16 ppm and 6.48 ppm corresponded to the
addition of the para-substituted aromatic ring. Additionally, the appearance of four new
aromatic peaks in the 13C NMR and observing the expected M+H+ ion at m/z 272.1035
by high resolution mass spectrometry confirmed the structure of 4.

Figure 2.1 Aromatic region of the 500 MHz 1H NMR spectrum of 4 in d6-DMSO.

2.3

Bis-Alkylation of 4

Alkylation and bis-alkylation of aromatic amines is a common reaction with several
examples in the literature using many different reagents. In one representative example,
alkylation of 4-methoxyaniline with ethylene oxide in the presence of propionic acid and
water gave 69% of the bis-alkylated product (Scheme 2.4, A).140 In this reaction, the acid
first protonates ethylene oxide to activate it towards nucleophilic attack by the aniline and
release of ring strain provides a strong driving force for ring opening.
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A second example used 2-chloroethanol, calcium carbonate and potassium iodide in water
to give N,N-bis-alkylated aniline in 86% yield (Scheme 2.4, B).141 The reaction likely
proceeds via Finkelstein conversion of 2-chloroethanol to 2-iodoethanol, followed by
nucleophilic substitution by the aniline nitrogen and loss of iodide as a leaving group. In
a third example, alkylation of 4-bromoaniline using 2-bromoethanol and sodium
bicarbonate gave 76% of the bis-alkylated product (Scheme 2.4, C).142 2-Bromoethanol
was used neat as the reagent and solvent in this reaction.

Scheme 2.4 Three literature precedents for the bis-alkylation of aromatic amines.140-142

Bis-alkylation of 4 was explored by Nicholas Kirk using neat 2-bromoethanol and
potassium carbonate (Scheme 2.5). The reaction was problematic, however, being limited
in scale by both the workup and purification procedures. Kirk’s workup involved
concentrating the mixture under reduced pressure and extracting with ethyl acetate and
brine solutions. Purification required complex and lengthy column chromatography.
When performed on a large scale (11.6 g 4), I noted that several impurities were being
formed during the concentration step leading to reduced yield (28%). To circumvent this,
I found that the product could be precipitated directly from the 2-bromoethanol reaction
mixture by addition of excess brine. The crude precipitate was then easily filtered and
recrystallised (–20 °C) from hot ethanol. The simplified workup procedure allowed more
practical and rapid access to larger quantities of 5. The reaction was successfully
performed two more times (4.0 g and 6.6 g 4) and gave acceptable yields (62% and 53%,
respectively), affording a total of 12.3 g of 5 across the three reactions.
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Scheme 2.5 Bis-alkylation of 4 with neat 2-bromoethanol yielded 5 on multi-gram scale.

2.3.1

Spectroscopic Evidence for the Formation of 5

Evidence for the formation of 5 was clearly observed in the1H NMR spectrum (Figure
2.2), where a new quartet had appeared at 3.51 ppm, along with a triplet at 3.37 ppm, both
with integration 4H. The two new signals corresponded to addition of two chemically
equivalent ethanol groups to the aryl NH2 group of 4. When recorded in d6-DMSO, the
alcohols appeared as a 2H triplet at 4.70 ppm due to coupling from the adjacent CH2,
which in turn appeared as an apparent quartet due to coupling from both the alcohol and
adjacent CH2 groups. The singlet at 4.05 ppm with an integration of 2H corresponded to
the benzylic CH2. The appearance of two new aliphatic signals at 58.1 and 53.3 ppm in
the 13C NMR supported addition of the two ethanol chains. Observation of the expected
M+H+ ion at m/z 360.1559 by high resolution mass spectrometry confirmed formation of
5.

Figure 2.2 Aliphatic region of the 500 MHz 1H NMR spectrum of 5 in d6-DMSO.

2.4

Bis-TBS Protection of 5

Protection of the two alcohol groups was found by Nicholas Kirk to be essential for
success of the ensuing Knoevenagel condensation, presumably because the reaction
requires an absence of acidic protons. The protecting group selected was TBS as it is
simple to install and later remove under mild conditions. It is also base stabile, which is
important as the Knoevenagel reaction is performed under basic conditions. There are
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many literature precedents for the protection of structurally similar bis-ethanolamines
with TBS groups. One representative example is shown in Scheme 2.6, where tertbutyldimethylsilyl chloride (TBDMSCl) and imidazole in dimethylformamide (DMF)
were used to produce 95% of the desired bis-TBS-protected diol.143

Scheme 2.6 Literature precedent for bis-TBS protection of a bis-ethanolamine
structurally related to 5.

The method of converting 5 to 6 developed by Nicholas Kirk using TBDMSCl/imidazole
in dichloromethane reportedly gave good yields (86%). Kirk used recrystallisation from
pet. spirit for product purification, which was easily adaptable to scale-up. I performed
Kirk’s procedure three times on increasing scale (3.0 g, 4.2 g and 4.5 g of 5) and obtained
a consistent yield (86%, Scheme 2.7) of 6 in each case, yielding a total of 16.0 grams of
6 from the three reactions.

Scheme 2.7 Bis-TBS protection of 5.

2.4.1

Mechanism of Bis-TBS Protection

The mechanism for the bis-TBS-protection of 5 uses the catalyst imidazole to first form
an activated imidazolium-chloride salt from TBDMSCl (Scheme 2.8). Activation of the
silicon atom for nucleophilic attack by alcohols in this way significantly increases the rate
of reaction.144 After the first protecting group is added, the process then repeats on the
second alcohol due to the excess of TBDMSCl/imidazole present, yielding bis-TBS
protected 6.
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Scheme 2.8 Mechanism for the Bis-TBS protection of 5.

2.4.2

Spectroscopic Evidence for the Formation of 6

Addition of two TBS groups was supported by the appearance of two large singlets in the
far upfield region of the 1H NMR spectrum (Figure 2.3). The first singlet at 0.85 ppm was
highly shielded and integrated for 18 protons, corresponding to the two tert-butyl moieties
of the TBS groups. The singlet at 0 ppm integrating for 12 protons corresponded to the
four methyl groups; two each attached to the two silicon atoms. Additionally, the
appearance of three new aliphatic peaks at 26.0, 18.4 and –5.2 ppm in the

13

C NMR

spectrum supported successful addition of two chemically equivalent TBS groups.
Finally, observation of the expected M+H+ ion at m/z 588.3289 by mass spectrometry
confirmed formation of 6.

Figure 2.3 Aliphatic region of the 500 MHz 1H NMR spectrum of 6 in d6-DMSO.
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Knoevenagel Condensation of 6

The key step in Nicholas Kirk’s synthesis of 1 was a Knoevenagel condensation between
6 and N-protected pyrrole aldehyde 7. Closely related Knoevenagel reactions were
developed in the Kelso Lab at UOW by Kirk and others for the synthesis of
2-(2-nitrophenyl)acetic esters and amides (Table 2.1).138 Optimisation of the reactions by
previous students showed that condensations with pyrrole-2-carbaldehydes required
addition of a methyl carbamate protecting group to the pyrrole nitrogen. Use of potassium
carbonate with 18-crown-6 in tetrahydrofuran (THF) at reflux was found to work with a
variety of esters and amides, typically giving a ~1:1 mixture of cis/trans isomers for esters
and almost exclusively cis products for amides, albeit in lower yields.

Table 2.1 Knoevenagel reactions between 2-(2-nitrophenyl)acetic esters and amides
developed previously in the Kelso Lab.138

R

Cis, Yield %

Trans Yield %

OEt

42

35

OMe

36

40

OAll

41

33

NHEt

21

0

NHPh

22

<5

NHBn

16

<5

Nicholas Kirk was the first to trial condensing 6 with aldehyde 7 using the above
conditions (K2CO3, 18-crown-6, THF, reflux), and he obtained (Z)-8 in modest yield
(41% cis and 22% trans, Scheme 2.9). This yield was achieved only once by Kirk in eight
small-scale attempts and post-analysis of his NMR data indicated that the product was of
low purity.
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Scheme 2.9 Knoevenagel condensation with 6 trialled on small scale by Nicholas Kirk.139

2.5.1

Knoevenagel Reaction Mechanism

A plausible mechanism for the condensation reaction that accounts for in situ
pyrrole-N-deprotection is outlined in Scheme 2.10. Potassium carbonate initiates the
reaction by abstracting a proton from the 2-(2-nitrophenyl)-acetic amide portion of 6 to
generate a benzylic carbanion, with the K+ counterion chelated by 18-crown-6. The
‘naked’ carbanion then adds to the aldehyde group of 7 with the resulting oxyanion
attacking the neighbouring carbonyl carbon of the N-methylcarbamate to form a
5-membered oxazolidine ring. Collapse of the oxyanion leading to cleavage of the C-N
bond and loss of pyrrolate as the leaving group (in preference to cleavage of the C-O bond
and loss of methoxide) then ensues. The basic pyrrolate anion abstracts the remaining
benzylic proton and methyl carbonate is eliminated to provide alkene (Z)-8 as a mixture
of cis and trans isomers. It is possible that an intramolecular hydrogen bond between the
nascent pyrrole N-H and amide carbonyl oxygen favours formation of the cis-product.

Scheme 2.10 Proposed mechanism for the formation of (Z)-8 by the Knoevenagel
condensation of 6 with pyrrole aldehyde 7.
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Optimising the Yield of (Z)-8

The Knoevenagel reaction was the lowest yielding step in Kirk’s synthesis of 1 so
considerable effort was invested into attempts to optimise the reaction conditions. The
reaction would typically proceed for about 3 hours and then no further product would
form (by thin layer chromatography, TLC analysis) despite a large amount of the starting
materials 6 and 7 remaining. When the reaction was left for longer than 3 hours, two new
side products started to form. The first side product was identified as pyrrolizinone 11,
which was hypothesised to form from the desired product (Z)-8 after proton abstraction
from the pyrrole nitrogen under the basic reaction conditions. Cyclisation of the pyrrolate
anion onto the amide carbonyl would lead to cleavage of the amide bond and release of
the 4-aminoaniline derivative 12 (Scheme 2.11). Compound 12 was not able to be isolated
from the reaction as the electron rich 4-aminoaniline was unstable and rapidly
decomposed. Deliberate formation of pyrrolizinones using a related procedure was later
optimised by Nicholas Kirk to produce a variety of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3ones that showed potent anti-angiogenic activity.145

Scheme 2.11 Proposed mechanism for the formation of pyrrolizinone side product 11
from the desired product (Z)-8 during the Knoevenagel reaction.

The second side product observed in the Knoevenagel reaction was N-aryl oxindole 13,
apparently formed by nucleophilic displacement of the arylnitro group by the amide
nitrogen (Scheme 2.12). Whilst uncommon, intramolecular cyclisation of amides onto
arylnitro groups has been reported.146
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Scheme 2.12 Proposed mechanism for the formation of N-aryl oxindole side product 13
from the desired product (Z)-8 during the Knoevenagel reaction.

It was thought that the basic conditions and heating of the Knoevenagel reaction was
causing (Z)-8 to undergo these side reactions. Attempts to optimise the yield of (Z)-8 were
performed using small scale reactions (~30 mg) with a variety of carbonate bases/crown
ethers and solvents (Table 2.2). The products were not isolated but each reaction was
analysed for the presence of (Z)-8 by TLC comparison to a standard, with the presence of
the product further confirmed by mass spectrometry. Of all the bases trialled, only
potassium carbonate and caesium carbonate delivered (Z)-8 in THF or acetonitrile.
Despite these and many other attempts, no improvements to Kirk’s original conditions
were identified.

Table 2.2 Representative selection of conditions trialled in attempts to optimise the
Knoevenagel reaction.

Base/Crown Ether

DMF

CH3CN

THF

Cs2CO2

No Reaction

Low Yield

No Reaction

K2CO3/18-crown-6

No Reaction

Medium Yield

Highest Yield

Na2CO3/15-crown-5

No Reaction

No Reaction

No Reaction

Li2CO3/12-crown-4

No Reaction

No Reaction

No Reaction

It was postulated that grinding the potassium carbonate into a fine powder instead of using
the slightly granular form might accelerate the reaction and allow more of (Z)-8 to form
before the side reactions commenced. When tested side-by-side, use of granular
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potassium carbonate and the finely ground form did not change the yield of (Z)-8. In the
end, I was able to implement Kirk’s original method on a large enough scale to generate
sufficient quantities of pure material for this study. Performing the reaction three times
using 1.0, 2.2 and 5.0 g of 6 produced a total of 1.7 g of (Z)-8 in 21% yield. The trans
product, which was only observed in trace quantities, had previously been investigated in
a series of isomerisation reactions by Kirk but encouraging results were not obtained.
Isomerisation of (E)-8 could be partially achieved using catalytic H2SO4 in THF,
producing a 19% yield of the desired (Z)-8 with 62% recovery of (E)-8. Base-promoted
isomerisation using triethylamine or N,N-diisopropylethylamine (DIPEA) was not
successful, instead producing the oxindole derivative 13 as the major product.

2.5.3

Spectroscopic Evidence for the Formation of (Z)-8

The Knoevenagel condensation gave a complex mixture of desired and side products that
had to be individually isolated and characterised. During the characterisation it was
important to confirm that the cis and not the trans isomer was being isolated. The desired
cis-product was hypothesised to contain an intramolecular hydrogen bond between the
pyrrole N-H and the amide C=O (Figure 2.4). This postulation was based on previous
observations

by

X-ray

crystallography

of

this

H-bond

in

the

related

2-(2-nitrophenyl)acetic esters and amides (Table 2.1).138 Based on this earlier work, the
pyrrole N-H was expected to appear in the 1H NMR spectrum between 11-13 ppm for the
cis-product and 6-7 ppm for the trans product. For compound (Z)-8, the pyrrole N-H
signal appeared at 12.10 ppm, confirming the desired cis-product had been isolated.
Assignment of cis stereochemistry was further confirmed by the appearance of a nuclear
overhauser effect spectroscopy (NOESY) correlation between the alkene hydrogen and
the nearby ortho-proton of the 2-nitrophenyl ring, which is not possible in the trans
isomer.

Figure 2.4 The pyrrole NH forms a hydrogen bond to the amide carbonyl in (Z)-8.
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Bis-TBS Deprotection of (Z)-8

With the key Knoevenagel condensation complete, the second last step in the synthesis
involved removing the TBS protecting groups from the two alcohols before final
conversion to alkyl chlorides. The most common methods for removing TBS groups from
alcohols uses fluoride ions, driven by formation of the very strong Si-F bond (565
kJ.mol-1).147 The literature provided a relevant precedent where two TBS groups were
simultaneously removed from a nitroimidazole carbamate prodrug structurally related to
our target molecule. Use of tetrabutylammonium fluoride (TBAF) in this precedent gave
a high yield of the bis-alcohol (88%, Scheme 2.13, A).148 A second precedent was
identified in a paper reporting the synthesis of a self-immolative nitrogen mustard
prodrug, wherein two TBS groups were deprotected using triethylamine trihydrofluoride
in 88% yield (Scheme 2.13, B).149 Both methods appeared promising but as triethylamine
trihydrofluoride produces highly toxic HF, TBAF was chosen as the preferred reagent for
the reaction.

Scheme 2.13 Literature precedents for bis-TBS deprotection of bis-alcohols using TBAF
or EtN3•3HF.148-149

Nicholas Kirk found that adding acetic acid to buffer the reaction was essential for
obtaining a high yield of 9 (85%). Using Kirk’s method, I successfully performed the
reaction four times on increasing scale (0.2 g, 0.4 g, 0.5 g and 0.7 g of (Z)-8) with
consistent yields (86%, Scheme 2.14) to generate a total of 0.95 g of pure 9.

Scheme 2.14 Bis-TBS-deprotection of (Z)-8 to afford 9.
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Spectroscopic Evidence for the Formation of 9

Removal of the two TBS-protecting groups was clearly evident from the 1H and 13C NMR
spectra of 9, where loss of the two large singlets in the 1H NMR spectrum at 0.89 and
0.04 ppm (Figure 2.5) and the three peaks in the 13C NMR at 26.0, 18.4 and –5.2 ppm
(Figure 2.6) was observed. There was also a slight downfield shift in the 1H NMR signals
of the bis-ethanolamine CH2 groups, which moved from 3.73 and 3.48 in (Z)-8 to 3.79
and 3.52 ppm, respectively, in 9.

Figure 2.5 Aliphatic region of the 500 MHz 1H NMR spectrum of 9 (bottom) showing
loss of the TBS signals present in (Z)-8 (Top). Both spectra were recorded in CDCl3.

Figure 2.6 Aliphatic region of the 500 MHz

13

C APT NMR spectrum of 9 (bottom)

recorded in CDCl3 showing loss of the three TBS carbon signals present in (Z)-8 (Top).
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Bis-Mesylation/Chlorination of 9 to give Mutual Prodrug 1

The final step in the synthesis of 1 involved converting the two alcohol groups of 9 to
primary alkyl chlorides. Nitrogen mustards are a well-studied class of compounds and
several methods have been reported for the conversion of bis-alcohols to bis-chlorides. In
the above-mentioned synthesis of a nitroimidazole carbamate prodrug (Section 2.6),
conversion to the mustard was carried out in two steps. Mesylation was carried out first
in pyridine using mesyl chloride and triethylamine and subsequent chlorination with
lithium chloride in DMF gave the mustard in 83% over the 2 steps (Scheme 2.15, A).148
In another example, aniline mustards were synthesised from bis-alcohols using thionyl
chloride in dichloroethane in 25% yield (Scheme 2.15, B).150

Scheme 2.15 Literature precedents for the conversion of bis-alcohols to aniline
mustards.148, 150

Nicholas Kirk attempted the bis-chlorination of 9 using the 2-step mesylation/chlorination
procedure. He was able to achieve a yield of 79% over the two steps and noted that the
bis-mesylate could not be isolated due to its low stability. I repeated Kirk’s conditions
twice using 150 mg and 300 mg of 9 and obtained 1 in consistent yield (80%, Scheme
2.16). The reaction required immediate and very careful isolation and transfer of the crude
bis-mesylate into the second chlorination reaction. In an attempt to simplify the procedure
for further scale-up, single step conversions with phosphoryl chloride and thionyl chloride
were trialled on small scales with remaining quantities of 9 but both reactions gave
multiple products, including insoluble polymer. Using Kirk’s original method, I was able
to obtain sufficient quantities of 1 (210 mg in total) to explore the chemical reductions
(Section 4.1) and biological testing (Section 4.2) aims of the thesis.
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Scheme 2.16 Two-step conversion of 9 to the target semaxinib|4-aminoaniline mustard
mutual prodrug 1.

2.8

2D Spectroscopic Analysis of 1

NMR data for 9 and 1 were almost identical, consistent with the minor changes expected
after transforming the two primary alcohols into primary alkyl chlorides. Within the
aromatic region of the 1H-NMR spectrum, all signals were accounted for (Figure 2.7). Of
key interest was the pyrrole N-H peak, which was observed at 12.04 ppm due to the
intramolecular hydrogen bond it forms to the carbonyl oxygen of the amide. Only slight
changes were observed in the aliphatic 1H NMR chemical shifts of the mustard CH2
groups, which moved from 3.79 and 3.52 in 9 to 3.70 and 3.60 ppm in 1 (Figure 2.8).

Figure 2.7 Aromatic region of the 500 MHz 1H-NMR spectrum of 1 recorded in CDCl3.
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Figure 2.8 Aliphatic region of the 500 MHz 1H- NMR spectrum of 1 recorded in CDCl3.

2.8.1
The

13

13

C APT NMR Analysis of 1

C NMR of 1 was complex owing to the 21 different carbon types, including 10

quaternary carbons and required an attached proton test (APT) 13C NMR spectrum to aid
assignment of each signal (Figure 2.9 and Figure 2.10). The carbons with attached protons
were assigned using a combination of gradient-selected heteronuclear single quantum
coherence (gHSQC), gradient-selected correlation spectroscopy (gCOSY) and NOESY
spectra. The quaternary carbons C2 and C8 were assigned from a gradient-selected
heteronuclear multiple bond coherence (gHMBC) spectrum.

Figure 2.9 Aromatic region of the 500 MHz 13C APT NMR spectrum of 1 recorded in
CDCl3. The peaks at 166.88 and 149.75 ppm were evident in the gHMBC spectrum.
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Figure 2.10 Aliphatic region of the 500 MHz 13C APT NMR spectrum of 1 recorded in
CDCl3.

2.8.2

NOESY NMR Analysis of 1

The NOESY spectrum of 1 showed only two visible NOE correlations (Figure 2.11); one
between a methyl group on the pyrrole and its adjacent alkene proton. This NOE provided
definitive assignments for the two chemically similar methyl groups on the pyrrole. The
other NOE observed was between one of the pairs of methylene protons on the nitrogen
mustard and the adjacent protons of the 4-aminoaniline ring. This NOE allowed definitive
assignment of both pairs of methylene protons on the nitrogen mustard as well as the two
pairs of equivalent phenylenediamine protons.

Figure 2.11 NOESY correlations of 1 recorded in CDCl3 (500 MHz)

2.8.3

gCOSY NMR Analysis of 1

After applying a diagonal suppression to the gCOSY spectrum of 1, five 3JH-H correlations
were observed (Figure 2.12). These correlations were as expected for the pairs of vicinal
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protons in 1. The correlations allowed definitive assignment of the protons around the
nitrobenzene ring by starting at the heavily deshielded doublet at 8.03, ppm corresponding
to the proton adjacent to the nitro group and walking the correlations around the aromatic
ring. Also observed was a correlation between the two pairs of chemically equivalent
protons on the 4-aminoaniline ring and a correlation between the two pairs of methylene
protons on the nitrogen mustard.

Figure 2.12 3JH-H correlations observed in the 500 MHz gCOSY NMR spectrum (with
diagonal suppression) of 1 recorded in CDCl3.

2.8.4

gHSQC NMR Analysis of 1

The aromatic region of the gHSQC spectrum of 1 revealed eight different C-H
correlations (red, Figure 2.13). The correlations between these carbons and their attached
protons allowed assignment of each of these carbon atoms based upon their attached
proton signals.

Figure 2.13 Aromatic region of the 500 MHz gHSQC spectrum of 1 recorded in CDCl3.
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The aliphatic region of the gHSQC spectrum of 1 contained four correlations; two
corresponding to CH2 (blue) signals and two arising from CH3 carbons (red, Figure 2.14).
The two CH2 signals corresponded to the pairs of methylene protons on the nitrogen
mustard arms and allowed assignment of their respective carbons. The two CH3 signals
corresponded to the two methyl groups on the pyrrole.

Figure 2.14 Aliphatic region of the 500 MHz gHSQC spectrum of 1 recorded in CDCl3.

2.8.5

gHMBC NMR Analysis of 1

The aromatic region of the gHMBC spectrum of 1 displayed many correlations (Figure
2.15), especially within each of the phenyl rings. Most of the correlations were 3JH-C (red)
although several 2JH-C correlations (blue) were also present. The large number and variety
of multi-bond correlations present allowed definitive assignment of each of the as yet
unassigned quaternary carbons within the molecule.

Figure 2.15 Aromatic region of the 500 MHz gHMBC spectrum of 1 recorded in CDCl3,
2

JH-C correlations are shown in blue and 3JH-C correlations in red.
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The aliphatic region of the gHMBC spectrum also contained several 3JH-C and 2JH-C
correlations (Figure 2.16). Both methyl groups on the pyrrole showed a 2JH-C correlation
to their adjacent quaternary carbons, along with 3JH-C correlations to the next carbon. The
two pairs of methylene protons on the nitrogen mustard exhibited 2JH-C correlations within
each chain and 3JH-C correlations through the nitrogen atom into the other chain. A 3JH-C
correlation was also observed between the methylene protons next to the nitrogen and the
quaternary carbon of the attached 4-aminoaniline ring. This correlation allowed
unambiguous assignment of this tertiary carbon from the other chemically similar tertiary
carbon on the 4-aminoaniline ring.

Figure 2.16 Aliphatic region of the 500 MHz gHMBC spectrum of 1 recorded in CDCl3.

2.9

Summary of the Scale-Up Synthesis of 1

The total synthesis of 1, having been originally scoped on small scale by Nicholas Kirk,
was repeated here, improved in parts and successfully scaled up to provide adequate
quantities of the semaxinib|4-aminoaniline mustard mutual prodrug 1 for chemical
(Section 4.1) and biological testing (Section 4.2). The synthesis was completed in 6 steps
in an overall yield of 6.2% (Scheme 2.17), producing at total of 190 mg of pure 1. The
synthesis still poses challenges that could be addressed in the future, if needed. Firstly,
bis-alkylation of 4 with 2-bromoethanol was a long reaction (5 days) that produced only
a moderate yield of 5 (62%). One way to potentially improve this reaction would be to
use ethylene oxide in place of 2-bromoethanol, although as a toxic gas this presents its
own challenges. The other problematic step in the synthesis was the Knoevenagel
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condensation, where a maximum yield of only 21% of the cis isomer was obtained after
extensive optimisation efforts. Work described in Chapter 5 showed that moving the
Knoevenagel reaction to earlier in the synthesis is a promising alternative.

Scheme 2.17 Summary of the scaled-up synthesis of 1. Total quantities of compounds
synthesised across all reactions are indicated.
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Chapter 3: Synthesis of Semaxanib|Floxuridine Mutual
Prodrug 2
3.1

Route Development

I had previously explored a pilot route towards the semaxanib|floxuridine mutual prodrug
2 during my 2014 Honours research project in the Kelso Research Lab at UOW (Scheme
3.1). The route I pursued started from the commercially available drug floxuridine, which
was bis-silyl protected at its 1° and 2° alcohols using TBDMSCl and imidazole to obtain
14 in 97% yield. Subsequent benzoylation of the imide nitrogen of 14 with benzoyl
chloride (BzCl) in pyridine gave 15 in 96% yield. The third step involved selective silyldeprotection of the less sterically hindered 1° alcohol (aqueous trichloroacetic acid, 4.2
M in THF 1:4)151 to give 16 (52% yield). Esterification of the floxuridine derivative 16
with 2-(2-nitrophenyl)acetic acid gave ester 17 (80% yield).

Scheme 3.1 Pilot synthesis of semaxanib|floxuridine Mutual Prodrug 2 scoped during my
Honours research in 2014 at UOW. The yields shown represent the highest yields
obtained in each step.
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Submitting 17 to the novel Knoevenagel condensation with N-methylcarbamoyl pyrrole
aldehyde 7 gave the cis/trans isomers (Z)-18 and (E)-18 in only 4% and 6% yields,
respectively.138 The final steps involved sequential removal of the TBS (Et3N.3HF, 62%
yield) and benzoyl (NH3/MeOH, 76% yield) protecting groups to give 2 (13 mg), albeit
in low purity. The major goal in this chapter of my PhD studies was to improve and scale
up the synthesis so that sufficient quantities of 2 could be obtained in pure form for
chemical and biological studies (Chapter 4).

3.2

TBS Protection of Floxuridine

The first step in the synthesis was the bis-TBS protection of commercially sourced
floxuridine. The closest literature precedent for this reaction came from the reported
bis-TBS-protection of thymidine,152 an almost identical compound differing only in
replacement of the fluorine atom with a methyl group (Scheme 3.2).

Scheme 3.2 Literature precedent for bis-TBS protection of thymidine.153

During my Honours year, the bis-TBS-protection of floxuridine was carried out at room
temperature in CH2Cl2 for 24 hours using 3 equivalents (eq.) of TBDMSCl and 3.5 eq. of
imidazole relative to floxuridine. The reaction was carried out once with 0.2 g and twice
with 5.0 g floxuridine and high yields were consistently obtained (97%).

In my PhD studies I had focused on scaling up the reaction to allow access to ample
quantities of later intermediates in the synthesis. The reaction was successfully scaled up
to a maximum of 25 g of floxuridine, which gave 46.8 g of pure 14 (97% yield).
Purification at this scale using column chromatography was unattractive so multiple
recrystallisation conditions were trialled. Recrystallisation at −20 °C after dissolution in
boiling pet. spirit and slow cooling was found to give pure 14. The reaction was performed
a total of four times on increasing scale (5.0 g, 8.2 g, 25.0 g, 25.2 g floxuridine) with a
consistently high yields obtained (84%, 77%, 97% and 78% yield, respectively),
providing a total of 105 g of 14 over the course of my PhD.
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Mechanism of Bis-TBS Protection

In this reaction, the imidazole acts as a nucleophilic catalyst that attacks the silicon atom
using its pyridine-like nitrogen and displaces the chloride (Scheme 3.3). The more
nucleophilic primary alcohol of floxuridine then attacks the silicon atom of the TBSimidazolium cation, generating the TBS-protected primary alcohol and imidazole·HCl.
The reaction then repeats on the secondary alcohol to provide the bis-TBS-protected 14.

Scheme 3.3 Mechanism for the bis-TBS protection of the 1° and 2° alcohols of
floxuridine using TBDMSCl and imidazole.

3.2.2

Spectroscopic Evidence for the Formation of 14

Consistent with the addition of two TBS protecting groups, two new large singlets and
two doublets were observed in the upfield region of the 1H NMR spectrum of 14 (Figure
3.1). The two singlets at 0.92 and 0.88 ppm integrated for 9 protons each, corresponding
to the chemically non-equivalent tert-butyl moieties of the two TBS groups. The two
apparent doublets at 0.12 and 0.07 ppm integrated for 6 protons each, corresponding to
the two methyl groups attached to the two silicon atoms. The apparent doublets arise from
the nearby chirality of the ribose ring, causing the methyl groups to be diastereotopic; i.e.
each methyl group is in a unique chemical environment. These apparent doublets are
therefore actually four individual singlets arising from the four chemically non-equivalent
methyl groups attached to the silicon atoms. Additionally, the appearance of eight new
aliphatic peaks at 26.0, 25.8, 18.5, 18.1, –4.5, –4.7, –5.4 and –5.5 ppm in the 13C NMR
spectrum supported incorporation of two chemically non-equivalent TBS protecting
groups. As seen in the 1H spectrum, the two pairs of methyls attached to the silicon atoms
are diastereotopic, experiencing different chemical environments due to the nearby
chirality of the ribose ring, leading to all four methyl signals appearing. Observation of
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the expected M+H+ ion at m/z 475.2460 by high resolution mass spectrometry confirmed
formation of 14.

Figure 3.1 Appearance of the TBS signals in the 500 MHz 1H NMR spectrum of 14. The
spectrum was recorded in CDCl3.

3.3

2,4-Dimethoxybenzoyl Protection of 14

The lowest yielding step in my Honours year synthesis of 2 was the Knoevenagel
condensation, which gave only 4% of the desired (Z)-18. This was partly attributed to
unwanted deprotection of the benzoyl group during the reaction. It was thought that this
may be overcome by addition of two o,p-methoxy electron donating groups to the
aromatic ring. Electron donation from the o,p-methoxy groups was predicted to lessen the
electrophilic character of the benzoyl carbonyl carbon, leading to reduced susceptibility
to inadvertent deprotection by nucleophiles (Figure 3.2).

Figure 3.2 The presence of electron donating o,p-methoxy groups was predicted to
reduce electrophilicity of the benzoyl carbonyl group, stabilising it towards nucleophiles
and avoiding inadvertent deprotection during the Knoevenagel reaction.
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The closest literature precedent for installation of the o,p-dimethoxybenzoyl group came
from the previously mentioned paper reporting bis-TBS-protection of thymidine (Section
3.2),152 wherein the authors subsequently installed a benzoyl group onto the imide
nitrogen in 90% yield (Scheme 3.4).

Scheme 3.4 Literature precedent for the benzoyl protection of bis-TBS protected
thymidine.

During my Honours year, benzoyl protection of 14 to give 15 was carried out at room
temperature in pyridine over 48 hours using 4 eq. of benzoyl chloride. Although high
yielding (97%), the product was difficult to isolate due to the large amount of pyridine
that needed to be removed. Similar conditions using pyridine as the solvent/base/catalyst
were initially investigated in my PhD for the reaction of 14 to give the new 2,4dimethoxybenzoyl protected 20 (Table 3.1). Isolated yields were lower than expected
(Entry 1), possibly due to difficulties in isolating the product, along with the lower
electrophilicity of 2,4-dimethoxybenzoyl chloride due to the presence of the two electron
donating methoxy groups. Heating the reaction (Entries 2 and 3) gave only minor
improvements. It was postulated that switching from N,N-diisopropylethylamine
(DIPEA)/pyridine to a DIPEA/4-dimethylaminopyridine (DMAP) combination in
dichloromethane might both improve the yield and aid purification, especially on a large
scale. The new conditions afforded 20 in 87% yield (Entry 4) and the purification was
simplified as the DMAP, DIPEA and unreacted 2,4-dimethoxybenzoyl chloride were all
removed by HCl(aq) and sat. NaHCO3(aq) washes during workup. It was noted that
distillation of the 2,4-dimethoxybenzoyl chloride was essential for the reaction to proceed
in good yield. 2,4-Dimethoxybenzoyl chloride was freshly prepared from 2,4dimethoxybenzoic acid by reaction with oxalyl chloride in dichloromethane using
catalytic DMF, followed by distillation.154 Over the course of my PhD, the optimised
reaction was repeated a total of eight times (0.1 g, 0.5 g, 0.6 g, 4.9 g, 5.0 g, 9.1 g, 10.0 g,
22.8 g of 14), affording a total of 59.2 g of 20 in consistently high yields.
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Table 3.1 Optimisation of 2,4-dimethoxybenzoyl protection of 14 to give 20.

Entry Catalyst

Base

Solvent

Temp °C

Time (h)

Yield (%)

1

Pyridine

DIPEA

Pyridine

r.t.

48

46

2

Pyridine

DIPEA

Pyridine

45

48

48

3

Pyridine

DIPEA

Pyridine

65

48

51

4

DMAP

DIPEA

CH2Cl2

45

24

87

3.3.1

Mechanism of 2,4-Dimethoxybenzoyl Protection of 14 with DMAP/DIPEA

In this reaction, the nucleophilic pyridine nitrogen of the DMAP catalyst reacts with the
electrophilic 2,4-dimethoxybenzoyl chloride to produce an activated N-acylpyridinium
salt (Scheme 3.5). The imide nitrogen then acts as a nucleophile, attacking the carbonyl
carbon of the N-acylpyridinium species to displace DMAP and produce 20 and
DMAP∙HCl. DIPEA then neutralises the DMAP∙HCl to regenerate the DMAP catalyst.

Scheme

3.5

Mechanism

for

N-2,4-dimethoxybenzoylation

of

14

with

2,4-dimethoxybenzoyl chloride in the presence of catalytic DMAP and DIPEA.

3.3.2

Spectroscopic Evidence for the Formation of 20

The 1H NMR spectrum of 20 (Figure 3.3) showed three new aromatics signals and two
new singlets consistent with two methoxy groups. A doublet at 8.07 ppm was coupled to
a doublet of doublets at 6.59 ppm, which was also coupled to a doublet at 6.38 ppm. These
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signals corresponded to the three protons around the newly installed dimethoxybenzoyl
group. Two large singlets observed at 3.85 ppm and 3.76 ppm, both integrating at 3H,
indicated the presence of two methoxy groups. In addition to these peaks, all of the
original peaks from the TBS-protected floxuridine 14 were observed in the spectrum of
20 except for the imide N-H. The appearance of nine new peaks in the 13C NMR spectrum
supported successful addition of the 2,4-dimethoxybenzoyl protecting group. Finally,
observation of the expected M+H+ ion at m/z 639.2933 by high resolution mass
spectrometry confirmed formation of 20.

Figure 3.3 Section of the 500 MHz 1H NMR spectrum of 20 (CDCl3) showing the
presence of 2,4-dimethoxybenzoyl signals.

3.4

Primary Alcohol Selective Deprotection in 20

To achieve the desired Steglich esterification (Section 3.5), it was envisaged that selective
TBS deprotection of the less hindered 1° alcohol of 20 to provide the required 21 could
be achieved using aqueous trichloroacetic acid (TCA, 4.2 M) in THF (1:4).151 The use of
THF as co-solvent with H2O has been reported to improve the selectivity of 5′-desilylation
and also to reduce unwanted depurination side products.155 The milder reagent
trichloroacetic acid (pKa = 0.66) was reported to be superior to trifluoroacetic acid (TFA)
(pKa = 0.23) in terms of 5′-desilylation selectivity with 2′,5′-disilylated nucleosides.151

These conditions had previously been successful for the benzoyl protected compound 15
during my Honours work (52%). The key literature precedent that led to use of these
conditions described the selective TBS deprotection of the corresponding bis-TBS
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protected uridine (Scheme 3.6). Although very similar in structure, it was predicted that
the extra 2'-hydroxyl group in the protected uridine would add more steric hindrance
around its 2° alcohol, thus driving preferential deprotection of the 1° alcohol leading to
the very high yield (98%). Based on this, lower selectivity was expected for the monodeprotection of the less hindered 20.

Scheme 3.6 Literature precedent reporting selective 1° alcohol TBS-deprotection of
uridine.151

The first attempted mono-deprotection of 20 gave 21 in 50% yield. The structures of the
side products were tentatively identified using 1H-NMR, with the reaction producing 20%
of recovered starting material 20, ~6% of the unwanted 2° mono alcohol and 25% of the
bis-deprotected compound (Figure 3.4).

Figure 3.4 Typical yields of recovered starting material, the desired mono-alcohol 21 and
two side products formed during TCA deprotection of 20.

The deprotection of 20 was completed using 40 eq. of TCA in 1:4 H2O/THF a total of
seven times on increasing scale (0.1 g, 0.4 g, 0.8 g, 2.3 g, 3.9 g, 17.9 g and 29.7 g of 20).
The respective yields obtained were 50%, 39%, 47%, 42%, 46%, 31% (over 2 steps) and
37% (over 2 steps). The two larger scale reactions were carried out using crude 20 and
purified only after TBS deprotection for practical reasons. Hence, their yields were
consistent with the other reactions. A total of 17.3 g of 21 was synthesised over the course
of my PhD.
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Spectroscopic Evidence for the Formation of 21

Removal of one TBS protecting group was evident in the 1H-NMR spectrum of 21 from
loss of half of the TBS peaks originally present for 20 (Figure 3.5). The disappearance of
the corresponding three peaks in the 13C-NMR spectrum of 21 also supported successful
removal of one TBS protecting group. Additionally, the 1H-NMR data showed a slight
chemical shift in the methylene signal adjacent to the revealed primary alcohol (20  3.95
ppm, 21  3.93 ppm) supporting that it was indeed the primary alcohol that had undergone
selective deprotection. Finally, observation of the expected M+H+ ion at m/z 525.2068 by
high resolution mass spectrometry confirmed the structure of 21.

Figure 3.5 Removal of one TBS group halved the number of TBS signals detected in
1

H-NMR (CDCl3) of 21 (relative to 20).

3.5

Steglich Esterification of 21

In the literature there are only a few examples of esterification reactions with nucleosides
and none with the fluorinated floxuridine. One relevant example, however, coupled a
structurally similar TBS-protected thymidine and an alkyl carboxylic acid using
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) and DMAP in dichloromethane
(55%, Scheme 3.7).

Scheme 3.7 Literature precedent demonstrating esterification of TBS-protected
thymidine.156
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I found during my 2014 Honours studies that 2-(2-nitrophenyl)acetic acid could be
esterified with the related benzoyl-protected compound 16 under similar Steglich
esterification conditions using dicyclohexylcarbodiimide (DCC; instead of EDCI) to
provide ester 17 in 80% yield (Scheme 3.1).157 When the same (DCC) conditions were
trialled on compound 21 during my PhD, the product 22 was formed in very high yield
(Scheme 3.8). The reaction was carried out a total of five times on increasing scale 0.05
g (43%), 0.2 g (82%), 1.7 g (66%), 4.7 g (92%), 9.3 g (87%). In all cases the reaction
proceeded well, with lower yields in some reactions observed only because of purification
challenges due to the large amount of dicyclohexylurea (DCU) by-product formed. A
process for removing the urea by-product was identified whereby cooling the mixture
upon completion of the reaction to – 20 °C overnight in a freezer caused the DCU to
precipitate. The mixture could then simply be filtered and washed with cold
dichloromethane before standard extraction and purification. This key improvement to
the workup procedure led to consistently high yields at multi-gram scale. In total 17.8 g
of pure 22 was synthesised.

Scheme 3.8 Steglich esterification of 21 with 2-(2-nitrophenyl)acetic acid gave 22 in
excellent yield.

3.5.1

Mechanism of Steglich Esterification

The Steglich esterification uses DCC as the coupling reagent and DMAP as a nucleophilic
catalyst (Scheme 3.9). The reaction begins with the neutralisation of the carboxylic acid
with DMAP acting as the base. Once neutralised, the carboxylate nucleophile attacks
DCC, whose nascent anion is then protonated by the pyridinium salt of DMAP to
regenerate the catalyst. DMAP then displaces DCC from the carboxylic acid to form a
highly reactive acyl pyridinium salt, with DCU formed in this process as a by-product.
The nucleophilic alcohol then attacks the carbonyl group of the acyl pyridinium ion to
form the ester bond and regenerate the DMAP catalyst.
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Scheme 3.9 Mechanism for the DCC-mediated Steglich esterification of 21 with 2-(2nitrophenyl)acetic acid to form 22.

3.5.2

Spectroscopic Evidence for the Formation of 22

Addition of the 2-(2-nitrophenyl)acetic acid group to 21 produced several new signals in
the aromatic region of the 1H NMR spectrum of 22 (Figure 3.6), including two new
doublets of doublets and two new triplets of doublets. These splitting patterns arise from
the ortho and meta coupling of each of the new aromatic protons in the 2-(2nitrophenyl)acetic acid phenyl ring. The downfield doublet of doublets at 8.17 ppm is
de-shielded due to the presence of the ortho nitro group. The benzylic methylene protons
were obscured by the ribose C-O signals in the 1H-NMR spectrum but they were evident
from the integration and signals in the

13

C NMR spectrum. In the

13

C NMR spectrum

eight new peaks (relative to 21) were observed, supporting successful introduction of the
2-(2-nitrophenyl)acetic group. Finally, observation of the expected M+H+ ion at m/z
688.2338 by high resolution mass spectrometry confirmed the structure of 22.
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Figure 3.6 Steglich esterification produced diagnostic aromatic signals in the 500 MHz
1

H-NMR spectrum (CDCl3) of 22.

3.6

Knoevenagel Condensation of 22

The key step in the synthesis of 2 was the Knoevenagel condensation of 22 with pyrrole
aldehyde 7. Previous attempts at the Knoevenagel condensation between 17 and 7 during
my Honours year (Scheme 3.1) produced only low yields of (Z)-18 (4%) and (E)-18 (6%).
This was partially attributed to the unstable benzoyl protecting group, which would
deprotect during the reaction. With the more stable 2,4-dimethoxybenzoyl protecting
group newly installed on 22, disappointingly, only a minor improvement was seen using
the standard Knoevenagel conditions ((Z)-23, 10% and (E)-23, (11%), Scheme 3.10).
Substantial quantities of the starting material (55% recovery of 22) remained unreacted
and could be resubmitted to the reaction. Despite this, the yield of the reaction was still
very low thus significant effort was invested into identifying reaction side-products to
understand what was limiting formation of the desired product.

The first side product identified was the pyrrolizinone 11, as observed previously in the
Knoevenagel condensation with 6 in section 2.5.2. However, 11 appeared to form only in
small quantities (<1% yield) so this did not explain the low reaction yield (Scheme 3.10,
B). The major side-product of the reaction was identified as the methyl carbonate ester of
the protected floxuridine 25 (20%, Scheme 3.10, B).
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Scheme 3.10 A) Knoevenagel condensation of 22 with pyrrole aldehyde 7 gave (Z)-23
and (E)-23 in modest yields. B) Starting material 22 and side products 11 and 25 were
also isolated from the reaction.

3.6.1

Proposed Mechanism for the Formation of 25

To explain the formation of side product 25, a mechanism was proposed involving the
formation of methoxide after loss of the N-methylcarbamoyl protecting group of pyrrole
aldehyde 7 (Scheme 3.11, A). During the Knoevenagel reaction, the methyl carbamate
protecting group is probably lost as methyl carbonate, as explained in section 2.5.1. The
methyl carbonate group could decompose into carbon dioxide and methoxide. The
methoxide formed could then deprotect unreacted pyrrole aldehyde 7, releasing dimethyl
carbonate (Scheme 3.11, B). The ability of methoxide to deprotect the pyrrole aldehyde
7 was chemically confirmed by stirring a small amount of the pyrrole aldehyde 7 in THF
with sodium methoxide, which led to quantitative deprotection. An equivalent of
methoxide could also cleave the ester bond in the starting material 22 by
transesterification (Scheme 3.11, C), releasing methyl 2-(2-nitrophenyl)acetate and
protected floxuridine derivative 21. However, methyl 2-(2-nitrophenyl)acetate was not
observed in the complex mixture of products and was only inferred from the proposed
mechanism. The 1° alcohol group of 21 could then react with the newly formed dimethyl
carbonate, regenerating methoxide and producing the methyl carbonate side product 25.
One piece of evidence that supports this mechanism is the ratio of products to the side
product 25. In the mechanism proposed, only one molecule of 25 could form from each
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molecule of (Z)-23 or (E)-23. This would explain why the yield of 25 is the same as the
total yield of cis- and trans-23.

Scheme 3.11 Proposed mechanism for the formation of methoxide during the
Knoevenagel reaction and subsequent formation of the major side-product 25.

3.6.2

Attempts to Optimise the Knoevenagel Reaction

The hypothesis that methoxide was being formed in the reaction was tested by adding
methoxide

scavengers

(Table

3.2).

The

first

scavenger

trialled

was

tert-Butyl(chloro)diphenylsilane (TBDPSCl) a silylating reagent that is very reactive
towards oxygen nucleophiles like methoxide. However, no improvement was seen in the
reaction yield. The next idea was to add different sized molecular sieves (3-5 Å) capable
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of sequestering methoxide (and water). Of these reactions, only the 3 Å molecular sieves
produced any product but no improvement in the reaction yield was seen.

Table 3.2 Knoevenagel reactions performed in the presence of methoxide scavengers.

Entry

Methoxide Scavenger

(Z)-23 (%)

(E)-23 (%)

1

TBDPSCl

~10

~10

2

3 Å Ground Molecular Sieves

~10

~10

3

4 Å Ground Molecular Sieves

No Reaction

No Reaction

4

5 Å Ground Molecular Sieves

No Reaction

No Reaction

In addition to exploring methoxide scavengers, a series of alternative N-protecting groups
for the pyrrole-2-aldehyde were considered as a means of improving the reaction yield.
These protecting groups considered were trifluoroacetyl, trimethylsilyl and mesyl groups
(Scheme 3.12).

Multiple attempts at generating the N-trifluoroacetyl pyrrole using trifluoroacetic
anhydride led only to formation of polymeric products. It was thought that the
trimethylsilyl protecting group might add to the aldehyde to form the silyl enol ether due
to silicon’s high affinity for oxygen. However, this did not occur and once again only
polymeric by-products were formed.

Mesylation of the pyrrole-2-aldehyde with mesyl chloride/KH gave a low yield of 26
(27%) but it provided sufficient material to trial some Knoevenagel reactions. The
mechanism of mesylation proceeds in a similar fashion to carbamoylation with methyl
chloroformate to form 7. First, potassium hydride abstracts the pyrrole N-H to form the
potassium pyrrolate salt, which then acts as a nucleophile to attack the mesyl chloride
sulphur atom and displace chloride as the leaving group.
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Scheme 3.12 Attempts to synthesise alternative N-protected pyrrole-2-aldehydes for use
in the Knoevenagel reaction.

The mesyl-protected pyrrole aldehyde 26 was submitted to model Knoevenagel reactions
with ethyl 2-(2-nitrophenyl)acetate as a simple surrogate for 22 (Scheme 3.13, A). No
desired product was formed under the usual conditions, with 26 instead undergoing Smethyl deprotonation followed by intramolecular cyclisation onto the neighbouring
aldehyde, yielding 27 (Scheme 3.13, B). Once formed, 27 was unstable and could only
be briefly characterised by 1H and 13C NMR as the nascent alcohol eliminated water to
give the stable novel N-heteroaryl fused vinyl sultam 28 (Scheme 3.13, B).

Scheme 3.13 N-Mesyl pyrrole aldehyde 26 did not undergo the desired Knoevenagel
reaction but instead formed a N-heteroaryl fused vinyl sultam, the first example of a
compound from this class.
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At the time of synthesis (March 2016), 27 and 28 were both novel structures, with the
fused pyrrole sulfone being a unique heterocyclic ring system. At the end of 2017,
however, the group of Laha et al published three articles describing the same bicyclic ring
system.158-160 In their work, a series of N-heteroaryl fused vinyl sultams were synthesised
and their chemistry explored (Figure 3.7).

Figure 3.7 Published series of pyrrole N-heteroaryl fused vinyl sultams related to
compound 28 and their versatile chemistry.159

Although low yielding, the original Knoevenagel conditions were able to deliver
sufficient quantities of (Z)-23 to allow completion of the synthesis. The ability to resubmit
recovered starting material 22 to repeat reactions allowed enough prodrug 2 to be
synthesised for all chemical and biological studies (Chapter 4). The reaction was
completed six times on increasing scale (0.1 g, 1.0 g, 1.5 g, 3.4g, 4.9g, 5.0g of 22) with
consistent (albeit low) yields. A total of 1.0 g of (Z)-23 was synthesised during my PhD
work.

The trans product (E)-23, was substantially more difficult to obtain pure than (Z)-23, due
to its increased polarity. This gave it a Rf very close to the starting material 22 and the
N-methylcarbamoyl deprotected derivative of 7. Isomerisation of a small quantity (~30
mg) (E)-23 using catalytic H2SO4 in THF gave similarly poor results as (E)-8, observed
by TLC. It was instead found to be practically more convenient to focus on recovery of
unreacted starting material 22 and performing multiple reactions to obtain (Z)-23.
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Spectroscopic Evidence for the Formation of (Z)-23

Addition of the pyrrole fragment led to several new signals appearing in the aromatic
region of the 1H NMR spectrum of (Z)-23 relative to 22 (Figure 3.8). A broad singlet
appeared at 11.73 ppm, corresponding to the pyrrole N-H hydrogen bonded to the nearby
carbonyl oxygen of the ester group (see Section 2.5.3). This observation confirmed that
the cis isomer had been isolated as the same peak in (E)-23 appeared at 6.71 ppm,
consistent with our previous findings. The intramolecular H-bond in (Z)-23 made the
compound significantly less polar than (E)-23 making the two isomers easily separable
by silica gel column chromatography. A singlet was observed at 6.85 ppm corresponding
to the newly introduced alkene hydrogen. A tight doublet at 5.94 ppm with very fine
splitting corresponded to the aromatic proton on the pyrrole (H13′′), which showed 4JH,H
coupling (1.5 Hz) to the pyrrole N-H (H11′′).

Figure 3.8 Downfield region of the 500 MHz 1H-NMR (CDCl3) spectrum of (Z)-23
showing all of the expected signals, including the highly deshielded pyrrole N-H signal
indicating the presence of an H-bond to the ester carbonyl oxygen.

The CH2 signal of the 2-nitrophenlacetyl fragment of 22 had disappeared in (Z)-23 and
two new singlets at 2.36 and 2.18 ppm had appeared, each showing an integration of 3H.
These singlets corresponded to the two methyl groups on the newly introduced pyrrole
moiety. In the

13

C NMR spectrum, seven new carbon peaks were observed, consistent

with introduction of the pyrrole. Finally, observation of the expected M+H+ ion at m/z
793.2916 by high resolution mass spectrometry confirmed formation of (Z)-23.
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2,4-Dimethoxybenzoyl Deprotection of (Z)-23

With the core structure of 2 in place, the final two steps in the synthesis involved
removing the 2,4-dimethoxybenzoyl and TBS protecting groups of (Z)-23. It was
postulated that in deprotecting the 2,4-dimethoxybenzoyl protecting group first, the TBS
protecting group would sterically shield the potentially liable ester of (Z)-23 from
ammonolysis, leading to a higher yield over these two final steps. The closest literature
precedent for the reaction reported the quantitative benzoyl deprotection of N3-benzoyl3′,5′-O-(di-tert-butylsilanediyl)-2′-O-methyluridine using methanolic ammonia (Scheme
3.14).161

Scheme 3.14 Literature precedent for benzoyl deprotection of a structurally related
uridine derivative.161

Before committing any of the advanced intermediate (Z)-23 to the debenzoylation
reaction, a model reaction was investigated using the more freely available precursor 20
(Scheme 3.15). The reaction was found to proceed in quantitative yield after two hours.

Scheme 3.15 Model 2,4-dimethoxybenzoyl deprotection reaction with 20 delivered 14 in
quantitative yield.

Encouraged by this finding, deprotection the (Z)-23 was attempted on 100 mg scale using
2 mL of 7 N methanolic ammonia, which delivered the desired 24 in 82% yield (Table
3.3, Entry 1).
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Table 3.3 2,4-Dimethoxybenzoyl deprotection of (Z)-23.

Entry

(Z)-23 (mg)

7N NH3/MeOH (mL)

24, % Yield

1

104

2

82

2

204

4

79

3

300

6

75

The reaction was repeated two more times on 200 mg and 300 mg scales, with both
reactions providing over 75% yields. A total of 374 mg of 24 was produced from the three
reactions.

3.7.1

Spectroscopic Evidence for the Formation of 24

Successful deprotection of the 2,4-dimethoxybenzoyl group was evident in the 1H NMR
spectrum of 24, with all signals arising from this group disappearing (Figure 3.9). Within
the aromatic region, in (Z)-23 disappearance of the two doublets and one doublet of
doublets from the 2,4-dimethoxybenzoyl was accompanied by the appearance of a broad
singlet at 8.43 ppm integrating for 1H, corresponding to the newly formed 5-fluorouracil
N-H. Within the aliphatic region, two singlets at 3.85 and 3.71 ppm integrating for 3H in
the spectrum of 23 were absent in 24, consistent with loss of the two methoxy groups.
The disappearance of nine peaks in the

13

C NMR spectrum supported successful

deprotection. Finally, observation of the expected M+H+ ion at m/z 629.2443 by high
resolution mass spectrometry confirmed formation of 24.
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Figure 3.9 Downfield region of the 500 MHz 1H-NMR (CDCl3) spectrum of 24.

3.8

TBS Deprotection of 24 to Mutual Prodrug 2

The final reaction in the synthesis of 2 was removal of the TBS protecting group from the
secondary alcohol. The closest literature precedent for this reaction involved a high
yielding (72%) TBS-deprotection of the secondary alcohol of a deoxyuridine derivative
(Scheme 3.16).162

Scheme 3.16 Literature precedent showing TBS-deprotection of a deoxyuridine
derivative.162

Using the same conditions as in the literature precedent, the first attempted deprotection
with 65 mgs of 24 delivered 24 mg of 2 (Table 3.4, 49% yield). The reaction appeared to
proceed well by TLC analysis, but the impurities were difficult to separate from 2 by
standard column chromatography on silica gel. The reaction was repeated two more times
using 128 mg and 177 mg of 24. Different chromatography solvents were trialled in
attempts to simplify isolation of 2. Eventually it was discovered that 2 could be obtained
in pure form (69% yield) using silica gel column chromatography with a gradient of
0-50% acetone in pet. spirit. A total of 301.6 mg of 2 was produced from these reactions.
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Table 3.4 Optimisation of Purification of TBAF deprotection of 24.

Entry

24 (mg)

1M TBAF (mL)

Chromatography Solvent

2, % yield

1

65

0.5

Ethyl acetate/Pet. Spirit

49

2

128

1.0

MeOH/CH2Cl2

66

3

177

1.5

Acetone/Pet. Spirit

69

3.9

2D Spectroscopic Analysis of 2

Full 2D NMR characterisation of 2 was undertaken after completion of the synthesis.
Within the aromatic region of the 1H-NMR, all protons were successfully accounted for
(Figure 3.10). The prodrug was confirmed as the correct cis isomer by the presence of the
heavily deshielded pyrrole N-H signal (H-11′′,  11.66 ppm) arising from its
intramolecular hydrogen bond to the nearby ester carbonyl oxygen (C-1′′). In CDCl3, both
the imide N-H (H-3) and the deprotected 2° alcohol proton (H-6′) exchanged with solvent
deuterium and did not appear in the spectrum.

Figure 3.10 Aromatic region of the 500 MHz 1H-NMR spectrum of 2 recorded in CDCl3.

Removal of the TBS group saw loss of its characteristic singlet at 0.87 ppm and associated
apparent doublet at 0.06 ppm (Figure 3.11). The ribose CH2 signal (H2ʹ) was obscured by
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the CH3 methyl signal (H15ʹʹ). The presence of this signal was confirmed from the 5H
integration of the peak at 2.15 ppm, and from the gHSQC spectrum.

Figure 3.11 Aliphatic region of the 500 MHz 1H-NMR spectrum of 2 recorded in CDCl3.

3.9.1

13

C APT Analysis of 2

The 13C APT spectrum of 2 was complex due both to the large number of unique chemical
environments of the carbons within the molecule and also the splitting of peaks that
occurs due to the presence of the fluorine atom at C5 (Figure 3.12). The fluorine atom
causes the peak for C5 measured (140.4 ppm) to split into a doublet with a coupling
constant of J = 236.7 Hz. This falls within the literature range for a typical C-F coupling
constant (162 – 280 Hz).163 The adjacent carbons C4 (157.2 ppm) and C6 (123.7 ppm)
were also split into doublets with coupling constants J = 27.0 Hz and J = 33.3 Hz,
respectively.
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Figure 3.12 Aromatic and Aliphatic regions of the 500 MHz

13

C-NMR spectrum of 2

recorded in CDCl3.

3.9.2

gCOSY Analysis of 2

The gCOSY spectrum of 2 showed the expected correlations around the nitroaromatic
ring (Figure 3.13). These correlations helped to assign H6ʹʹ and H7ʹʹ starting from the
diagnostic H5ʹʹ doublet, which is deshielded due to its location ortho to the electron
withdrawing nitro group.
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Figure 3.13 Selected correlations observed in the 500 MHz gCOSY spectrum of 2 (with
diagonal suppression) recorded in CDCl3.

3.9.3

gHSQC Analysis of 2

Correlations for each proton-attached carbon were observed in the aromatic (Figure 3.14)
and aliphatic (Figure 3.15) regions of the gHSQC spectrum of 2. The gHSQC revealed
the location of the ‘hidden peak’ for H1ʹ, which was obscured by the pyrrole methyl H15ʹʹ
peak at 2.15 ppm. The gHSQC also allowed for assignment of each of the non-quaternary
carbons within 2.

Figure 3.14 Aromatic region of the 500 MHz gHSQC spectrum of 2 recorded in CDCl3.
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Figure 3.15 Aliphatic region of the 500 MHz gHSQC spectrum of 2 recorded in CDCl3.

3.9.4

gHMBC Analysis of 2

The gHMBC of 2 showed many correlations within 2 due to the large number of
individual carbon environment in the molecule. Of key interest in the aromatic region
(Figure 3.16) was the C-H correlations between C3ʹʹ and H5ʹʹ, 7ʹʹ and 9ʹʹ and C14ʹʹ and
H9ʹʹ, which allowed the overlapping peaks of C3ʹʹ and C14ʹʹ to be differentiated.

Figure 3.16 Aromatic region of the 500 MHz gHMBC spectrum of 2 recorded in CDCl3.

The Aliphatic region of the gHMBC spectrum of 2 (Figure 3.17) was useful for assigning
the methyl signals for H15ʹʹ and H16ʹʹ, which could not be distinguished by 1H-NMR
alone. was Assignment was evident from the the correlations that H15ʹʹ made to C9ʹʹ and
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C10ʹʹ, beyond the range expected for correlations from H16ʹʹ. In comparison, H16ʹʹ only
made the correlations to C12ʹʹ and C13ʹʹ.

Figure 3.17 Aliphatic region of the 500 MHz gHMBC spectrum of 2 recorded in CDCl3.

3.10

Summary of the Synthesis of 2

The total synthesis of 2, having been originally attempted on small scale during my
Honours year, was improved and successfully scaled up to provide sufficient
semaxanib|floxuridine mutual prodrug 2 for chemical and biological testing (Chapter 4).
The synthesis was completed in 7 steps in an overall yield of 2.1% (Scheme 3.17) to
produce a total of 301.6 mg of pure mutual prodrug 2. The synthesis still poses challenges
that should be addressed in the future, especially the problematic Knoevenagel
condensation where a maximum yield of only 10% (21% combined cis/trans) was
obtained after considerable optimisation attempts. To improve both this synthesis and the
previously discussed synthesis of the mutual prodrug 1, work carried out in Chapter 5
showed that moving the Knoevenagel reaction to earlier in the synthesis is a promising
alternative route.
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Scheme 3.17 Summary of the completed synthesis of 2. Total quantities of each
compound produced over the course of my PhD are shown.
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Chapter 4: Proof-of-Concept Chemical Reductions and
in vitro Biological Evaluation
4.1

Proof-of-Concept Chemical Reductions

Chemical reactions were performed on 1 and 2 to establish whether spontaneous
intramolecular cyclisation occurred following reduction of the arylnitro group, leading to
release of semaxanib (SU5416) 3 and the respective cytotoxins; floxuridine and 4aminoaniline mustard, from the prodrugs. It was anticipated that partial reduction of the
nitro group and spontaneous cyclisation of the intermediate hydroxylamine might also
occur, resulting to formation of the N-hydroxyindolin-2-one 29 (Figure 4.1). To probe
these processes, reduction of the two mutual prodrugs was investigated using three
standard nitroaromatic reduction conditions: (a) Fe(0) in CH3COOH:EtOH:H2O (1:1:1)
with sonication,164 (b) FeCl3.6H2O/Zn in DMF:H2O (1:1)165 and (c) NaBH4/Pd-C in
MeOH:H2O (2:1).166

Figure 4.1 Proof-of-concept chemical reduction reactions performed with mutual
prodrugs 1 and 2.

4.1.1

Mechanism of Chemical Nitroaromatic Reductions

The mechanism of arylnitro group reduction involves a series of electron transfers, proton
transfers and dehydration steps to achieve the 6-electron reduction. The exact sequence
of these events has been the subject of many detailed electrochemical studies. In the first
example with Fe(0), nitro reduction may be initiated by electron transfer to form an anion
radical167 or by protonation to form a cation capable of accepting an electron.168 The
reduction proceeds via in stepwise fashion, first to the nitrosobenzene (which is not
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commonly isolatable),169 followed by reduction to the more stable hydroxylamine and
finally the desired amine. The FeCl3.6H2O/Zn reaction proceeds in a similar fashion,
although the Fe(III) needs to initially be reduced by Zn(0) to Fe(0) and the zinc oxidised
to Zn(II) via the reaction:
3 Zn + 2 FeCl3 → 3 ZnCl2 + 2 Fe
The Fe(0) species is then capable of reducing the nitrobenzene in an analogous process
to the above reaction. The NaBH4/Pd-C reduction doesn’t invoke radical processes,
instead reducing the arylnitro group by addition of hydride ions from a palladium on
activated carbon catalyst.

4.1.2

Arylnitro Chemical Reduction Measurements

The chemical reductions were monitored by TLC analysis. The reactions were quenched
after complete consumption of the starting material by filtering through celite. Reactions
were all conducted on a 30 mg scale and the isolated yields of 3 and 29 were determined
after purification by preparative TLC (Table 4.1). Isolation and quantitation of the yields
of the 4-aminoaniline mustard and floxuridine cytotoxins was not performed as these are
inferred from formation of indoline-2-ones 3 and 29. In the case of the 4-aminoaniline
mustard, isolation was not possible anyway as the compound is highly unstable and
rapidly decomposes (personal observation).

Table 4.1 Chemical reduction reactions performed on mutual prodrugs 1 and 2
Prodrug
1

2

Reduction

Yield 3

Yield 29

Yield 3+29

(%)

(%)

(%)

1

80

14

94

DMF/H2O

3

53

32

85

NaBH4/Pd-C

MeOH/H2O

0.5

43

37

80

Fe/CH3COOH

EtOH/H2O

1

84

11

95

FeCl3.6H2O/Zn

DMF/H2O

3

40

51

91

NaBH4/Pd-C

MeOH/H2O

0.5

37

45

82

Solvent

t (h)

Fe/CH3COOH

EtOH/H2O

FeCl3.6H2O/Zn

Conditions

Semaxanib 3 was isolated from all reactions within 0.5-3 h in yields ranging from
37−84%. N-hydroxy semaxanib 29 was also isolated in 11-51% yield. The combined
yields of indoline-2-ones 3 and 29 were thus invariably high (80-94%), indicating that
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cyclisation after reduction within the scaffold is highly favoured. Downfield-shifting of
the pyrrole-NH signals in the 1H NMR spectrum of 1 ( 12.04 ppm) and 2 ( 11.66 ppm)
had confirmed the presence of an intramolecular hydrogen bond between the pyrrole-NH
and carbonyl oxygen atoms in these prodrugs (Section 1.13).138 It seems likely therefore
that this H-bond in 1 and 2 is acting as a pseudo-acid catalyst to promote spontaneous
indolin-2-one cyclisation after reduction.

The success of these reduction reactions provided chemical proof-of-concept that these
compounds could potentially do the same in vivo, thus justifying cell-based evaluation of
their biological activity as a hypoxia-activated anti-tumour mutual prodrugs (Section 4.2).

Formation of N-hydroxy semaxanib 29 in the reactions, while not ideal, was not
considered a major concern as this compound is also a potent inhibitor of VEGFR-2.170
Therefore, if the prodrugs were to be used in vivo, ejection of 29 directly into a tumour in
addition to 3 after hypoxia activation would also be expected to contribute to anti-tumour
effects.

4.2

In Vitro Biological Evaluation of 1 and 2

Preliminary biological testing of 1 and 2 was carried out at the University of Auckland
by A/Prof. Adam V. Patterson, Dr. Jeffery B. Smaill and Dr. Christopher P. Guise using
MDA-MB-468 triple-negative breast cancer cells and SW620 colon cancer cells.128 For
prodrug 1, melphalan was selected as the clinically relevant nitrogen mustard control171
and for prodrug 2 the comparator was Floxuridine. Melphalan is commonly used in the
treatment of multiple myeloma, ovarian cancer, neuroblastoma, rhabdomyosarcoma and
breast cancer. The breast cancer cell line MDA-MB-468 was chosen for use in this study
as it has previously been shown to be sensitive to nitrogen mustards.172-173 Floxuridine is
used to treat advanced colon, kidney and stomach cancers. Colon cancer cell line SW620
was selected for use as it has been shown to be sensitive to both floxuridine and 5-FU.174175

Tirapazamine (Section 1.10.2) and TH-302 (Section 1.12.2) were chosen as hypoxia-

activated cytotoxin positive controls for the assay. Tirapazamine has previously been
demonstrated to show excellent hypoxia selectivity (100-200 fold) in cell suspension
cultures.107 TH-302 has shown up to 300-fold hypoxia-selective activity in HNE-1
cells.121 The compounds sent for preliminary biological testing were all determined to be
>90% pure by 1H NMR analysis.
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The prodrugs were assessed first for their degree of deactivation relative to their cytotoxin
control compounds under aerobic conditions (Table 4.2). The degree of prodrug
deactivation

was

determined

using

the

deactivation

ratio

(DR

=

aerobic

IC50prodrug/aerobic IC50control). The degree of hypoxia-selective cytotoxic activation was
determined as the hypoxic cytotoxicity ratio (HCR), which shows whether the cells are
more sensitive to the prodrugs and effectors under anoxic conditions (HCR = aerobic
IC50prodrug/anoxic IC50prodrug).

Table 4.2 In vitro evaluation of the hypoxia-selective cytotoxicity of drug treatments.
Cell line

Drug

DRa

HCRb

1.00  0.11

0.81  0.16

-

1.2-fold

Floxuridine

27.42  12.52

45.53  6.10

-

<1-fold

1

8.31  0.95

7.38  0.88

8.3-fold

1.1-fold

83.88  40.93 247.96  80.56 3.1-fold

<1-fold

MDA-MB-468 Melphalan

2

SW620

Aero IC50 (µM) Anox IC50 (µM)

Tirapazamine

105.2

1.304

-

81-fold

TH-302

4.403

0.0062

-

710-fold

Melphalan

1.81  0.25

1.22  0.10

-

1.5-fold

Floxuridine

0.96  0.40

1.48  0.53

-

<1-fold

1

11.48  6.57

12.67  4.93

6.3-fold

<1-fold

2

18.70  14.81

13.96  5.39 19.4-fold

1.3-fold

Tirapazamine

91.03

1.2

-

76-fold

TH-302

20.6

0.052

-

396-fold

Sensitivity of MDA-MB-468 and SW620 cells to hypoxia-activated mutual prodrugs 1
and 2 and their parent cytotoxins under aerobic (Aero) and anoxic (Anox) conditions.
Antiproliferative IC50 values are shown (mean  std dev, n = 3). The activity of two
positive control hypoxia-activated cytotoxins Tirapazamine96 and TH-302121 are included
for comparison (n = 1). aThe deactivation ratio (DR) indicates the degree of deactivation
of the prodrug relative to the effector under aerobic conditions (i.e. DR = Aero prodrug
IC50/Aero control cytotoxin IC50). bThe hypoxic cytotoxicity ratio (HCR) indicates
whether cells are more sensitive to the prodrugs or effectors under anoxic conditions
(HCR = aerobic IC50/anoxic IC50).
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For prodrug 1, 8.3-fold and 6.3-fold deactivation was observed in the two cell-lines, while
3.1-fold and 19.4-fold deactivation was seen with 2. It is proposed that for 1, the amide
bond pulls electron density away from the mustard nitrogen, leading to decreased DNA
reactivity (and hence cytotoxicity) in the prodrug. In the case of 2, Floxuridine is an
antimetabolite that would be inactivated by the ester linkage to the bulky
2-(2-nitrophenyl)acetate moiety. The deactivation observed with prodrug 2 relative to
floxuridine suggests that the ester bond remained intact under the assay conditions.
The ability of the prodrugs to undergo nitroaromatic bioreduction and cyclisation to
release the respective cytotoxins was determined using the hypoxic cytotoxicity ratio
(HCR = Aerobic IC50/Anoxic IC50). Under the assay conditions used here, unfortunately
neither prodrug showed evidence for activation under anoxia.

The two positive controls Tirapazamine and TH-302 both showed substantial activation
under hypoxic conditions, with Tirapazamine displaying 76-fold and 81-fold activation
in the cell lines and TH-302 showing 710-fold and 396-fold activation under anoxic
versus aerobic conditions. These positive control results confirmed that the assays were
able to detect hypoxic activation, and were in agreement with the reportedly high hypoxic
selectivity of Tirapazamine (100-200 fold in cell suspension cultures).107 Similarly, the
results generated for TH-302 matched quite well with previous reports showing 300-fold
hypoxic activation in HNE-1 cells.121
Both parent control drugs melphalan and floxuridine didn’t show any increased activation
under hypoxia. This was expected as both cytotoxins that act via reaction
with/misincorporation into DNA rather than through hypoxia-driven processes. An
explanation for why mutual prodrugs 1 and 2 were unable to be activated and show
enhanced cytotoxicity under hypoxic conditions was explored next.

4.3

Pulse Radiolysis One-Electron Reduction Potential Measurements

To examine one possible reason for why 1 and 2 did not show enhanced cytotoxicity
under anoxia, one-electron reduction potentials (E[1]) for the arylnitro groups in the
prodrugs were explored. It is accepted that nitroaromatic prodrugs show greatest hypoxiaselective activation when E[1] falls within the range −330 to −450 mV.176 Nitroaromatics
that fall below this range typically are unable to be effectively reduced by cellular
reductases. Tirapazamine, which performed well in the above assay, contains an aromatic
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di-N-oxide with a one-electron reduction potential at the bottom of this desired range
(E[1] = −450).177 The positive control compound TH-302, which contains a
nitroimidazole, also displays a one electron reduction potential within the desired range
(E[1] = −407 mV).178

Pulse radiolysis was the technique used to measure the 1-electron reduction potential of
the 1 and 2. This technique characterises the electron affinity of nitroaromatic compounds
and, by inference, their willingness to accept an electron from human oxidoreductases.
Fast reaction chemistry experiments were performed on the University of Auckland’s 4
MeV DYNARAY linear accelerator using a PC-controlled, custom-built optical
absorption detection system. These experiments were performed by A/Prof. Robert F.
Anderson. Background on the experiments is provided below.

Pulse radiolysis is a fast-kinetic method of initiating and studying reactions occurring on
a timescale faster than approximately one hundred microseconds. The technique involves
exposing a sample of material to a beam of accelerated electrons (2-10 MeV) generated
by a linear accelerator (Figure 4.2). The pulse duration is usually 2-200 ns long and
directed towards a sample contained in a quartz or glass cell. The resulting chemical
reactions are monitored using UV-visible absorption spectroscopy. A UV-visible source
of light is directed into the sample perpendicular to the electron beam. After passing
through the sample, the light is diffracted by a monochromator, the signal is enhanced by
a photomultiplier and then recorded by an oscilloscope/computer.

Figure 4.2 Schematic of pulse radiolysis experiments.179
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The data contained within the absorption spectra allows identification of free radicals and
the kinetics of their formation and decay. This process has been used routinely to study
nitroaromatic compounds and their one-electron nitro radical anion reduction
products.180-181

4.3.1

Reduction Potential Measurements with 2

A stock solution of prodrug 2 was prepared in 0.42 M tert-butanol, 5 mM phosphate
buffer (pH 7). A UV-visible spectrum was recorded to obtain the extinction coefficient,
which was used to determine the concentration of the compound in test solutions. Oneelectron reduction of the compound (2, 50 M) by the e-aq was carried out by pulse
radiolysis (3 Gy in 200 ns) of deaerated phosphate buffered solutions (2.5 mM, pH 7)
containing tert-butanol (0.1 M to scavenge the ∙OH and ∙H radicals). Bleaching of the
ground state at 400 nm (−5.55 mAbs Gy-1) and absorbance increases at 350 nm (+2.71
Gy-1) gave relatively stable transients over 10 ms (Figure 4.3).

Figure 4.3 Changes in UV-vis absorption with sequential doses of -irradiation of 2 in an
evacuated solution containing formate ions (25 mM) at pH 7 (after initial removal of a
small contaminant concentration of O2).
Redox equilibrium was established against triquat (TQ2+, Figure 4.4) (E(1) = −548 ± 7
mV) for three mixtures of 2 / TQ2+: 100-400 M / 50 M and controls (at 385 nm).
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K
TQ2+ + 2.-

TQ+. + 2

Kav. = 4.69 ± 0.69 E = −(RT/F)(lnK) = 40 ± 4 mV Ecor = −11 mV (ionic strength)
E(2/2.-) = −509 ± 8 mV

Figure 4.4 Chemical structure of viologen triquat (TQ2+) used to establish redox
equilibrium.

4.3.2

Reduction Potential Measurements with 9

Reduction potential measurements for 1 were hampered by poor aqueous solubility so the
measurements were instead obtained with its bis-alcohol precursor 9 as a proxy. It was
rationalised that the remoteness of the alcohols from the arylnitro group should limit their
influence on the reduction potential, whilst increasing aqueous solubility. A stock
solution of 9 was prepared in 0.42 M tert-butanol, 5 mM phosphate buffer (pH 7). A UVvis spectrum was recorded to obtain the extinction coefficient, which was used to
determine the concentration of the compound in test solutions. One-electron reduction of
9 (85 M) was carried out by pulse radiolysis (3 Gy in 200 ns) of deaerated phosphate
buffered (2.5 mM, pH 7) solutions containing tert-butanol. Initial fast bleaching of the
ground state absorbance at 400 nm was followed by further bleaching at 400 nm and
absorbance increases at 350 nm over 35 s (Figure 4.5). The rate of the secondary change
in absorbance was dependent on the concentration of 9, implying that the e-aq adds to two
sections of 9 (nitro group and elsewhere) followed by intermolecular electron transfer to
fully form the nitro radical anion.
Redox equilibrium was established against triquat (TQ2+) (E(1) = −548 ± 7 mV) for 3
mixtures of 9 / TQ2+: 50-75 M / 75-200 M and controls (at 385 nm).

K
TQ+. + 9

TQ2+ + 9.-

Kav. = 1.26 ± 0.21 E = −(RT/F)(lnK) = 6 ± 1 mV Ecor = −8 mV (ionic strength)
E(9/9.-) = −550 ± 8 mV
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Figure 4.5 Changes in UV-visible absorption with sequential doses of -irradiation of 9
in an evacuated solution containing formate ions (25 mM) at pH 7.

4.3.3

Conclusions

Based on the above measurements, it was concluded that the lack of bioreductive
activation observed with the prodrugs under anoxia in the cellular assays was due to their
low nitroaromatic one-electron reduction potentials. As described above, it is accepted
that nitroaromatic prodrugs show greatest hypoxia-selectivity when E[1] falls within the
range −330 to −450 mV.176 With E[1] for 9 (−550 ± 8 mV, representative of 1) and 2
(−509 ± 8 mV) falling well below this, the prodrugs are unable to accept electrons from
one-electron reductases at appreciable rates and are therefore incapable of undergoing
bioreduction in cells under anoxia. An approach for increasing the prodrug reduction
potentials was the focus of Chapter 6.
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Chapter 5: Development of a New Divergent Route
Towards Mutual Prodrugs
5.1

Synthetic Strategy

While waiting for mutual prodrugs 1 and 2 to undergo biological and reduction potential
testing at the University of Auckland, an alternative and more divergent synthesis was
scoped that could potentially deliver many mutual prodrugs bearing a diverse range of
different cytotoxins. The syntheses of 1 and 2 (Chapters 2 and 3), whilst successful, were
long, multi-step linear sequences that suffered from low yields in the key Knoevenagel
step i.e. 21% and 10%, respectively, for the cis alkene intermediates (Z)-8 and (Z)-23. In
the new divergent strategy, the Knoevenagel reaction would be completed earlier in the
synthesis on a simpler, less functionalised ester substrate (Scheme 5.1). The cis-alkene
product (expected to be obtained in higher yield) could then be pyrrole N-protected (32)
and converted to carboxylic acid 33 by de-esterification. This advanced common
intermediate 33 could then be directly coupled to diverse cytotoxins containing free
amino or alcohol groups, delivering a variety of amide and ester-linked mutual prodrugs
(after N-BOC deprotection of the pyrrole).

Scheme 5.1 Proposed divergent strategy that could allow rapid access to a diverse range
of amide and ester-linked mutual prodrugs.
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The allyl ester 30 was selected for the Knoevenagel reaction with 7 because earlier work
by other PhD students in the Kelso Lab (Nicholas Kirk and Pichit Sudta) had shown that
this substrate produces the highest yields of alkene products ((Z)-31 41% and (E)-31 33%,
respectively) under the optimised reaction conditions. Kirk and Sudta also demonstrated
that allyl ester (Z)-31 could be deprotected using tetrakis(triphenylphosphine)
palladium(0) and morpholine to give the free carboxylic acid in good yield (84%).
However, when their acid lacking a pyrrole N-protecting group was subjected to standard
amide and ester coupling conditions an alternative reaction took place, where the pyrrole
nitrogen cyclised onto the activated carboxylic acid to form a pyrrolizin-3-one (Scheme
5.2). Whilst frustrating for this work, this accidental discovery spurred off-shoot
investigations that led to publications describing new angiogenesis inhibitors and
antimalarials.145,

182

Nevertheless, for the new divergent route to be viable, this

observation meant that the pyrrole nitrogen must be protected prior to deallylation and
subsequent amide/ester coupling to cytotoxins. It was expected that the BOC protecting
group would be a suitable pyrrole N-protecting group.

Scheme 5.2 Intramolecular cyclisation to a pyrrolizin-3-one occurs upon activation of the
carboxylic acid when attempting amide or ester coupling reactions with the pyrrole
nitrogen unprotected.

5.2

Esterification of 2-(2-nitrophenyl)acetic acid with Allyl Alcohol

Esterification of 2-(2-nitrophenyl)acetic acid with allyl alcohol had previously been
explored in the Kelso Lab using two different approaches (Scheme 5.3). Basic conditions
with allyl bromide and potassium carbonate in acetone provided a 74% yield of the
desired allyl ester 30. Acidic conditions using allyl alcohol as the solvent at reflux with
catalytic sulphuric acid gave a slightly higher yield (88%). For the new divergent
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synthesis, the higher yielding acid-catalysed esterification method was explored and
scaled up from the previous 3 g scale to 10 g.

Scheme 5.3 Established methods from the Kelso Lab for the synthesis of allyl ester 30.
Method A) K2CO3, allyl bromide, acetone, rt, 74%. Method B) allyl alcohol, cat. H2SO4,
reflux, 88%.

I performed the esterification reaction twice on a 10-gram scale. On the first attempt, a
disappointing 64% yield was obtained. On the second attempt, the workup procedure was
modified to include a sodium hydroxide washing step (instead of saturated sodium
bicarbonate) to more effectively remove unreacted starting acid and simplify purification.
These changes increased the isolated yield to 83% and provided a total of 18 g of pure
ester 30 from the two reactions.

5.3

Knoevenagel Reaction of 30 with 7

The Knoevenagel reaction of allyl ester 30 with pyrrole-2-carbaldehyde 7 had previously
been explored in the Kelso Lab by PhD candidate Pichit Sudta on a 1 g scale. Sudta’s
reaction produced (Z)-31 and (E)-31 in 41% and 33% yields, respectively (Scheme
5.4).138 To access larger quantities of the desired acid 33, this key reaction needed to be
scaled up. When I attempted the reaction with 8 g of 30 it appeared to proceed well by
TLC analysis, however, purification at this larger scale proved to be challenging. Crude
(Z)-31 and (E)-31 fractions had to first be fractionated using silica gel column
chromatography with ethyl acetate/petroleum spirit as the eluent and then subjected to
further purification using column chromatography with acetone/petroleum spirit as
eluent. This tedious process yielded only 20% of the cis-alkene (Z)-31 and 21% of the
trans-alkene (E)-31. While these yields were lower than had been observed at smaller
scale, sufficient quantities of (Z)-31 (2.25 g) were nonetheless obtained from this single
reaction to advance the synthesis, so further optimisation was not explored.
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Scheme 5.4 Knoevenagel reactions of 30 with 7 afforded (Z)-31 41% and (E)-31 33%
when performed on a 1 g scale (Kelso Lab PhD student Pichit Sudta). When I performed
the reaction (once) under the same conditions at 8 g scale, lower yields ((Z)-31 20%,
(E)-31 21%) were obtained.

5.4

N-BOC Protection of (Z)-31

As discussed above, when the carboxylic acid (Z)-31 bearing an unprotected pyrrole
nitrogen was subjected to coupling conditions, an intramolecular cyclisation to the
pyrrolizin-2-one occurred instead of forming the desired amide or ester. The BOC
protecting group was chosen to address this issue due to its ease of protection/deprotection
and stability under typical coupling reaction conditions. Pyrrole N-BOC protection had
been scoped by Pichit Sudta using potassium hydride (to deprotonate the pyrrole nitrogen)
and BOC anhydride (BOC2O) in THF, which gave 32 in 75% yield (Scheme 5.5).
Although the yield for the reaction was high, its use of pyrophoric KH carried significant
risks, especially if performed on a larger scale, so I consulted the literature for possible
alternatives.

Scheme 5.5 N-BOC protection of (Z)-31 using potassium hydride affords 32 in 75% yield
when performed on a small scale (Pichit Sudta).

A suitable precedent was identified for a series of related pyrroles that used BOC2O in
the presence of DMAP in acetonitrile to carbamoylate pyrrole nitrogens (Scheme 5.6).183
With yields above 90% obtained in the absence of any strong base for these closely related
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analogues, including pyrroles bearing aldehyde groups at the 2-position, this reaction
looked to provide an excellent alternative.

Scheme 5.6 Literature precedent for the N-BOC protection of diverse pyrroles using
BOC2O and DMAP in the absence of strong base.183

The first reaction attempted on a pilot 200 mg-scale resulted in a high yield of 32 (78%)
after 3 hours of stirring at room temperature. It was noted, however, that some yield was
lost during isolation due to not completely removing all of the acetonitrile before
attempting a dichloromethane/water extraction, and that the presence of DMAP
complicated purification by column chromatography because it smeared throughout the
column. The reaction was next scaled up to 1.3 g. In this second attempt, acetonitrile was
completely removed by evaporation prior to extraction and a 1 M HCl washing step was
added to the workup to more effectively remove DMAP before column chromatography.
These changes raised the isolated yield of 32 to 98%, affording ample quantities of 32
(~1.7 g) to continue with the synthesis (Scheme 5.7).

Scheme 5.7 Optimised N-BOC protection of (Z)-31 using BOC2O and DMAP in
acetonitrile.
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Deallylation of 32 to Acid 33

Pichit Sudta had previously explored deallylation of BOC-protected 32 using 10 mole
percent (relative to 32) tetrakis(triphenylphosphine)palladium(0) and morpholine in THF
at room temperature on a 200 mg-scale, achieving a yield of 79%. In my first attempt at
this reaction performed on 100 mg, a yield of 74% was obtained. When I scaled the
reaction up to 1.2 g the yield was improved to 82% (Scheme 5.8).

Scheme 5.8 Deallylation of 32 with Pd(PPh3)4 and morpholine provided acid 33.

5.5.1

Mechanism of Palladium-Catalysed Deallylation of 32

The allyl group has long been used as an effective protecting group for carboxylic acids
and alcohols due to its ease of installation, stability and facile removal under mild
conditions using a palladium(0) catalyst (Tsuji–Trost reaction).184 The catalytic
mechanism involves a palladium redox cycle, where Pd(0) is first oxidised and later
returned to Pd(0) after reduction (Figure 5.1). The reaction is initiated by formation of πinteractions between the alkene π-electrons and the palladium atom, leading to oxidative
addition of the palladium to the allyl group. Ensuing loss of carboxylate as a leaving group
results in formation of a π-allyl cation. A nucleophile (in this case morpholine) then
regenerates the palladium(0) species by trapping the allyl cation and forming
4-allylmorpholine. As the process is catalytic in palladium, 10 mole percent is sufficient
to effect transformation of 32 to 33, with an excess of morpholine used to drive product
formation.
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Figure 5.1 Mechanism of deallylation of 32 using a palladium(0) catalyst and
morpholine.

5.6

Esterification of 33 with Floxuridine

With approximately 750 mg of N-BOC-carboxylic acid 33 in hand, a series of
esterification reactions were attempted using unprotected floxuridine. It was expected that
the more reactive primary alcohol of floxuridine would esterify in preference to its
hindered secondary alcohol (Table 5.1). The first attempt trialled the same conditions
(DCC, DMAP in dichloromethane) that were used to prepare ester 22 from 21 during the
synthesis of 2 (Section 3.5). However, this led only to a mix of the symmetrical anhydride
of 33 and another common side product observed with DCC ester couplings,185 the N-acyl
urea of 33. The related carbodiimide coupling reagent N,N'-diisopropylcarbodiimide
(DIC) gave similar results, producing a mix of the N-acyl urea and anhydride of 33. It
was speculated that the electrophilic character of the activated 2-(2-nitrophenyl)acetic
moiety had been substantially reduced upon introduction of the conjugated alkene, while
the large pyrrole N-BOC protecting group also added considerable steric hindrance
around the carboxylic acid that could hamper approach of the incoming alcohol
nucleophile.

Other coupling reagents were trialled next, including EDCI with hydroxybenzotriazole
(HOBt), HBTU, hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU)
and

(benzotriazol-1-yloxytris(dimethylamino)phosphonium

hexafluorophosphate)

(BOP), but in all cases only the unreacted HOBt/HOAt activated esters were isolated. The
next attempt involved converting the carboxylic acid 33 to the highly reactive acid
fluoride using tetramethylfluoroformamidinium hexafluorophosphate (TFFH). In
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addition to the high electrophilicity of acid fluorides, it was rationalised that the very
small fluorine atom would reduce steric bulk around the activated carbonyl group,
allowing easier access by the sterically bulky floxuridine nucleophile. Although the acid
fluoride appeared to form after reacting 33 with TFFH (by TLC analysis), addition of
floxuridine produced multiple products that could not be isolated and identified.

Table 5.1 Attempted esterification reactions with 33 and floxuridine.

Floxuridine

Reagents

Additives/Base

(eq.)

(eq.)

(eq.)

1.2

1.2 DCC

0.1 DMAP

CH2Cl2

1.2

1.2 DIC

0.1 DMAP

CH2Cl2

2.0

1.1 EDCI

2.0

1.5 HBTU

2.0

1.1 HOBt,

Solvent

Product Yieldsa
21% N-Acyl Urea
36% Anhydride
N-Acyl Urea and
Anhydride mixture

CHCl3

HOBt Ester

4.0 DMAP

DMF

HOBt Ester

1.5 HATU

4.0 DMAP

DMF

HOAt Ester

1.1

1.0 BOP

1.5 DIPEA

CH2Cl2

HOBt Ester

1.1

1.0 TFFH

CH2Cl2

Decomposition

4.0 DMAP

0.1 DMAP,
5.0 Et3N

trace product,
1.2 DEAD,
1.2

1.2 PPh3

-

THF

11%
a

Products with no listed yields were identified by MS and 1H NMR spectroscopy only.

They were not isolated and characterised.
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Speculating that the pyrrole nitrogen might be donating electron density via conjugation
into the activated carboxylic acid group and thus reducing its electrophilic reactivity, a
Mitsunobu-type esterification was investigated next using the reagent diethyl
azodicarboxylate (DEAD). Esterification using the Mitsunobu reaction inverts the
reactivity, whereby the alcohol is transformed into an electrophile and the carboxylate
acts as the nucleophile. When the reaction was attempted, some trace of the desired
product appeared to form (MS analysis), however, a competing intramolecular side
reaction appeared to predominate. The cyclised 2,3′anhydrofloxuridine product (Table
5.1) arises from reaction of the secondary alcohol of floxuridine, which upon being
activated by DEAD after successful esterification of the primary alcohol was displaced
by one of the 5-flurouridine carbonyl groups via intramolecular cyclisation.

5.6.1

Mechanism of N-Acyl Urea and Anhydride Formation

Coupling reactions with carbodiimides like DIC and DCC can lead to isolation of N-acyl
ureas and/or anhydrides when the activated carboxylic acid is not sufficiently
electrophilic or the reacting alcohol has low nucleophilicity.186 The mechanism of their
formation starts as intended, with the carboxylate reacting with the carbodiimide to form
an O-acyl isourea (Scheme 5.9).

Scheme 5.9 Mechanism of N-acyl urea and symmetrical anhydride formation during
carbodiimide-mediated ester coupling reactions with 33.
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This intermediate can then be displaced by catalytic DMAP to form a highly reactive acyl
pyridinium salt, which then reacts with the alcohol to give the desired ester. If, however,
the final reaction with the alcohol is slow, one of two side reactions can occur. The first
occurs after intramolecular rearrangement of the O-acyl isourea to the more stable,
unreactive N-acyl urea. If the carboxylate is nucleophilic enough, the second side reaction
occurs, where a second molecule of the acid reacts with the O-acyl isourea (or acyl
pyridinium salt) to form the symmetrical anhydride.

5.6.2

Mechanism of HOBt/HOAt Ester Formation

The coupling reagents HBTU and HATU are commonly used in peptide synthesis to form
amides due to their mild activating properties, resistance to racemisation and high
yields.187 They can also be used in esterification reactions via their activation of
carboxylic acids to HOBt or HOAt esters. To form these activated esters, the carboxylate
anion attacks the HATU or HBTU to form an unstable O-acyl(tetramethyl)isouronium
salt (Scheme 5.10). This salt is then displaced by the newly formed HOBt or HOAt anion,
affording the activated ester and tetramethylurea. Typically, this ester would then be
displaced by the alcohol nucleophile, in our case floxuridine. This displacement did not
occur, however, and the unreacted HOAt and HOBt ester intermediates were isolated
instead of the desired ester.

Scheme 5.10 Explanation for why HOAt/HOBt esters of 33 were isolated from attempted
HATU/HBTU-mediated ester couplings with floxuridine.
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Mechanism for the Formation of 2,3′Anhydrofloxuridine Derivative

The attempted coupling reactions suggested that the activated derivatives of carboxylic
acid 33 are electrophilic but the floxuridine primary alcohol is a relatively poor partner
nucleophile. Steric hindrance around the activated carboxylic acid due to the spatially
close and bulky BOC-group, along with the large activating groups, were probably
contributing to low reactivity with the bulky floxuridine. The Mitsunobu reaction was
therefore trialled as a way of inverting reactivity, where the alcohol is activated to become
an electrophile and the carboxylate acts as the nucleophile.188

The mechanism of the Mitsunobu reaction commences with nucleophilic addition of
triphenylphosphine to DEAD, producing a basic betaine that deprotonates carboxylic acid
33 (Scheme 5.11). The primary alcohol of floxuridine then attacks the
triphenylphosphonium phosphorous atom, leading to formation of an oxyphosphonium
cation following loss of diethyl hydrazine-1,2-dicarboxylate. The carboxylate anion then
reacts with the electrophilic oxyphosphonium cation, generating the desired product after
loss of triphenylphosphine oxide. Due to the presence of the unprotected secondary
alcohol, rather than stopping at the desired product a second Mitsunobu reaction ensues.
Here, the secondary alcohol is similarly activated to an oxyphosphonium cation that
undergoes an intramolecular cyclisation reaction with the adjacent carbonyl oxygen of
the fluorouridine, leading to formation of the bridged-bicyclic side product.

Scheme 5.11 Mechanism of the Mitsunobu reaction of 33 with floxuridine and
subsequent intramolecular cyclisation leading to a bridge-bicyclic side product.
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In hindsight, this side-reaction should have been expected as related substrates in the
literature were found to undergo the same intramolecular cyclisation when subjected to
Mitsunobu conditions. For example, when benzoic acid and unprotected floxuridine were
subjected to the Mitsunobu reaction, the bridged-bicyclic 2,3′anhydrofloxuridine benzoyl
ester was formed in 90% yield (Scheme 5.12).189

Scheme 5.12 Literature example of a Mitsunobu reaction that resulted in formation of a
bridged-bicyclic floxuridine derivative.189

5.7

Trial Esterification Reactions with 33 and Benzyl Alcohol

To better understand the reactivity of carboxylic acid 33, floxuridine was replaced with
the simpler benzyl alcohol in further esterification trial reactions (Table 5.2).
Interestingly, benzyl alcohol showed similar results to floxuridine, whereby using BOP
as the coupling reagent yielded only the HOBt ester, whereas the Mitsunobu reaction gave
the desired benzyl ester 34 in quantitative yield. These findings lent evidence to the above
suggestion that electrophilic activated derivatives of 33 show low reactivity, probably
because of steric hinderance from the neighbouring pyrrole N-BOC group. On the other
hand, the oxyphosphonium cation generated from the alcohol in the Mitsunobu reaction
could easily undergo reaction with the carboxylate anion of 33.

Table 5.2 Trial esterification reactions with 33 and benzyl alcohol.

Benzyl Alcohol (eq.)

Reagents (eq.)

Solvent

Yielda

1.1

1.0 BOP, 1.5 DIPEA

CH2Cl2

Quantitative HOBt Ester

2.0

2.0 DEAD, 2.0 PPh3

THF

Quantitative 34

a

The HOBt ester was not stable and only identified by MS and 1H NMR spectroscopy.

The desired 34 was isolated by preparative TLC and fully characterised.
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Trial Amide Couplings with 33 and Benzylamine

With a promising Mitsunobu procedure now established to form esters of 33, attention
was turned to trialling amide couplings of 33 with the simple model amine benzylamine
(Table 5.3). Activation of 33 to the acid fluoride with TFFH once again led to a
degradation of the starting material and no observable product formation. Reaction with
the coupling reagent BOP provided trace amounts of the desired amide but the major
isolable product was the HOBt ester of 33. Encouragingly, reaction of 33 with 4
equivalents of benzylamine and HBTU gave a high yield of the benzyl amide 35 (>80%).
Use of the more reactive HATU gave a quantitative yield of 35 on a small scale (26 mg
of 33).

Table 5.3 Trial amide coupling reactions with 33 and benzylamine.

Benzylamine Coupling Reagent Additive/Base
(eq.)

Yielda

Solvent

(eq.)

(eq.)

1.1

1.0 TFFH

1.1

1.0 BOP

1.5 DIPEA

CH2Cl2

4.0

1.5 HBTU

2.5 DIPEA

THF

>80% yield 35

4.0

1.5 HATU

2.5 DIPEA

THF

Quantitative 35

5.0 Et3N,
0.1 DMAP

CH2Cl2

Starting Material
Degraded
Trace Product,
Mainly HOBt Ester

a

The HOBt ester was not stable and only identified by MS and 1H NMR spectroscopy.

The desired 35 was isolated by preparative TLC and fully characterised.

5.9

Conclusions and Future Directions

At this point in the project, results were received back from the University of Auckland
showing that the reduction potentials of 1 and 2 were too low to support hypoxia-selective
activation of the prodrugs (Chapter 4.3). To address this issue, new derivatives were
designed that contained additional electron withdrawing groups on the nitroaryl triggering
moiety in an attempt to raise the reduction potentials. Further work on the divergent
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synthesis described above was thus put on hold and the focus switched to using the
original synthesis to create the target analogues (Chapter 6).

Although it potentially allows diverse cytotoxins to be appended in a single step to the
prodrug scaffold, the new divergent synthesis offers no advantages in terms of accessing
analogues carrying substituents in the nitroaryl ring, as these groups need to be preinstalled prior to the Knoevenagel reaction. Nevertheless, the insights gained in this
chapter could be applied if/when the optimal electron withdrawing substituents are
identified. For instance, the Knoevenagel reaction could be implemented with the allyl
ester of the substituted 2-(2-nitrophenyl)acetate that is eventually identified (Scheme
5.13), and then the rest of the divergent route could be deployed to access mutual prodrugs
containing multiple different cytotoxins, linked via esters or amides using the Mitsunobu
and HATU chemistry developed here.

Scheme 5.13 Proposed future strategy allowing practical access to diverse amide and
ester-linked mutual prodrugs containing addition electron withdrawing substituents on
the nitroaryl ring to increase the reduction potential.

-100-

Chapter 6

Geraud N. Sansom

Chapter 6: Optimisation of Prodrug Nitroaromatic
Reduction Potentials
6.1

Overview and Synthetic Strategy

To address the issue of poor bioreductive activation that was observed with mutual
prodrugs 1 and 2 under anoxia (Section 4.2), which was attributed to their low
nitroaromatic one-electron reduction potentials (Section 4.3.3), a new series of model
compounds were designed to explore ways of increasing the reduction potentials towards
the target minimum of −450 mV.

The effects of electron withdrawing substituents on the nitroaromatic one-electron
reduction potential has been extensively studied. As part of the development of new
trinitrobenzene-based explosives, a series of simple substituted mono- and dinitrobenzene
analogues were synthesised and their one-electron reduction potentials measured (Figure
6.1).190 In this example, it was observed that appending strong electron withdrawing
substituents, such as additional nitro groups, onto the nitrobenzene substantially increases
one-electron reduction potentials (~200 mV).

Figure 6.1 Nitroaromatic one-electron reduction potentials of a series of substituted
mono- and dinitrobenzene derivatives from the literature.190

The changes in reduction potentials through addition of electron withdrawing substituents
can be described by the Hammett equation, a linear free-energy relationship between
benzoic acid derivatives with meta- and para-substituents, described as follows:
𝑙𝑜𝑔

𝐾
= 𝜎𝜌
𝐾0

The equation describes the log ratio of the equilibrium constant, K, for a given reaction
with substituent R with the equilibrium constant, K0, of the unsubstituted derivative. The
right side of the equation is described by the reaction constant ρ (dependant on the type
of reaction) and the substituent constant σ (dependant on the R substituent). In this
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equation, an electron donating group like a para-methoxy substituent would have a
negative substituent constant (σ = −0.268), whilst an electron withdrawing group would
have a positive substituent constant (e.g. para-fluoro σ = +0.062, para-trifluoromethyl σ
= +0.54 and para-nitro σ = +0.778).191

Based on the above, we hypothesised that addition of electron withdrawing substituents
onto the nitroaryl ring of 1 and 2 would likely increase their reduction potentials.
Conveniently, attaching electron withdrawing groups to the indoline-2-one of Semaxanib
produces only minor changes in kinase inhibition.192 Thus, introduction of these groups
should not diminish the kinase/angiogenesis inhibitory properties of the indolin-2-one
portion of prodrugs after hypoxia-triggered release into tumours. Additionally, Denny et
al showed that electron withdrawing groups do not affect the cyclisation rates of
2-(2-aminophenyl)acetamides formed upon reduction of 2-(2-nitrophenyl)acetamide
prodrugs.125 Cyclisation of the modified mutual prodrugs should therefore not be
impaired.

To simplify testing of the hypothesis that installation of electron withdrawing groups
increases the reduction potential of the prodrug scaffold, model compounds were
designed that included a simple allyl ester in place of the cytotoxin. This change meant
that the reliable allyl ester Knoevenagel chemistry described in Chapter 5 could be
deployed in the synthesis. It was envisioned that addition of simple, unreactive electron
withdrawing groups such as fluorine and trifluoromethyl to the nitroaryl ring would
facilitate testing of the hypothesis while maintaining compatibility with our established
chemistry. To this end, six target compounds were proposed, four containing fluorine
atoms at the 3, 4, 5 and 6-positions (compounds (Z)-42-45, respectively, Scheme 6.1) and
two containing trifluoromethyl groups at the 3 and 4-positions (compounds (Z)-46 and
(Z)-47). All of the required F/CF3-substituted 2-(2-nitrophenyl)acetic acids for these
targets were commercially available.
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Scheme 6.1 Proposed synthesis of allyl ester model prodrugs (Z)-42-45 containing
electron withdrawing fluorine and trifluoromethyl groups on the nitroaryl ring.

Synthesis of the model prodrugs first required generating the allyl esters and then
performing the Knoevenagel condensation. The reduction potentials of each cis-product
could be measured and compared to the unaltered parent (Z)-31, as well as prodrugs 1
(and 9). The new compounds could also be submitted to chemical reduction reactions to
establish whether the presence of the F/CF3 groups affects the subsequent indolin-2-one
cyclisation. An undergraduate research project (CHEM341) student (Jessica Semken)
joined the project in Semester 1, 2019 to assist with synthesis of the 4-F (and 5-F
analogues (Z)-43 and (Z)-44, respectively.

6.2

Synthesis of Ally Esters 36-41

The synthesis of allyl esters 36-41 from the commercial fluorinated and
trifluoromethylated 2-(2-nitrophenyl)acetic acid precursors used the method described in
Section 5.2 (Table 6.1). The reactions all proceeded well with > 80% yields obtained for
the fluorinated analogues 36-39 and > 70% for the trifluoromethyl derivatives 40 and 41.
Approximately one gram of each ester was synthesised, providing ample quantities for
the Knoevenagel reaction and subsequent chemical testing of the targets.
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Table 6.1 Synthesis of allyl esters 36-41.

2-(2-nitrophenyl)acetic acid

Ester

Yield (%)

3-F

36

86

4-F

37

80

5-F

38

84

6-F

39

80

4-CF3

40

71

5-CF3

41

70

6.3

Discovery of a Nucleophilic Aromatic Substitution Route to Novel

Pyrroloquinoline Fluorophores
The first attempt at the Knoevenagel reaction (performed by Jessica Semken) with allyl
ester 37 and pyrrole-2-aldehyde 7 under the standard conditions (Section 5.3) produced
none of the desired product (Z)-43. Instead, a crystalline yellow solid was isolated as the
major product, which fluorescence bright blue when held in solutions under UV light or
sunlight (Figure 6.2).

A)

B)

Figure 6.2 Unexpected side product formed in the attempted Knoevenagel reaction of 7
with 4-F allyl ester 37. A) Crystal used to obtain the X-ray structure. B) Crystals dissolved
in pet. spirit displayed bright blue fluorescence under 365 nm UV light.
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Analysis of the NMR spectrum of the new compound revealed that although the
characteristic pyrrole methyl groups were clearly still present, the pyrrole NH signal had
disappeared and the 1H and 13C chemical shifts of the nitroaryl ring signals had all shifted
considerably. It was proposed that after initial formation of the Knoevenagel product(s),
the pyrrole N-H had cyclised via intramolecular nucleophilic aromatic substitution onto
the nitroaryl group (with loss of HNO2), forming the pyrroloquinoline 48 (Figure 6.3).
The 2D NOESY spectrum revealed two key NOE correlations that supported this
structure, the first being between one of the pyrrole methyl groups and the ortho CH on
the phenyl ring. The second was a NOE between the newly formed alkene proton and the
other pyrrole methyl group.

While the NMR data supported the proposed structure, further evidence was sought from
X-ray crystallography. Small samples of the compound were dissolved in hexane, Et2O,
CH2Cl2, EtOH and 2-PrOH in separate vials containing a needle outlet to allow slow
evaporation of the solvent over a three-week period. Hexane yielded large needle-like
crystals that were found to be suitable for X-ray structure determination (Dr. Christopher
Richardson, UOW). The X-ray diffraction data confirmed that the structure was indeed
48 (Figure 6.3). With the structure of the compound now confirmed, its isolated yield was
calculated at 38%.

Figure 6.3 X-ray crystal structure of unexpected fluorescent side product 48 (courtesy of
Dr Christopher Richardson, UOW). Key correlations observed in the 2D NOESY
spectrum of 48 are indicated. Crystallographic data are provided in Appendix 1.
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Nucleophilic aromatic substitution of the pyrrole nitrogen onto the nitroaryl ring (with
loss of HNO2) was an intriguing finding. Upon delving into the literature, examples could
be found of indoles undergoing related intermolecular reactions with highly electron
deficient nitroaromatics. One such example involved nucleophilic substitution of
4-nitrophthalonitrile with indole in the presence K2CO3 in DMF (Scheme 6.2).193 Our
new reaction, however, represents the first example of a pyrrole undergoing an
intramolecular nucleophilic aromatic substitution-based cyclisation with a arylnitro
group.

Scheme 6.2 Literature report of intermolecular nucleophilic aromatic substitution of
indole onto 4-nitrophthalonitrile.193

Further searching of the literature identified a series of azole (pyrrole or imidazole)-fused
quinoline ring systems structurally related to 48.194 The compounds were synthesised in
a related way, where an unprotected azole-NH reacted with an ortho-halo substituted
ethyl phenylacetate or phenyl acetonitrile in the presence of K3PO4 (Scheme 6.3). The
reaction was initiated by a similar Knoevenagel condensation to ours, where the azoleNH of the Knoevenagel alkene product subsequently undergoes nucleophilic aromatic
substitution with the ortho-halogen atom. Most of these analogues are reportedly
fluorescent yellow solids, although their fluorescent properties, (e.g. absorption/emission
maxima, extinction coefficients, quantum yields etc.) were not detailed.

Scheme 6.3 Literature report on the synthesis of azole (pyrrole or imidazole)-fused
quinolones related to 48.194
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Optimisation of Knoevenagel Reaction Conditions

As the first Knoevenagel reaction with 37 produced only 48, the reaction was modified
in an attempt to reduce formation of this side product. It was hypothesised that heating
the reaction was driving the nucleophilic aromatic substitution after initial formation of
the desired cis-alkene (Z)-43. We postulated that the presence of the additional electron
withdrawing fluorine atom might be allowing the Knoevenagel reaction to proceed at
room temperature, despite all previous studies from the Kelso Lab showing that
unsubstituted 2-(2-nitrophenyl)acetic esters required heat for the Knoevenagel reaction to
proceed. Attempting Knoevenagel reactions with 7 and allyl esters 36 and 37 at room
temperature delivered the desired products after 18 hours, yielding the typical mixtures
of cis and trans isomers (Z)-42 28%, (E)-42 26% (Table 6.2, Entry 1) and (Z)-43 13%,
(E)-43 19% (Table 6.2, Entry 2). None of the fluorescent side product analogous to 48
was observed in the reactions. The room temperature Knoevenagel reaction conditions
were next trialled with allyl ester 38, however, after 20 hours only trace amounts of the
cis/trans-alkene products were detected by TLC analysis. However, increasing the
temperature for this substrate to 45 °C and heating for an additional 24 hours generated
the desired alkenes (Z)-44 22% and (E)-44 21% (Table 6.2, Entry 3).

Table 6.2 Knoevenagel reactions with allyl esters 36-38.

Entry

Allyl Ester

Temperature

Time (h)

Product

1

36, X = 3-F

r.t.

18

(Z)-42 28%, (E)-42 26%

2

37, X = 4-F

r.t.

18

(Z)-43 13%, (E)-43 19%

3

38, X = 5-F

45 °C

44

(Z)-44 22%, (E)-44 21%

6.4.1

Knoevenagel Reaction with Allyl Ester 39

Surprisingly, when the 6-allyl ester 39 was subjected to room temperature Knoevenagel
conditions, the nucleophilic aromatic substitution cyclisation occurred, forming
pyrroloquinoline 49 (Scheme 6.4, 11%). However, in this reaction the fluorine atom
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served as a much better activator and leaving group, undergoing the reaction in preference
to the nitro group. The higher reactivity of the fluorine allowed the reaction to proceed
at room temperature. In contrast to 48, compound 49 was a bright red solid that did not
fluoresce under UV light. As compound 49 was the major reaction product at room
temperature and none of the desired alkene products were observed in this Knoevenagel
reaction, efforts to produce the 6-fluoro model prodrug target (Z)-45 were abandoned.

Scheme 6.4 Knoevenagel reaction of 39 with 7 at room temperature produced
intramolecular nucleophilic aromatic substitution product 49.

6.4.2

Knoevenagel Reaction with Allyl Ester 40

When allyl ester 40 was subjected to the room temperature Knoevenagel reaction for 18
hours only small amounts of the desired alkene products were visible by TLC analysis,
and heating the reaction at 45 °C for 24 hours led to a complex mixture of products
(Scheme 6.5). Nevertheless, the desired cis/trans alkenes (Z)-46 and (E)-46 were able to
be isolated in 9% and 6% yields, respectively. The intramolecular nucleophilic aromatic
substitution product 50 was also isolated in 14% yield. When dissolved in pet. Spirit, 50
displayed the same bright blue fluorescence as 48 under 280 nm UV light. An additional
side product corresponding to the methylallyl malonate diester 51 was also isolated in 4%
yield from the reaction. Compound 51 presumably forms when the carbanion of 40
attacks the methyl carbamate protecting group of 7 rather than the aldehyde.

Scheme 6.5 Knoevenagel reaction of 40 with 7 produced a mixture of the desired alkenes
(Z)-46 and (E)-46, along with side products 50 and 51.
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Knoevenagel Reaction with Allyl Ester 41

When allyl ester 41 was subjected to the room temperature Knoevenagel conditions for
18 hours none of the desired alkenes were formed and only trace amounts of nucleophilic
aromatic substitution product 52 were detected by TLC analysis. Heating the reaction at
45 °C for 24 hours gave none of the desired alkenes but increased the isolated yield of 52
to 34% (Scheme 6.6). The side product, 52, displayed similar fluorescent properties to
the other novel pyrroloquinolones 48 and 50, fluorescing blue under 280 nm UV light. It
appears that the highly electron withdrawing trifluoromethyl substituent located para to
the nitro group was activating the compound and strongly driving nucleophilic aromatic
substitution after formation of the Knoevenagel products. Attempts to synthesise the cisalkene (Z)-47 were abandoned.

Scheme 6.6 Knoevenagel reaction of 41 produced nucleophilic aromatic substitution
product 52 as the major product.

6.5

Pulse Radiolysis One-Electron Reduction Potential Measurements

The cis-alkenes (Z)-42, (Z)-43, (Z)-44 and (Z)-46 and the parent unsubstituted alkene
(Z)-31 were sent to the University of Auckland for pulse radiolysis nitroaryl one-electron
reduction potential measurements (as previously described in Section 4.3). The
compounds were found to be considerably less soluble in aqueous solution compared to
the prodrug structures 2 and 9. While (Z)-31 was soluble in 2 M aqueous tert-butanol, the
other new compounds required 4 M tert-butanol to achieve sufficient concentrations for
radiolysis measurements.

6.5.1

Reduction Potential of Unsubstituted Parent (Z)-31

A stock solution of the parent compound (Z)-31 was prepared in 2 M tert-butanol
containing 5 mM phosphate buffer pH 7. A UV-vis spectrum was recorded to obtain the
extinction coefficient, which was used to determine the concentration of the compound
in test solutions. One-electron reduction of (Z)-31 (50 M) by the e-aq was carried out
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upon pulse radiolysis (3 Gy in 200 ns) in deaerated phosphate buffer (5 mM, pH 7).
Spectral changes following one-electron reduction (relative to unreduced compound)
over a limited wavelength region were obtained (Figure 6.4). The initial radical anion
underwent a spectral change at ca. 0.5–1 x 104 s-1 to another intermediate. The absorption
spectrum of the unreduced compound, measured after the experiments, was taken to
obtain the corrected spectra of the radical intermediates. This observation pointed to slow
decomposition of solutions of (Z)-31.

Figure 6.4 Spectral changes following pulse radiolysis (3 Gy in 200 ns) of (Z)-31, 75 M
in deaerated aqueous solution containing tert-butanol (2 M) and phosphate buffer (5 mM,
pH 7), 5 s and 200 s after the pulse. Spectra corrected for the absorption of the prepulsed spectrum, dashed line.
Redox equilibrium was established against triquat (TQ2+) (E(1) = −548 ± 7 mV) for 3
mixtures of (Z)-31 / TQ2+: 50-127 M / 50-100 M, maintaining 2 M tert-butanol / 5 mM
phosphate pH 7.

K
TQ+. + (Z)-31

TQ2+ + (Z)-31.-

Kav. = 0.068 ± 0.006 E = −(RT/F)(lnK) = −69 ± 3 mV Ecor = −8 mV (ionic strength)
E((Z)-31/(Z)-31.-) = −625 ± 8 mV
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At -625 mV, the reduction potential of (Z)-31 was considerably lower than the values
obtained previously with prodrugs 2 (−509 ± 8 mV) and 9 (−550 ± 8 mV). It was not
expected that changing the distal cytotoxin group to a vinyl ester would have such a
dramatic effect; i.e. lowering the reduction potential by ~120 mV. To confirm this result,
a second sample of (Z)-31 was sent for testing and the electron transfer standard tetraquat
(TeQ2+, Figure 6.5) was used in place of triquat.

Figure 6.5 Chemical structures of triquat (TQ2+) and tetraquat (TeQ2+) standards used to
establish redox equilibria for one-electron pulse radiolysis reduction potential
measurements.
Redox equilibria were established against tetraquat (TeQ2+) (E(1) = −635 ± 5 mV) for 2
mixtures of (Z)-31 / TeQ2+: 75-84.5 M / 100-300 M, maintaining 2 M tert-butanol / 5
mM phosphate pH 7.

K
TeQ+. + (Z)-31

TeQ2+ + (Z)-31.-

Kav. = 2.45 ± 0.21 E = −(RT/F)(lnK) = 23 ± 2 mV Ecor = −10 mV (ionic strength)
E((Z)-31/(Z)-31.-) = −622 ± 6 mV

The new value was found to be in very close agreement with the earlier measurement. It
was speculated that there could be a structural difference in the alignment of the
conjugated systems in (Z)-31 and 2 that give rise to this change. Whilst this observation
meant that the reduction potentials of the new series of allyl ester model compounds could
not be directly compared to the values obtained earlier for 2 and 9, they could still be
compared to each other and to the parent unsubstituted compound (Z)-31 since they were
all allyl esters. Comparing the new substituted derivatives to the parent (Z)-31 thus
provided a direct readout of how adding the fluorine and trifluoromethyl groups affects
the one-electron reduction potential of the scaffold.
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Reduction Potential (Z)-42

Redox equilibrium was established against tetraquat (TeQ2+) (E(1) = −635 ± 7 mV) for 3
mixtures of (Z)-42 / TeQ2+: 50 M / 300 M, in 2 M tert-butanol / 5 mM phosphate pH
7.

K
TeQ2+ + (Z)-42.-

TeQ+. + (Z)-42

Kav. = 3.03 E = −(RT/F)(lnK) = 30 mV Ecor = −10 mV (ionic strength)
E((Z)-42/(Z)-42.-) = −615 ± 10 mV

6.5.3

Reduction Potential of (Z)-43

It was observed that (Z)-43 was less soluble in aqueous solution so the tert-butanol
concentration was increased from 2 M to 4 M. Redox equilibrium was established against
triquat (TQ2+) (E(1) = −548 ± 7 mV) for a mixture of (Z)-43 / TQ2+: 96 M / 100 M, in
4 M tert-butanol / 5 mM phosphate pH 7.

K
TQ2+ + (Z)-43.-

TQ+. + (Z)-43

Kav. = 0.119 E = −(RT/F)(lnK) = −55 mV Ecor = −9 mV (ionic strength)
E((Z)-43/(Z)-43.-) = −612 ± 7 mV

6.5.4

Reduction Potential of (Z)-44

Once again, (Z)-44 was not as soluble in aqueous solution so the tert-butanol
concentration was increased from 2 M to 4 M. Redox equilibrium was established against
triquat (TQ2+) (E(1) = −548 ± 7 mV) for a mixture of (Z)-44 / TQ2+: 131 M / 100 M,
in 4 M tert-butanol / 5 mM phosphate pH 7.

K
TQ+. + (Z)-44

TQ2+ + (Z)-44.-

Kav. = 0.202 E = −(RT/F)(lnK) = −41 mV Ecor = −9 mV (ionic strength)
E((Z)-44/(Z)-44.-) = −598 ± 7 mV
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Reduction Potential Measurement of (Z)-46

Redox equilibrium was established against tetraquat (TeQ2+) (E(1) = −635 ± 7 mV) for 3
mixtures of (Z)-46 / TeQ2+: 50-124 M / 300-800 M, in 2 M tert-butanol / 5 mM
phosphate pH 7.

K
TeQ+. + (Z)-46

TeQ2+ + (Z)-46.-

Kav. = 16.7 ± 2.28 E = −(RT/F)(lnK) = 72 ± 4 mV Ecor = −12 mV (ionic strength)
E((Z)-46/(Z)-46.-) = −575 ± 10 mV

6.5.6

Summary of One-Electron Reduction Potential Measurements

The measured nitroaromatic one-electron reduction potentials of (Z)-31, (Z)-42, (Z)-43,
(Z)-44 and (Z)-46 are summarised in Table 6.3. Whilst all measured values were far off
the desired −450 mV threshold required for bioreductive activation, it seems this can
partly be attributed to the allyl ester. Nevertheless, comparing potentials within the series
to the unsubstituted parent (Z)-31 revealed some key insights. A fluorine atom at either
the ortho- or meta-position (relative to the nitro) produced small increases in the reduction
potential (~10 mV), whereas fluorine at the para-position produced a greater increase
(~25 mV). As predicted, the stronger electron withdrawing trifluoromethyl substituent
provided a larger boost of ~50 mV. Compared to (Z)-43, which contains a fluorine atom
at the same position (meta to the nitro group), the 4-CF3 derivative (Z)-46 displayed a
reduction potential that was ~40 mV higher. From these data, it would appear that the
greatest increases in reduction potential within this series would come from a paratrifluoromethyl substituent, but this molecule (i.e. (Z)-47) was unable to be synthesised
using our current chemistry. New chemistry would need to be developed to synthesise
(Z)-47 and confirm this assertion.

-113-

Chapter 6

Geraud N. Sansom

Table 6.3 Summary of pulse radiolysis one-electron reduction potential measurements.

Tert-Butanol

Electron Transfer

One-Electron

Concentration

Reagent

Reduction Potential

(Z)-31, X = H

2M

Triquat (TQ2+)

−625 ± 8 mV

(Z)-31, X = H

2M

Tetraquat (TeQ2+)

−622 ± 6 mV

(Z)-42, X = 3-F

2M

Tetraquat (TeQ2+)

−615 ± 10 mV

(Z)-43, X = 4-F

4M

Triquat (TQ2+)

−612 ± 7 mV

(Z)-44, X = 5-F

4M

Triquat (TQ2+)

−598 ± 7 mV

(Z)-46, X = 4-CF3

2M

Tetraquat (TeQ2+)

−575 ± 10 mV

Allyl Ester

Even though none of the synthesised molecules reached the target reduction potential
range of −330 to −450 mV, it was postulated that a 50 mV or more increase in the
nitroaromatic one-reduction potential of the mutual prodrugs 2 (−509 ± 8 mV) and 9
(−550 ± 8 mV), such as might be expected with introduction of a CF3 group at the 5position, could bring the compounds close to the range for useful bioreductive activation.
Extensive structure activity relationship assays performed by Sugen, inc. in the
development of semaxanib and sunitinib has already shown some tolerability for
substitution at the 5- position. Whilst the 5-CF3 substituted is novel, the 5-CH3 derivative
showed comparable tyrosine kinase inhibition (IC50) in assays with platelet-derived
growth factor (25.5 µM, relative to semaxanib 20.26 µM) and the VEGF receptor Flk-1
(0.3 µM, relative to semaxanib 1.04 µM).192 In the same assays, the 4-F analogue of
semaxanib gave a slightly improved profile relative to semaxanib for platelet-derived
growth factor (18.2 µM) and the VEGF receptor Flk-1 (<0.78 µM).192

6.6

Chemical Reductions with Fe/CH3COOH

Introduction of the electron withdrawing substituents onto the nitroaromatic ring could
affect the ability of the scaffold to undergo spontaneous cyclisation following reduction.
It was therefore important to establish whether cyclisation still occurred after chemical
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reduction. To investigate this, one of the chemical reductions explored earlier (Section
4.1), namely Fe(0) in CH3COOH:EtOH:H2O (1:1:1),164 was applied to the new cis allyl
esters (Table 6.4).

Table 6.4 Summary of chemical reductions of allyl ester cis derivatives.

Cis Allyl Ester

Product

Yield (%)

(Z)-31, X = H

3

78

(Z)-42, X = 3-F

N.A.

(Z)-43, X = 4-F

53

75

(Z)-44, X = 5-F

54

80

(Z)-46, X = 4-CF3

N.A.

Trace product mixed with
isomerised (E)-42

Trace product mixed with
isomerised (E)-46

Reduction of the unsubstituted parent (Z)-31 gave semaxanib 3 in 78% yield, which was
comparable to the yield obtained from the unsubstituted ethyl ester (Nicholas Kirk,
81%).139 Both (Z)-43 and (Z)-44 gave good yields of their fluorinated semaxanib
derivatives (53 75%, 54 80%, respectively). When the same conditions were applied to
(Z)-42 and (Z)-46, both allyl esters gave complicated mixtures of isomerised starting
material and unidentifiable side products. This was an unexpected result, possibly arising
from the greater electron withdrawing properties leading to ease of donation of electrons
from the pyrrole nitrogen into the nitroaromatic system, and subsequent isomerisation
(Scheme 6.7). This was postulated to occur due to the resonance stabilisation afforded by
the para-trifluoromethyl (relative to alkene) substituent in the case of (Z)-46, and
increased electron withdrawing effects of the nitroaryl group with an ortho-fluorine atom
in the case of (Z)-42. When the pyrrole nitrogen donates electrons into the nitroaromatic
system, the cis-alkene displays greater single bond character and free rotation to the trans
product is possible.
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Scheme 6.7 Resonance forms of (Z)-46 that allow free rotation around the alkene bond.

6.7

Conclusions and Future Directions

Four novel cis-allyl ester model compound containing electron withdrawing substituents
on the nitroaryl ring were synthesised and tested for one-electron reduction potentials and
spontaneous cyclisation after nitroaryl group chemical reductions. The electronic
properties of the nitroaryl group were systematically explored, with the para position
(relative to the nitro) identified as giving the greatest increase in reduction potential. The
more electron withdrawing trifluoromethyl group was shown to produce greater increases
in reduction potential than fluorine substituents.

6.7.1

Future Work on Hypoxia Activated Mutual Prodrugs

The chemical reductions studies on the synthesised cis allyl esters showed that electron
donation of the pyrrole nitrogen into the nitroaromatic could present a dilemma in
continued synthesis of new derivatives. One possible way to alleviate this issue would be
to modify the angiogenesis inhibitor portion of the molecule from semaxanib to the more
functionalised, FDA approved drug sunitinib (Section 1.3.1). Sunitinib is a superior
angiogenesis inhibitor to semaxanib but also benefits from having an amide appendage
attached to the pyrrole ring. The carbonyl of this amide could act as an electron sink for
the pyrrole nitrogen, both addressing the problem of isomerisation whilst also increasing
the nitroaryl one-electron reduction potentials further by pulling electron density away
from the nitroaryl group through conjugation. This could be further enhanced by applying
the lessons learnt here from the pulse radiolysis studies and incorporating a para (relative
to the nitro) trifluoromethyl substituent (Figure 6.6).

Figure 6.6 Proposed mutual prodrug based on the FDA-approved drug sunitinib,
incorporating an additional para (relative to the nitro) trifluoromethyl substituent.
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Future Work on Pyrroloquinoline Fluorophores

An exciting outcome from this work was the discovery of a novel intramolecular
nucleophilic aromatic substitution-based cyclisation of the pyrrole nitrogen onto the
nitroaryl group. In our synthesis, this produced an undesired side product, however, the
pyrroloquinolines as a class have not been extensively explored and could potentially be
useful probes; for example, as fluorescent tags for proteins. It was clear from this study
that heating the Knoevenagel reactions to higher temperatures favours this cyclised
product over the cis/trans alkenes and increases the yield of pyrroloquinolines (Section
6.3). Using the chemistry described in Chapter 5, the allyl group could be easily removed
from pyrroloquinolines like 48, 50 and 52 using Pd(PPh3)4/morpholine (Section 5.5). The
Mitsunobu coupling conditions developed in Section 5.7 could then be used to attach a
polyethylene glycol spacer containing a terminal maleimide, which could in turn be
attached to proteins via reaction with Cys residues (Scheme 6.8). Altering the electron
withdrawing substituents on the nitroaryl ring precursors and trialling a variety of
appendages on the pyrrole could allow tailoring of the fluorescent properties, and
potentially pharmacokinetic properties for in vivo imaging applications.

Scheme 6.8 Proposed synthesis of proteins labelled with pyrroloquinoline fluorescent
tags using the chemistry developed in Chapters 5 and 6.
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Chapter 7: Experimental
7.1

General Methods

All solvents were purchased as Analytical Reagent grade and used without further
purification. The term pet. spirit refers to petroleum spirit within the boiling range 40-60
°C.

7.1.1

Chromatography

Analytical TLC was performed using aluminium-backed sheets of Merck TLC Silica Gel
60 F254. Compounds were visualised under UV light and by staining with
4-methoxybenzaldehyde or ammonium molybdate. Preparative TLC was performed
using glass-backed sheets of Whatman Partsil PK6F 60Å silica with a thickness of 1000
µm. Gradient flash column chromatography was performed using Scharlan Silica Gel 60,
0.04-0.06 mm (230-400 mesh ASTM).

7.1.2

Melting Points

Melting points (M.P.) were measured on a Reichart hot stage equipped with a eurotherm
temperature controller and are uncorrected.

7.1.3

Polarimetry

Optical rotations (O.R.) were measured using a 1 mL cell in a Jasco P-2000 polarimeter.
Twelve measurements were taken and the average used to calculate specific rotation.

7.1.4

Infrared Spectroscopy

Infrared spectra were obtained on a Nicolet Avatar 360 FT-IR spectrometer fitted with a
Smart Omni-Sampler germanium crystal accessory.

7.1.5
1

Nuclear Magnetic Resonance Spectroscopy

H NMR spectra were recorded at 500 MHz on a Varian Unity 500 Inova spectrometer.

The spectra were recorded in CDCl3 and chemical shifts were referenced to
tetramethylsilane (δ 0.00 ppm). Multiplicities are denoted as s (singlet), d (doublet), t
(triplet), br (broad) or m (multiplet). 13C NMR and 13C APT spectra were recorded at 126
MHz on a Varian Inova 500 spectrometer. Compound structures were confirmed with 2D
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NMR experiments, including gCOSY, NOESY, gHSQC and gHMBC spectra. 1H and 13C
NMR spectra for all synthesised compounds are provided in the Appendix.

7.1.6

Mass Spectrometry

Electrospray ionization mass spectra were recorded on a micromass Platform LCZ
spectrometer. ESI-high resolution mass spectra were recorded on a Waters XEVO QToF
spectrometer with leucine encephalin as the internal standard.

7.2

Synthesis of N-(4-aminophenyl)-2-(2-nitrophenyl)acetamide 4

2-(2-nitrophenyl)acetic acid (10.151 g, 56.0 mmol), p-phenylenediamine (6.690 g, 61.9
mmol) and HBTU (23.469 g, 61.9 mmol) were stirred in under argon in a round bottom
flask in CH2Cl2 (100 mL) at 0 °C for 10 minutes. DIPEA (22.4 mL, 131.7 mmol) was
then added dropwise over 10 minutes to the stirring solution and the reaction allowed to
warm to room temperature and stirring for 4 hours, monitored via TLC (EtOAc). The
reaction was then diluted with 250 mL CH2Cl2 added to a separating funnel and 300 mL
5 M HCl added and the product precipitated as a white solid in the aqueous layer. The
organic layer was removed and the aqueous layer washed with a further 3 x 200 mL
CH2Cl2. The aqueous layer was filtered, the solid collected and neutralised with 200 mL
5 M NaOH until the precipitate changed to a pale yellow colour. Solid was filtered dried
and recrystallised in hot ethanol to give 4 (12.110 g, 80%).
Rf = 0.25 (EtOAc). M.P. 168-170 °C. IR: (solid, ν/cm-1) 3344,
1684, 1517, 1424, 1410, 1357, 1307, 1275, 1237, 1175. 1H NMR
(500 MHz, d6-DMSO) δ 9.76 (s, 1H), 8.02 (d, J = 8.1 Hz, 1H),
7.69 (t, J = 7.5 Hz, 1H), 7.54 (t, J = 7.1 Hz, 3H), 7.54 (d, J = 7.5 Hz, 3H), 7.16 (d, J = 8.7
Hz, 3H), 6.48 (d, J = 8.7 Hz, 3H), 4.83 (s, 3H), 4.03 (s, 3H).

13

C NMR (126 MHz,

d6-DMSO) δ 166.9, 148.9, 144.4, 133.2, 133.0, 130.5, 127.9, 127.8, 124.1, 120.5, 113.5,
39.0. HREI-MS: m/z calculated for C1H14N3O3 [M+H+] 272.1030; observed 272.1035.

7.3

Synthesis of N-(4-(bis(2-hydroxyethyl)amino)phenyl)-2-(2-nitrophenyl)aceta

mide 5
A mixture of 4 (4.01 g, 14.8 mmol) and anhydrous K2CO3 (4.09 g, 30.0 mmol) was
prepared in 40 mL of 2-bromoethanol under argon. The reaction heated to 50 °C for 5
days and monitored via TLC (EtOAc). The product was precipitated with 500 mL H2O,
filtered and the aqueous layer treated with 200 mL saturated NaCl(aq) solution causing
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additional product to separate. The filtered solids combined, the impurities were
crystallised at room temperature from hot ethanol and filtered off. The crude residue was
recrystallised at −20 °C twice from hot ethanol to give 5 (3.31 g, 62%) as a yellow solid.
Rf = 0.65 (EtOAc). M.P. 132-134 °C. IR: (solid, ν/cm-1) 3276, 1653, 1559, 1539, 1517,
1507, 1340, 1261, 1180, 1074, 1049. 1H NMR (500 MHz,
d6-DMSO) δ 9.83 (s, 1H), 8.03 (t, J = 4.4 Hz, 1H), 7.69 (q,
J = 5.0 Hz, 1H), 7.55 (d, J = 7.4 Hz, 1H), 7.53 (t, J = 9.6
Hz, 1H), 7.30 (d, J = 9.0 Hz, 2H), 6.61 (d, J = 9.0 Hz, 2H), 4.70 (t, J = 5.4 Hz, 2H), 4.05
(s, 2H), 3.51 (q, J = 6.0 Hz, 4H), 3.37 (t, J = 6.3 Hz, 4H). 13C NMR (126 MHz, d6-DMSO)
δ 166.3, 149.0, 144.2, 133.4, 133.2, 130.7, 128.1, 127.6, 124.3, 120.7, 111.1, 58.1, 53.3,
40.1. HREI-MS: m/z calculated for C18H22N3O5 [M+H+] 360.1554; observed 360.1559.

7.4

Synthesis of N-(4-(bis(2-((tert-butyldimethylsilyl)oxy)ethyl)amino)phenyl)-2-

(2-nitrophenyl)acetamide 6
To a round bottom flask, 5 (4.53 g, 12.6 mmol), TBDMSCl (5.72 g, 37.9 mmol) and
imidazole (3.02 g, 44.3 mmol) were added and dissolved in 100 mL dry CH2Cl2 under
argon. The reaction was monitored via TLC (30% EtOAc: 70% pet. spirit). After 6 hours
the reaction was placed in the freezer overnight at −20 °C (to precipitate imidazole·HCl).
The imidazole·HCl was filtered off and the solution washed with saturated aqueous
NaHCO3 (3 × 100 mL) and saturated NaCl(aq) (1 × 100 mL), dried over anhydrous
MgSO4, filtered and concentrated in vacuo. The crude residue was purified by
recrystallisation at −20 °C from hot pet. spirit (75 mL) to give 6 (6.59 g, 89%) as a yellow
solid.
Rf = 0.76 (30% EtOAc: 70% pet. spirit). M.P. 118-119 °C.
IR: (solid, ν/cm-1) 2950, 1682, 1653, 1528, 1517, 1343,
1254, 1238, 1194, 1131, 1100, 1071, 929, 899, 836, 812.
1

H NMR (500 MHz, d6-DMSO) δ 9.83 (s, 1H), 8.02 (d, J = 8.2 Hz, 1H), 7.69 (t, J = 7.5

Hz, 1H), 7.55 (d, J = 5.9 Hz, 1H), 7.54 (t, J = 5.9 Hz, 1H), 7.30 (d, J = 8.9 Hz, 2H), 6.60
(d, J = 8.9 Hz, 2H), 4.05 (s, 2H), 3.69 (t, J = 5.9 Hz, 4H), 3.43 (t, J = 5.8 Hz, 4H), 0.85
(s, 18H), 0.00 (s, 12H). 13C NMR (126 MHz, CDCl3) δ 166.9,149.1, 145.5, 133.8, 133.5,
130.6, 128.6, 126.7, 125.3, 122.3, 111.8, 60.5, 53.9, 41.8, 26.0, 18.4, −5.2. HREI-MS:
m/z calculated for C30H50N3O5Si2 [M+H+] 588.3284; observed 588.3289.
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Synthesis of methyl 2-formyl-3,5-dimethyl-1H-pyrrole-1-carboxylate 7

A solution of potassium hydride (7.45 g, 186 mmol) in 30 mL of THF under argon was
cooled to 0 °C for 10 minutes. A solution 3,5-dimethyl-1H-pyrrole-2-carbaldehyde (15.3
g, 124 mmol) in 30 mL of THF was added dropwise and the solution stirred for 30 minutes
at 0 °C. A solution of methyl chloroformate (23.4 g. 248 mmol) in 40 mL of THF was
added slowly and the reaction allowed to warm to room temperature and monitored via
TLC (20% acetone: 80% pet. spirit). After 2 hours, the reaction was quenched with 50
mL ice cold water, extracted with EtOAc (3 × 150 mL), the organic layers combined and
washed with saturated NaCl(aq) (1 × 250 mL). Organic layer was dried over anhydrous
MgSO4, filtered and concentrated in vacuo. The crude product was purified by silica gel
column chromatography (100% pet. spirit to 10% acetone: 90% pet. spirit) and
concentrated in vacuo to yield 7 as a yellow solid (0.32 g, 73%).
Rf = 0.53 (20% acetone: 80% pet. spirit). M.P. 44-45 °C; IR: (solid, ν/cm1

) 1730, 1650, 1496, 1451, 1326, 1153, 765. 1H NMR (500 MHz, CDCl3) δ

9.99 (s, 1H), 5.89 (s, 1H), 3.96 (s, 3H), 2.38 (s, 3H), 2.30 (s, 3H). 13C NMR
(126 MHz, CDCl3) δ 181.3, 151.6, 138.4, 135.9, 130.5, 116.1, 54.5, 15.4, 13.0.
HREI-MS: m/z calculated for C9H12NO3 [M+H+] 182.0812; observed 182.0817.

7.6

Synthesis of (Z)-N-(4-(bis(2-((tert-butyldimethylsilyl)oxy)ethyl)amino)pheny

l)-3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)acrylamide (Z)-8
Potassium carbonate (2.35 g, 17.0 mmol) and 18-crown-6 (1.14 g, 4.3 mmol) were
dissolved in 50 mL dry THF and heated at 75 °C for 1 hour under nitrogen. A solution of
6 (5.01 g, 8.52 mmol) was prepared in 25 mL of dry THF, added slowly to the reaction
and left to stir at 75 °C for 1 hour. A solution of 7 (1.72 g, 9.47 mmol) in 25 mL of dry
THF was prepared and slowly added to the reaction. The reaction was then left for 3 hours
at 75 °C and monitored via TLC (30% EtOAc: 70% pet. spirit). The solvent was reduced
to less than 50 mL via rotary evaporation and transferred to a separating funnel with 100
mL of H2O. The aqueous layer was extracted with EtOAc (3 × 50 mL). Organic layers
were combined and washed with 100 mL of saturated NaCl(aq), dried over anhydrous
MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified
by gradient silica gel column chromatography (100% pet. spirit to 20% EtOAc: 80% pet.
spirit) to give (Z)-8 (1.22 g, 21%) as a red solid.
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Rf = 0.83 (30% EtOAc: 70% pet. spirit). M.P. 174-176 °C.
IR: (solid, ν/cm-1) 3313, 2928, 1654, 1612, 1595, 1514,
1379, 1360, 1322, 1289, 1250, 1095, 1054, 833, 810. 1H
NMR (500 MHz, CDCl3) δ 12.10 (br. s, 1H), 8.02 (dd, J
= 8.1, 1.2 Hz, 1H), 7.69 (td, J = 7.5, 1.0 Hz, 1H), 7.59 (dd, J = 7.6, 1.3 Hz, 1H), 7.54 (td,
J = 7.8, 1.3 Hz, 1H), 7.14 (d, J = 8.7 Hz, 2H), 6.68 (s, 1H), 6.63 (d, J = 8.8 Hz, 2H), 6.53
(s, 1H), 5.83 (d, J = 2.2 Hz, 1H), 3.73 (t, J = 6.4 Hz, 4H), 3.48 (t, J = 6.5 Hz, 4H), 2.29
(s, 3H), 2.11 (s, 3H), 0.89 (d, J = 0.7 Hz, 18H), 0.04 (d, J = 0.7 Hz, 12H). 13C NMR (126
MHz, CDCl3) δ 166.5, 149.7, 146.0, 136.4, 133.7, 133.6, 133.5, 129.5, 129.1, 128.8,
125.8, 125.0, 124.3, 124.3, 116.3, 111.7, 111.0, 60.4, 53.9, 26.0, 18.4, 13.8, 11.5, −5.2.
HREI-MS: m/z calculated for C37H57N4O5Si2 [M+H+] 693.3862; observed 693.3861.

7.7

Synthesis of (Z)-N-(4-(bis(2-hydroxyethyl)amino)phenyl)-3-(3,5-dimethyl-1

H-pyrrol-2-yl)-2-(2-nitrophenyl)acrylamide 9
A solution of (Z)-8 (0.50 g, 0.73 mmol) was prepared in 7 mL dry THF and cooled to 0
°C under argon. A mixture containing 3.5 mL 1 M TBAF (3.5 mmol) and 0.70 mL acetic
acid (12 mmol) was added dropwise to the reaction. The reaction was monitored via TLC
(EtOAc)

of

reaction

aliquots

obtained

after

mini-extractions

(saturated

NaHCO3(aq)/EtOAc). After 4 hours, the reaction was diluted with 50 mL EtOAc,
transferred to a separating funnel and extracted with saturated NaHCO3(aq) (3 × 50 mL)
and saturated NaCl(aq) (1 × 50 mL). The organic layer was dried over anhydrous MgSO4,
filtered and concentrated under reduced pressure. The crude residue was purified by
gradient silica gel column chromatography (50% EtOAc: 50% pet. spirit to 100% EtOAc)
to give 9 (0.290 g, 86%) as a red solid.
Rf = 0.60 (EtOAc). M.P. 102-104 °C. IR: (solid, ν/cm-1)
3274, 2868, 1641, 1513, 1341, 1321, 1262, 1235, 1202,
1179, 1151, 1041, 1001. 1H NMR (500 MHz, CDCl3) δ
12.02 (br. s, 1H), 8.01 (dd, J = 8.1, 1.2 Hz, 1H), 7.69 (td, J
= 7.5, 1.2 Hz, 1H), 7.59 (dd, J = 7.6, 1.1 Hz, 1H), 7.54 (td, J = 7.8, 1.4 Hz, 1H), 7.13 (d,
J = 8.9 Hz, 2H), 6.72 (s, 1H), 6.63 (d, J = 9.0 Hz, 2H), 6.54 (s, 1H), 5.83 (d, J = 2.6 Hz,
1H), 3.79 (t, J = 4.9 Hz, 4H), 3.52 (t, J = 4.9 Hz, 4H), 3.44 (br. s, 2H), 2.27 (s, 3H), 2.10
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 166.7, 149.7, 146.0, 136.3, 133.7, 133.7, 133.6,
129.8, 129.1, 129.0, 126.8, 125.0, 124.4, 124.3, 116.2, 113.0, 111.1, 60.8, 55.4 13.7, 11.6.
HREI-MS: m/z calculated for C25H29N4O5 [M+H+] 465.2132; observed 465.2138.
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Synthesis of (Z)-N-(4-(bis(2-chloroethyl)amino)phenyl)-3-(3,5-dimethyl-1H-

pyrrol-2-yl)-2-(2-nitrophenyl)acrylamide 1
A solution of 9 (0.22 g, 0.46 mmol) was prepared in 5 mL dry CH2Cl2 and cooled to 0
°C. Triethylamine (0.090 mL, 1.2 mmol) and methanesulfonyl chloride (0.19 mL, 1.4
mmol) were added to the reaction and stirring continued at 0 °C while monitoring via
TLC (EtOAc). After 1 hour, the reaction was diluted with 20 mL CH2Cl2 and transferred
to a separating funnel. The organic layer was extracted with saturated NaHCO3(aq) (3 ×
25 mL) and saturated NaCl(aq) (1 × 25 mL), dried over anhydrous MgSO4, filtered and
concentrated under reduced pressure without heating. The crude residue was taken up in
5 mL dry DMF and lithium chloride (0.20 mg, 4.7 mmol) was added. After heating at 50
°C for 45 minutes the reaction was transferred to a separating funnel containing 25 mL
H2O and extracted with CH2Cl2 (3 × 25 mL). The organic layers were combined, dried
over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude
residue was purified by gradient silica gel column chromatography (100% pet. spirit to
20% EtOAc: 80% pet. spirit) to give 1 (0.19 g, 80% over 2 steps) as a red solid. (Note:
The bis-mesylate is highly unstable when isolated in pure form after silica gel column
chromatography and is best used in crude form).
Rf = 0.81 (50% EtOAc: 50% pet. spirit). M.P. 180-182 °C.
IR: (solid, ν/cm-1) 3402, 2921, 2852, 1647, 1521, 1513,
1460, 1353, 1322, 1235, 1178, 1150, 747. 1H NMR (500
MHz, CDCl3) δ 12.04 (s, 1H), 8.03 (dd, J = 8.1, 0.8 Hz, 1H),
7.70 (td, J = 7.5, 1.1 Hz, 1H), 7.60 (dd, J = 7.5, 0.9 Hz, 1H), 7.56 (td, J = 7.8, 1.2 Hz,
1H), 7.21 (d, J = 8.9 Hz, 2H), 6.68 (s, 1H), 6.64 (d, J = 9.0 Hz, 2H), 6.55 (s, 1H), 5.83 (d,
J = 2.0 Hz, 1H), 3.70 (t, J = 7.0 Hz, 4H), 3.60 (t, J = 6.9 Hz, 4H), 2.28 (s, 3H), 2.11 (s,
3H).

13

C NMR (126 MHz, CDCl3) δ 166.9, 149.8, 144.0, 136.3, 133.8, 133.7, 133.7,

130.0, 129.2, 129.2, 127.8, 125.0, 124.6, 124.3, 115.9, 112.6, 111.1, 53.8, 40.6, 13.8,
11.6. HREI-MS: m/z calculated for C25H27Cl2N4O3 [M+H+] 501.1455; observed
501.1455.

7.9

Synthesis of 1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldi

methylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-5-fluoropyrimidine-2,4(1H,3H)-dion
e 14
A solution of TBDMSCl (45.91 g, 304.6 mmol) and imidazole (24.27 g, 356.6 mmol) in
CH2Cl2

(200

mL)

under

argon

was

cooled
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2'-Deoxy-5-fluorouridine (24.88 g, 101.1 mmol) dissolved in CH2Cl2 (100 mL) was
added slowly, the reaction allowed to warm to room temperature and monitored by TLC
(30% EtOAc: 70% pet. spirit). After 20 hours, the reaction mixture was placed in a freezer
(-20 °C) for 30 minutes (to precipitate the imidazole·HCl). The imidazole·HCl was
filtered off and the filtrate washed with cold CH2Cl2 (2 × 25 mL). The filtrate was
transferred to a separating funnel and washed with saturated NaHCO3(aq) (3 × 100 mL)
and saturated NaCl(aq) (1 × 100 mL), dried over anhydrous MgSO4 and concentrated in
vacuo. The crude residue was purified by recrystallisation from hot pet. spirit to yield 14
as a white solid (46.8 g, 97%).
Rf = 0.78 (30% EtOAc: 70% pet. spirit). M.P. 82-86 °C; O.R.
-1
[𝛼]25
𝐷 = + 18.8 (c 1.00, CHCl3). IR (solid, ν/cm ): 3469, 3360,

2952, 1737, 1655, 1628, 1592, 1504, 1472, 1458, 1436, 1372,
1317, 1255, 1144, 1091, 1066, 1025, 974, 884, 830, 783, 740, 676. 1H NMR (500 MHz,
CDCl3) δ 9.44 (br. s, 1H), 8.05 (d, J = 6.2 Hz, 1H), 6.29 (td, J = 6.3, 1.5 Hz, 1H), 4.40
(dt, J = 6.0, 4.9 Hz, 1H), 3.95-3.90 (m, 2H), 3.76 (dd, J = 11.9, 2.2 Hz, 1H), 2.31 (ddd, J
= 13.3, 6.1, 3.9 Hz, 1H), 2.05 (dt, J = 13.1, 6.4 Hz, 1H), 0.92 (s, 9H), 0.88 (s, 9H), 0.12
(d, J = 3.6 Hz, 6H), 0.07 (d, J = 3.0 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 157.1 (d, J
= 26.8 Hz), 149.0, 140.7 (d, J = 236.2 Hz), 124.4 (d, J = 34.1 Hz), 88.2, 85.7, 71.7, 62.8,
41.0, 26.0, 25.8, 18.5, 18.1, −4.5, −4.7, −5.4, −5.5. HREI-MS: m/z calculated for
C21H40FN2O5Si2 [M+H+] 475.2454; observed 475.2460.

7.10

Synthesis of 1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldim

ethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-3-(2,4-dimethoxybenzoyl)-5-fluoropyri
midine-2,4(1H,3H)-dione 20
2,4-Dimethoxybenzoyl chloride (79.10 g, 394.3 mmol) and DMAP (4.82 g, 39.4 mmol)
were dissolved in 150 mL of CH2Cl2 under argon. DIPEA (68.7 mL, 394.3 mmol) was
added slowly, and the reaction was heated at 45 °C for 15 minutes causing a deep red
colour to develop. A solution of 14 (46.79 g, 98.6 mmol) in 100 mL of CHCl2 was slowly
added and the reaction heated at 45 °C with monitoring by TLC (0.5% MeOH: 99.5%
CHCl3). After 16 hours, the reaction was transferred to a separating funnel and washed
with saturated NaHCO3(aq) (3 × 250 mL), 1 M aqueous HCl (3 × 250 mL), and saturated
NaCl(aq) (1 × 250 mL). The organic layer was separated, dried over anhydrous MgSO4
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and concentrated in vacuo. The crude residue was purified by silica gel column
chromatography (20% EtOAc: 80% pet. spirit) to yield 20 as a white solid (54.7 g, 87%).
Rf = 0.61 (30% EtOAc: 70% pet. spirit). M.P. 56-60 °C; O.R.
-1
[𝛼]25
𝐷 = + 15.3 (c 1.00, CHCl3). IR (solid, ν/cm ): 2955,

2930, 2857, 1738, 1701, 1666, 1602, 1571, 1459, 1396, 1341,
1290, 1273, 1249, 1214, 1193, 1165, 1106, 1067, 1024, 965,
939, 913, 882, 830, 812, 778, 752, 729, 717, 706, 669, 647,
634. 1H NMR (500 MHz, CDCl3) δ 8.08 (d, J = 6.2 Hz, 1H), 8.07 (d, J = 8.9 Hz, 1H),
6.59 (dd, J = 8.9, 2.2 Hz, 1H), 6.38 (d, J = 2.2 Hz, 1H), 6.29 (td, J = 6.3, 1.3 Hz, 1H),
4.41 (dt, J = 5.7, 3.3 Hz, 1H), 3.96-3.93 (m, 2H), 3.85 (s, 3H), 3.78 (dd, J = 12.0, 2.4 Hz,
1H), 3.76 (s, 3H), 2.31 (ddd, J = 13.1, 6.0, 3.7 Hz, 1H), 2.06 (dt, J = 13.2, 6.2 Hz, 1H),
0.94 (s, 9H), 0.87 (s, 9H), 0.15 (s, 3H), 0.14 (s, 3H), 0.07 (s, 6H). 13C NMR (126 MHz,
CDCl3) δ 167.0, 163.9, 161.9, 156.2 (d, J = 27.8 Hz), 148.1, 140.5 (d, J = 237.4 Hz),
136.4, 123.3 (d, J = 43.5 Hz), 113.3, 106.9, 98.9, 88.3, 85.8, 71.8, 62.9, 56.4, 55.9, 41.9,
26.0, 25.8, 18.6, 18.1, −4.5, −4.7, −5.4. HREI-MS: m/z calculated for C30H48FN2O8Si2
[M+H+] 639.2928; observed 639.2933.

7.11

Synthesis of 1-((2R,4S,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethy

l)tetrahydrofuran-2-yl)-3-(2,4-dimethoxybenzoyl)-5-fluoropyrimidine-2,4(1H,3H)dione 21
A solution of 20 (17.85 g, 27.9 mmol) in 168 mL of THF was cooled to 0 °C for 10
minutes. Trichloroacetic acid (89.05 g, 545.3 mmol) in 42 mL H2O was added slowly and
the reaction monitored by TLC (30% EtOAc: 70% pet. spirit). After 4 hours, the reaction
was quenched slowly with saturated NaHCO3(aq) (200 mL) and extracted with CH2Cl2 (3
× 200 mL). The organic fractions were combined, dried over anhydrous MgSO4 and
concentrated in vacuo. The crude residue was purified by silica gel column
chromatography (100% pet. spirit to 60% EtOAc: 40% pet. spirit) to give 21 as a white
solid (7.33 g, 50%).
Rf = 0.09 (30% EtOAc: 70% pet. spirit). M.P. 70-74 °C; O.R.
-1
[𝛼]25
𝐷 = + 10.8 (c 1.00, CHCl3). IR: (solid, ν/cm ) 2952, 1931,

2899, 2888, 2857, 2362, 1734, 1699, 1693, 1683, 1681, 1656,
1601, 1570, 1542, 1506, 1499, 1491, 1458, 1439, 1421, 1397,
1359, 1342, 1274, 1246, 1213, 1190, 1166, 1133, 1099, 1063,
1021, 993, 943, 906, 870, 832, 779, 753, 729, 719, 684, 671, 661, 647, 631, 628, 620,
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605. 1H NMR (500 MHz, CDCl3) δ 8.07 (d, J = 8.9 Hz, 1H), 8.06 (d, J = 6.3 Hz, 1H),
6.60 (dd, J = 8.9, 2.2 Hz, 1H), 6.38 (d, J = 2.1 Hz, 1H), 6.22 (t, J = 6.4 Hz, 1H), 4.47 (dt,
J = 5.7, 3.4 Hz, 1H), 3.96-3.90 (m, 2H), 3.86 (s, 3H), 3.78 (dd, J = 11.2, 1.9 Hz, 1H), 3.76
(s, 3H), 2.28 (ddd, J = 13.3, 6.1, 3.7 Hz, 1H), 2.20 (dt, J = 13.3, 6.4 Hz, 1H), 0.87 (s, 9H),
0.07 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 167.2, 163.8, 161.9, 156.4 (d, J = 27.4 Hz),
148.2, 140.5 (d, J = 238.8 Hz), 136.4, 124.3 (d, J = 34.4 Hz), 113.1, 107.0, 98.8, 88.0,
86.6, 71.9, 62.0, 56.4, 55.9, 41.5, 25.8, 18.0, −4.6, −4.8. HREI-MS: m/z calculated for
C24H34FN2O8Si [M+H+] 525.2063; observed 525.2068.

7.12

Synthesis of ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(3-(2,4-dimethoxy

benzoyl)-5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)
methyl 2-(2-nitrophenyl)acetate 22
A solution of 21 (9.34 g, 17.8 mmol), 2-(2-nitrophenyl)acetic acid (3.87 g, 21.4 mmol)
and DMAP (0.934 g, 7.64 mmol) in 250 mL of CH2Cl2 under argon was cooled to 0 °C.
A solution of DCC (4.41 g, 21.4 mmol) in 50 mL of CH2Cl2 was added slowly and the
reaction stirred at 0 °C and monitored by TLC (50% EtOAc: 50% pet. spirit). After 4
hours, the reaction was placed in a freezer (−20 °C) overnight (to precipitate the DCU
by-product). The urea by-product was filtered off and the residue washed with cold
CH2Cl2 (2 × 50 mL). The organic layer was transferred to a separating funnel and washed
with saturated NaHCO3(aq) (3 × 200 mL), 1 M aqueous HCl (3 × 200 mL) and saturated
NaCl(aq) solution (1 × 200 mL). The organic layer was dried over anhydrous MgSO4,
filtered and concentrated in vacuo. The crude residue was purified by gradient silica gel
column chromatography (100% pet. spirit to 60% EtOAc: 40% pet. spirit) to afford 22 as
a white solid (10.5 g, 87%).
Rf = 0.57 (50% EtOAc: 50% pet. spirit). M.P. 60-64 °C;
O.R. [𝛼]25
𝐷 = + 15.8 (c 1.00, CHCl3). IR: (solid, ν/cm
1

) 2958, 2930, 2903, 2856, 2361, 1735, 1700, 1693,

1684, 1665, 1639, 1601, 1570. 1562, 1541, 1526, 1507,
1499, 1489, 1468, 1457, 1439, 1420, 1397, 1373, 1344,
1274, 1255, 1212, 1194, 1166, 1132, 1101, 1087, 1019, 960, 880, 862, 832, 812, 782,
751, 718, 668, 621, 614, 608. 1H NMR (500 MHz, CDCl3) δ 8.17 (dd, J = 8.2, 1.0 Hz,
1H), 8.08 (d, J = 8.9 Hz, 1H), 7.65 (td, J = 7.5, 1.1 Hz, 1H), 7.62 (d, J = 6.2 Hz, 1H), 7.53
(td, J = 7.8, 1.2 Hz, 1H), 7.41 (d, J = 7.5 Hz, 1H), 6.60 (dd, J = 8.9, 2.2 Hz, 1H), 6.39 (d,
J = 2.1 Hz, 1H), 6.20 (t, J = 5.8 Hz, 1H), 4.44 (dd, J = 12.4, 3.0 Hz, 1H), 4.34-4.29 (m,
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2H), 4.13-4.03 (m, 3H), 3.86 (s, 3H), 3.77 (s, 3H), 2.28 (ddd, J = 13.5, 5.9, 3.8 Hz, 1H),
1.85 (dt, J = 13.1, 6.1 Hz, 1H), 0.86 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H). 13C NMR (126
MHz, CDCl3) δ 169.6, 167.2, 163.7, 161.9, 156.0 (d, J = 26.2 Hz), 148.5, 147.9, 140.4
(d, J = 239.1 Hz), 136.5, 134.3, 133.7, 129.4, 129.3, 125.6, 122.9 (d, J = 34.3 Hz), 113.0,
106.9, 98.8, 85.7, 85.2, 71.4, 63.9, 56.5, 55.9, 41.3, 40.2, 25.7, 18.0, −4.7, −4.9. HREIMS: m/z calculated for C32H39FN3O11Si [M+H+] 688.2332; observed 688.2338.

7.13

Synthesis of ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(3-(2,4-dimethoxy

benzoyl)-5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)
methyl (Z)-3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)acrylate (Z)-23
A solution K2CO3 (2.05 g, 14.7 mmol) and 18-crown-6 (0.962 g, 3.64 mmol) in 50 mL
dry THF under argon was heated at 75 °C for 1 hour. A solution of 22 (5.00 g, 7.27 mmol)
in 25 mL dry THF was added slowly to the reaction and a deep blue colour appeared.
After 1 hour of additional heating, a solution of 7 (1.48 g, 8.15 mmol) in 25 mL dry THF
was added slowly and the reaction was continued at reflux with monitoring by TLC (30%
EtOAc: 70% pet. spirit). After 18 hours, the reaction was concentrated under reduced
pressure to less than 50 mL and transferred to a separating funnel containing 100 mL of
H2O. The mixture was extracted with EtOAc (3 × 50 mL) and the organic layers
combined, washed with saturated NaHCO3(aq) (3 × 100 mL), saturated NaCl(aq) (1 × 100
mL), dried over anhydrous MgSO4 and concentrated in vacuo. The crude residue was
purified by silica gel column chromatography (100% pet. spirit to 60% EtOAc: 40% pet.
spirit) to give one fraction containing (Z)-23 with side product 25 and a second fraction
containing (E)-23, along with recovered starting material 22. The first fraction was further
purified by silica gel column chromatography (100% CHCl3) to yield cis product (Z)-23
as a red solid (0.551 g, 10%) and side product 25 as a red solid (0.851 g, 20%). The second
fraction was further purified by silica gel column chromatography (100% CHCl3) to yield
trans product (E)-23 as a red solid (0.605 g, 11%) and recovered starting material 22 (2.77
g, 55%).
Rf = 0.56 (30% EtOAc: 70% pet. spirit). M.P. 96-98 °C;
O.R. [𝛼]25
𝐷 = + 41.0 (c 0.10, CHCl3). IR: (solid, ν/cm
1

) 2951, 2928, 2856, 1739, 1667, 1602, 1571, 1544,

1523, 1457, 1395, 1344, 1248, 1213, 1182, 1146, 1131,
1109, 1084, 1020, 990, 941, 921, 892, 857, 832, 781,
753, 728, 710, 666, 643, 619, 610, 608, 597, 582, 555, 535. 1H NMR (500 MHz, CDCl3)
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δ 11.73 (br. s, 1H), 8.07 (dd, J = 8.2, 0.9 Hz, 1H), 8.06 (d, J = 8.9 Hz, 1H), 7.67 (t, J =
7.4 Hz, 1H), 7.50 (dt, J = 7.1, 5.3 Hz, 1H), 7.00 (d, J = 4.5 Hz, 1H), 6.85 (s, 1H), 6.59
(dd, J = 8.9, 2.1 Hz, 1H), 6.36 (d, J = 2.0 Hz, 1H), 6.12 (t, J = 6.5 Hz, 1H), 5.94 (d, J =
1.5 Hz, 1H), 4.37 (d, J = 12.1 Hz, 1H), 4.18 (d, J = 12.1 Hz, 1H), 4.14-4.02 (m, 2H), 3.85
(s, 3H), 3.71 (s, 3H), 2.36 (s, 3H), 2.35-2.19 (m, 1H), 2.18 (s, 3H), 1.97-1.88 (m, 1H),
0.85 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H).

13

C NMR (126 MHz, CDCl3) δ 167.4, 167.2,

163.7, 161.9, 155.9 (d, J = 25.6 Hz), 148.8, 147.9, 140.2 (d, J = 234.0 Hz), 137.0, 136.5,
135.5, 134.3, 133.0, 132.9, 132.6, 128.5, 124.6, 124.6, 122.7 (d, J = 33.6 Hz), 113.1,
112.1, 111.8, 106.9, 98.9, 85.7, 85.4, 72.8, 64.7, 56.4, 55.9, 41.0, 25.8, 18.0, 13.8, 11.7,
−4.7, −4.9. HREI-MS: m/z calculated for C39H46FN4O11Si [M+H+] 793.2911; observed
793.2916.
Rf = 0.34 (30% EtOAc: 70% pet. spirit). M.P. 76-78
°C; O.R. [𝛼]25
𝐷 = − 3.2 (c 0.10, CHCl3). IR: (solid,
ν/cm-1) 2953, 2926, 2854, 1737, 1698, 1665, 1601,
1569, 1557, 1525, 1504, 1489, 1457, 1424, 1397, 1379,
1344, 1274, 1248, 1219, 1170, 1147, 1132, 1111, 1085,
1021, 940, 896, 880, 856, 832, 813, 780, 752, 719, 700, 667, 646, 616, 609, 604. 1H NMR
(500 MHz, CDCl3) δ 8.20 (dd, J = 8.1, 1.2 Hz, 1H), 8.06 (d, J = 8.9 Hz, 1H), 7.84 (s, 1H),
7.75 (td, J = 7.5, 0.9 Hz, 1H), 7.67 (td, J = 7.9, 1.5 Hz, 1H), 7.56 (dd, J = 7.5, 1.3 Hz,
1H), 7.04 (d, J = 6.0 Hz, 1H), 6.71 (br. s, 1H), 6.59 (dd, J = 8.9, 2.2 Hz, 1H), 6.37 (d, J =
2.3 Hz, 1H), 6.11 (t, J = 7.0 Hz, 1H), 5.77 (d, J = 2.1 Hz, 1H), 4.40 (dd, J = 12.6, 2.1 Hz,
1H), 4.22 (dd, J = 12.6, 2.4 Hz, 1H), 4.18-4.15 (m, 1H), 4.09-4.07 (m, 1H), 3.86 (s, 3H),
3.73 (s, 3H), 2.33-2.27 (m, 1H), 2.21 (s, 3H), 1.97 (s, 3H), 1.85-1.77 (m, 1H), 0.85 (s,
9H), 0.06 (s, 3H), 0.05 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 167.2, 166.6, 163.7, 161.9,
156.0 (d, J = 27.8 Hz), 149.3, 147.8, 140.2 (d, J = 237.8 Hz), 136.4, 135.3, 134.4, 133.3,
132.3, 132.2, 130.1, 129.5, 125.4, 123.6, 122.7 (d, J = 33.6 Hz), 113.8, 112.9, 111.4,
106.9, 98.8, 86.0, 85.6, 72.8, 64.9, 56.4, 55.9, 41.3, 25.8, 18.0, 13.5, 11.6, −4.8, −4.9.
HREI-MS: m/z calculated for C39H46FN4O11Si [M+H+] 793.2911; observed 793. 2916.
Rf = 0.34 (30% EtOAc: 70% pet. spirit). M.P. 55-57 °C;
-1
O.R. [𝛼]25
𝐷 = + 13.6 (c 1.00, CHCl3). IR: (solid, ν/cm )

2955, 2927, 2856, 1738, 1665, 1601, 1570, 1504, 1457,
1397, 1355, 1277, 1248, 1213, 1166, 1131, 1078, 1020, 965,
938, 865, 832, 780, 751, 670, 646. 1H NMR (500 MHz,
CDCl3) δ 8.08 (d, J = 8.8 Hz, 1H), 7.69 (d, J = 5.9 Hz, 1H), 6.60 (d, J = 8.8 Hz, 1H), 6.38
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(s, 1H), 6.30 (t, J = 5.9 Hz, 1H), 4.43 (d, J = 11.9 Hz, 1H), 4.40-4.36 (m, 1H), 4.30 (d, J
= 11.9 Hz, 1H), 4.09-4.06 (m, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 3.76 (s, 3H), 2.37-2.29 (m,
1H), 2.14-2.06 (m, 1H), 0.87 (s, 9H), 0.07 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 167.1,
163.7, 161.9, 156.0 (d, J = 27.7 Hz), 155.5, 148.1, 140.7 (d, J = 238.6 Hz), 136.5, 122.9
(d, J = 34.4 Hz), 113.2, 106.9, 98.9, 85.7, 85.1, 71.9, 66.6, 56.4, 55.9, 55.4, 41.2, 25.8,
18.0, −4.6, −4.8. HREI-MS: m/z calculated for C26H35FN2O10SiNa [M+Na+] 605.1937;
observed 605.1943.

7.14

Synthesis of ((2R,3S,5R)-3-((tert-butyldimethylsilyl)oxy)-5-(5-fluoro-2,4-diox

o-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl (Z)-3-(3,5-dimethyl1H-pyrrol-2-yl)-2-(2-nitrophenyl)acrylate 24
A solution of (Z)-23 (0.300 g, 0.378 mmol) in 6 mL ammonia solution (7 N in methanol)
at 0 °C was prepared and the reaction monitored by TLC (30% EtOAc: 70% pet. spirit).
After 2 hours, the reaction was concentrated in vacuo and the crude residue was purified
by gradient silica gel column chromatography (100% pet. spirit to 40% EtOAc: 60% pet.
spirit) to yield 24 as a red solid (0.179 g, 75%).
Rf = 0.32 (30% EtOAc: 70% pet. spirit). M.P. 86-88 °C; O.R.
-1
[𝛼]25
𝐷 = + 8.0 (c 0.10, CHCl3). IR: (solid, ν/cm ) 2953, 2928,

2857, 1751, 1702, 1606, 1573, 1560, 1543, 1523, 1464, 1441,
1401, 1391, 1349, 1315, 1266, 1249, 1182, 1148, 1129, 1104,
1081, 1049, 1024, 1006, 970, 940, 883, 858, 831, 913, 778,
754, 711, 688, 670, 637, 617, 610. 1H NMR (500 MHz, CDCl3) δ 11.71 (br s, 1H), 8.43
(s, 1H), 8.05 (dd, J = 8.1, 0.7 Hz, 1H), 7.62 (t, J = 7.2 Hz, 1H), 7.48 (d, J = 8.3 Hz, 1H),
7.45 (t, J = 7.6 Hz, 1H), 6.95 (d, J = 4.9 Hz, 1H), 6.83 (s, 1H), 6.11 (t, J = 7.0 Hz, 1H),
5.93 (d, J = 1.9 Hz, 1H), 4.35 (d, J = 11.1 Hz, 1H), 4.18 (d, J = 12.2 Hz, 1H), 4.13-4.09
(m, 1H), 4.05-4.03 (m, 1H), 2.36 (s, 3H), 2.34-2.24 (m, 1H), 2.17 (s, 3H), 1.97-1.89 (m,
1H), 0.87 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 167.3, 156.5
(d, J = 28.2 Hz), 148.8, 148.4, 140.3 (d, J = 237.2 Hz), 137.1, 135.5, 134.1, 133.0, 132.9,
132.6, 128.4, 124.6, 124.6, 123.7 (d, J = 33.5 Hz), 112.1, 111.7, 85.7, 85.2, 72.7, 64.6,
40.9, 25.8, 18.1, 13.9, 11.7, −4.7, −4.8. HREI-MS: m/z calculated for C30H38FN4O8Si
[M+H+] 629.2437; observed 629.2443.
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Synthesis of ((2R,3S,5R)-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-

yl)-3-hydroxytetrahydrofuran-2-yl)methyl (Z)-3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2
-nitrophenyl)acrylate 2
A solution of 24 (0.177 g, 0.28 mmol) in 10 mL dry THF was prepared and cooled to 0
°C. A mixture of 1 M TBAF in THF (1.50 mL, 1.50 mmol) and glacial acetic acid (0.300
mL, 5.25 mmol) was prepared and slowly added to the reaction. The reaction was
monitored via mini-extractions (H2O/EtOAc) followed by TLC (50% EtOAc: 50% pet.
spirit). After 24 hours, the reaction was transferred to a separating funnel and 50 mL of
EtOAc was added. The organic layer was washed with H2O (3 × 50 mL) and saturated
NaCl(aq) (1 × 50 mL), dried over anhydrous MgSO4 and concentrated in vacuo. The crude
residue was purified by gradient silica gel column chromatography (100% pet. spirit to
50% acetone:50% pet. spirit) to yield 2 as a red solid (0.099 g, 69%).
Rf = 0.69 (EtOAc). M.P. 89-91 °C; O.R. [𝛼]25
𝐷 = + 54.3 (c
0.10, CHCl3). IR: (solid, ν/cm-1) 2954, 2929, 2856, 1692,
1607, 1572, 1560, 1543, 1522, 1502, 1471, 1441, 1393, 1341,
1315, 1265, 1180, 1149, 1129, 1101, 1080, 1047, 1025, 1006,
983, 970, 939, 922, 881, 858, 830, 810, 788, 779, 753, 711, 667, 650, 637, 617, 610. 1H
NMR (500 MHz, CDCl3) δ 11.66 (br s, 1H), 8.02 (d, J = 8.1 Hz, 1H), 7.61 (t, J = 7.4 Hz,
1H), 7.46 (d, J = 7.6 Hz, 1H), 7.42 (t, J = 7.8 Hz, 1H), 7.01 (s, 1H), 6.81 (s, 1H), 6.10 (t,
J = 6.5 Hz, 1H), 5.91 (s, 1H), 4.31 (d, J = 11.3 Hz, 1H), 4.24 (d, J = 11.5 Hz, 1H), 4.164.07 (m, 2H), 2.33 (s, 3H), 4.18-4.13 (m, 5H).

13

C NMR (126 MHz, CDCl3) δ 167.4,

157.2 (d, J = 27.0 Hz), 149.0, 148.5, 140.4 (d, J = 236.7 Hz), 136.9, 135.4, 134.2, 132.9,
132.8, 132.4, 128.4, 124.6, 124.5, 123.7 (d, J = 33.3 Hz), 112.0, 111.9, 85.3, 84.8, 71.9,
64.6, 40.1, 13.8, 11.6. HREI-MS: m/z calculated for C24H24FN4O8 [M+H+] 515.1573;
observed 515.1578.

7.16

Characterisation of Side Product 3,5-dimethyl-1-(methylsulfonyl)-1H-pyrro

le-2-carbaldehyde 26
Rf = 0.29 (20% EtOAc: 80% pet. spirit). M.P. 58-61 °C; IR (solid, ν/cm-1):
3009, 2959, 2927, 2871, 2859, 1724, 1651, 1573, 1481, 1439, 1424, 1379,
1357, 1337, 1289, 1230, 1175, 1154, 1073, 1048, 1004, 969, 891, 871, 858,
853, 826, 784, 766, 746, 708, 674, 662, 647, 625, 611, 608, 606. 1H NMR
(500 MHz, CDCl3) δ 9.91 (s, 1H), 5.97 (s, 1H), 3.42 (s, 3H), 2.46 (s, 3H), 2.33 (s, 3H).
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C NMR (126 MHz, CDCl3) δ 179.0, 140.9, 138.8, 130.7, 117.1, 43.5, 15.6, 12.6. HREI-

MS: m/z calculated for C8H12NO3S [M+H+] 202.0532; observed 202.0534.

7.17

Characterisation of Side Product 4,6-dimethylpyrrolo[1,2-b]isothiazole 1,1-

dioxide 27
Rf = 0.20 (20% EtOAc: 80% pet. spirit). 1H NMR (400 MHz, CDCl3) δ 5.89
(s, 1H), 5.31 (d, J = 6.1 Hz, 1H), 4.04 (dd, J = 13.7, 6.3 Hz, 1H), 3.74 (dd,
J = 13.7, 1.2 Hz, 1H), 2.88 (br s, 1H), 2.35 (s, 3H), 2.03 (s, 3H). 13C NMR
(126 MHz, CDCl3) δ 128.6, 126.1, 117.7, 117.2, 63.1, 61.5, 11.3, 10.1.

7.18

Characterisation of Side Product 4,6-dimethylpyrrolo[1,2-b]isothiazole 1,1-

dioxide 28
Rf = 0.69 (20% EtOAc: 80% pet. spirit). M.P. 68-70 °C; IR (solid, ν/cm-1):
3096, 2925, 1605, 1526, 1516, 1512, 1394, 1371, 1337, 1310, 1298, 1264,
1158, 1143, 1094, 1073, 1038, 996, 901, 800, 792, 694, 680, 628, 613. 1H
NMR (500 MHz, CDCl3) δ 7.04 (d, J = 6.6 Hz, 1H), 6.24 (d, J = 6.6 Hz, 1H), 5.80 (s,
1H), 2.46 (s, 3H), 2.03 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 134.5, 126.3, 126.2, 122.4,
122.1, 116.8, 11.7, 10.5. HREI-MS: m/z calculated for C8H10NO2S [M+H+] 184.0427;
observed 184.0428.

7.19

Proof of Concept Chemical Reductions with Fe(0) in CH3COOH

A mixture of 2 (0.030 g, 0.058 mmol) and Fe(0) (0.033 g, 0.584 mmol) was dissolved in
6 mL CH3COOH:EtOH:H2O (1:1:1) and sonicated for 1 hour at room temperature. After
consumption of starting material (TLC analysis), the reaction was filtered through celite
and washed with EtOH (30 mL). The mixture was concentrated under vacuum and
redissolved in Et2O (30 mL). The organic layer was extracted with 1 M NaOH(aq) (3 × 30
mL). The organic and aqueous layers were separated. The organic layer was dried over
anhydrous MgSO4, filtered and concentrated in vacuo to give crude 3. The aqueous layer
was acidified with 1 M HCl(aq) (100 mL) and extracted with Et2O (2 × 30 mL). The
organic layers were combined, dried over anhydrous MgSO4, filtered and concentrated in
vacuo to give crude 29. The crude products were purified by preparative TLC (20%
acetone: 80% pet. spirit) to yield 3 as a yellow solid (11.6 mg, 84%) and 29 as a yellow
solid (1.6 mg, 11%). The same procedure with 1 yielded 3 (11.4 mg, 80%) and 29 (2.1
mg, 14%).
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Proof of Concept Chemical Reductions with FeCl3 6H2O/Zn

A mixture of 2 (0.030 g, 0.058 mmol), FeCl3.6H2O (0.076 g, 0.281 mmol) and Zn(0) dust
(0.078 g, 1.198 mmol) was dissolved in 3 mL DMF:H2O (1:1) and stirred for 3 hours at
room temperature. After consumption of starting material (TLC analysis), the reaction
was filtered through celite and washed with Et2O (30 mL). The organic layer was
extracted with 1 M NaOH(aq) (3 × 30 mL) and the organic and aqueous layers collected
separately. The organic layer was dried over anhydrous MgSO4, filtered and concentrated
in vacuo to give crude 3. The aqueous layer was acidified with 1 M HCl(aq) (100 mL) and
extracted with Et2O (2 × 30 mL). The organic layers were combined, dried over
anhydrous MgSO4, filtered and concentrated in vacuo to give crude 29. The crude
products were purified by preparative TLC (20% acetone: 80% pet. spirit) to yield 3 as a
yellow solid (5.9 mg, 40%) and 29 as a yellow solid (7.1 mg, 51%). The same procedure
with 1 yielded 3 (7.6 mg, 53%) and 29 (4.8 mg, 32%).

7.21

Proof of Concept Chemical Reductions with NaBH4/Pd-C

A mixture of 2 (0.030 g, 0.058 mmol), NaBH4 (0.022 g, 0.582 mmol) and Pd-C (0.020 g)
was dissolved in 6 mL MeOH:H2O (2:1) and stirred for 30 minutes at room temperature.
After consumption of starting material (TLC analysis), the reaction was filtered through
celite and washed with Et2O (30 mL). The organic layer was extracted with 1 M NaOH(aq)
(3 × 30 mL) and the organic and aqueous layers collected separately. The organic layer
was dried over anhydrous MgSO4, filtered and concentrated in vacuo to give crude 3. The
aqueous layer was acidified with 1 M HCl(aq) (100 mL) and extracted with Et2O (2 × 30
mL). The organic layers were combined, dried over anhydrous MgSO4, filtered and
concentrated in vacuo to give crude 29. The crude products were purified by preparative
TLC (20% acetone: 80% pet. spirit) to yield 3 as a yellow solid (5.1 mg, 37%) and 29 as
a yellow solid (6.7 mg, 45%). The same procedure with 1 yielded 3 (6.1 mg, 43%) and
29 (5.6 mg, 37%).

7.22

In Vitro Biological Evaluation of 1 and 2

The methods used by our collaborators for the cell-based cytotoxicity assays are briefly
described here. MDA-MB-468 and SW620 cells were harvested and counted to identify
the required number of cells to obtain 1,000 cells per well in a 96-well plate. The cells
were centrifuged, excess supernatant was aspirated off and the cells either re-suspended
in aerobic media or taken into the anoxic chamber and re-suspended in anoxia-132-
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equilibrated media. The cells were then transferred to 96-well plates and incubated for 2
hours to allow attachment to the plate (100 µL per well) (Figure 7.1) Test compounds
were prepared from DMSO stocks to a final concentration of 300 µM. Media was
removed from the end well of the plate and replaced with 150 µL of media containing
drug. A multi-channel pipette was used to perform 3-fold dilutions down the plate (50 µL
at a time). Drug-free rows and cell-free rows were included as controls. After 4 hours of
drug exposure, the cells were removed from the two anoxic or normoxic chambers and
the wells washed 3 times to remove excess drug. Cells were then incubated in drug-free
media for 5 days before fixing with trichloroacetic acid, staining with sulforhodamine B
(to measure total protein) and measurements were obtained from a plate reader.195 The
sulforhodamine B dye binds to basic amino acids of cellular proteins, giving an indication
of total protein mass that can in turn be correlated to the number of cells. Based on the
original cell count, this number is used to determine the IC50 of each drug under the
relevant conditions.

Figure 7.1 Summary of the protocol used for in vitro testing of hypoxia-activated
cytotoxicity of mutual prodrugs 1 and 2.

7.23

Synthesis of allyl 2-(2-nitrophenyl)acetate 30

To a solution of 2-(2-nitrophenyl)acetic acid (10.021 g, 55.318 mmol) in neat distilled
allyl alcohol (50 mL, 735.19 mmol) 3 drops of conc. H2SO4 was added and the reaction
was refluxed under argon. The reaction was monitored by TLC (10% EtOAc: 90% pet.
spirit). After 20 hours and complete consumption of the starting material, the allyl alcohol
was removed under vacuum and the crude product was redissolved in EtOAc (100 mL).
The solution was extracted with 1M NaOH (3 × 100 mL), the organic layer collected,
dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude product was
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purified by isocratic silica gel column chromatography (20% EtOAc: 80% pet. spirit) to
yield 30 as a colourless oil (10.213 g, 83%).
Rf = 0.73 (10% EtOAc: 90% pet. spirit). IR: (oil, ν/cm-1): 3073, 2942,
2870, 1734, 1613, 1580, 1523, 1413, 1344, 1211, 1159, 986, 929, 862,
822, 788, 752, 713, 669, 485. 1H NMR (400 MHz, CDCl3) δ 8.12 (dd,
J = 8.2, 1.3 Hz, 1H), 7.60 (td, J = 7.5, 1.4 Hz, 1H), 7.48 (td, J = 7.8, 1.5 Hz, 1H), 7.37
(dd, J = 7.6, 1.1 Hz, 1H), 5.90 (ddt, J = 17.2, 10.4, 8.6 Hz, 1H), 5.30 (dq, J = 17.2, 1.5
Hz, 1H), 5.23 (dq, J = 10.4, 1.3 Hz, 1H), 4.62 (dt, J = 5.8, 1.4 Hz, 2H), 4.06 (s, 2H). 13C
NMR (101 MHz, CDCl3) δ 169.8, 149.0, 133.7, 133.5, 131.9, 129.8, 128.8, 125.4, 118.7,
66.0, 39.9. HREI-MS: m/z calculated for C11H12NO4 [M+H+] 222.0761; observed
222.0733.

7.24

Synthesis of allyl (Z)-3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)acryl

ate (Z)-31
A mixture of 30 (7.754 g, 35.051 mmol), K2CO3 (9.730 g, 70.401 mmol) and 18-crown6 (4.662 g, 17.650 mmol) was dissolved in dry THF (50 mL) and refluxed for 1 hour
under argon. A solution of 7 (7.227 g, 39.888 mmol) in dry THF (50 mL) was added
dropwise to the reaction mixture and the reaction monitored via TLC (20% EtOAc:80%
pet. spirit). After 17 hours, the reaction volume was reduced under vacuum and
redissolved in EtOAc (100 mL). The organic layer was extracted with saturated
NaHCO3(aq) (100 mL), the aqueous layer collected, washed with EtOAc (2 × 100 mL) and
the organic layers combined. The organic layer was then further extracted with saturated
NaCl(aq) (1 × 100 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo.
The crude product was purified by gradient silica gel column chromatography (100% pet.
spirit to 45% EtOAc:55% pet. spirit) to give one fraction containing crude (Z)-31 and a
second fraction containing crude (E)-31 and unreacted 30. The first fraction was further
purified by gradient silica gel column chromatography (100% pet. spirit to 5% acetone:
95% pet. spirit) to yield (Z)-31 as a red solid (2.248 g, 20%). The second fraction was
also further purified by gradient silica gel column chromatography (100% pet. spirit to
30% acetone: 70% pet. spirit) to yield (E)-31 as a red solid (2.352 g, 21%).
Rf = 0.78 (20% EtOAc: 80% pet. spirit). M.P. 70-72 °C; IR (solid,
ν/cm-1): 3300, 2360, 1685, 1577, 1570, 1542, 1517, 1507, 1364, 1312,
1182, 1144, 966, 932, 858, 790. 1H NMR (500 MHz, CDCl3) δ 11.83
(br s, 1H), 8.04 (d, J = 8.1 Hz, 1H), 7.62 (t, J = 7.5 Hz, 1H), 7.45 (d,
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J = 8.8 Hz, 1H), 7.43 (d, J = 7.8 Hz, 1H), 6.82 (s, 1H), 5.91 (s, 1H), 5.80 (ddt, J = 16.8,
11.1, 8.4 Hz, 1H), 5.15-5.08 (m, 2H), 4.56 (d, J = 5.4 Hz, 2H), 2.35 (s, 3H), 2.17 (s, 3H).
13

C NMR (126 MHz, CDCl3) δ 167.3, 148.8, 137.3, 134.4, 133.5, 132.8, 131.9, 131.5,

131.4, 127.9, 124.6, 124.5, 118.1, 114.1, 111.5, 65.6, 13.8, 11.7. HREI-MS: m/z
calculated for C18H19N2O4 [M+H+] 327.1339; observed 327.1342.
Rf = 0.49 (20% EtOAc: 80% pet. spirit). M.P. 102-105 °C; IR (solid,
ν/cm-1): 3455, 1687, 1610, 1557, 1524, 1343, 1257, 1232, 1068,
869, 733. 1H NMR (500 MHz, CDCl3) δ 8.20 (dd, J = 8.0, 1.1 Hz,
1H), 7.78 (s, 1H), 7.69 (td, J = 7.5, 1.2 Hz, 1H), 7.61 (td, J = 7.8,
1.4 Hz, 1H), 7.51 (dd, J = 7.5, 1.1 Hz, 1H), 6.76 (br s, 1H), 5.87 (ddt, J = 16.9, 11.1, 5.6
Hz, 1H), 5.74- (d, J = 1.6 Hz, 1H), 5.22-5.14 (m, 2H), 4.68-4.58 (m, 2H), 2.20 (s, 3H),
1.96 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 166.5, 149.4, 134.1, 133.7, 133.3, 132.6,
132.5, 130.6, 129.5, 127.6, 125.4, 123.6, 117.7, 116.3, 110.9. HREI-MS: m/z calculated
for C18H19N2O4 [M+H+] 327.1339; observed 327.1342.

7.25

Synthesis of tert-butyl (Z)-2-(3-(allyloxy)-2-(2-nitrophenyl)-3-oxoprop-1-en-

1-yl)-3,5-dimethyl-1H-pyrrole-1-carboxylate 32
A mixture of (Z)-31 (1.293 g, 3.961 mmol), BOC anhydride (1.2246 g, 5.611 mmol) and
DMAP (0.052 g, 0.427 mmol) was dissolved in dry acetonitrile (50 mL), under argon at
r.t. and monitored via TLC (10% EtOAc: 90% pet. spirit). After 3 hours and complete
consumption of starting material, the solvent was removed under reduced pressure and
the reaction redissolved in CH2Cl2 (50 mL). The solution was then extracted with 1M
HCl(aq) (1 × 50 mL) and saturated NaCl(aq) (1 × 50 mL), organic layer collected, dried
over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was
purified by gradient silica gel column chromatography (100% pet. spirit to 5% EtOAc:
95% pet. spirit) to yield 32 as a red solid (1.661 g, 98%).
Rf = 0.61 (20% EtOAc: 80% pet. spirit). M.P. 99-101 °C; IR (solid,
ν/cm-1): 2980, 2930, 1749, 1704, 1627, 1570, 1516, 1473, 1437, 1388,
1367, 1335, 1303, 1272, 1245, 1188, 1139, 1084, 1028, 1010, 987,
924, 879, 855, 794, 771, 750, 710, 668, 651, 620, 595, 552, 476, 447.
1

H NMR (500 MHz, CDCl3) δ 8.12 (d, J = 8.0 Hz, 1H), 7.94 (s, 1H), 7.45 (t, J = 7.4 Hz,

1H), 7.40 (t, J = 7.7 Hz, 1H), 7.25 (d, J = 7.5 Hz, 1H), 5.87 (ddt, J = 16.7, 10.9, 5.7 Hz,
1H), 5.62 (s, 1H), 5.24 (d, J = 17.3 Hz, 1H), 5.19 (d, J = 10.3 Hz, 1H), 4.62 (d, J = 5.1
Hz, 2H), 2.39 (s, 3H), 1.62 (s, 9H), 1.28 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 165.6,
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150.0, 148.6, 134.8, 134.8, 133.4, 133.3, 133.1, 132.1, 128.5, 127.3, 125.4, 124.9, 124.8,
118.5, 115.3, 84.5, 66.1, 28.2, 16.2, 11.6. HREI-MS: m/z calculated for C23H27N2O6
[M+H+] 427.1864; observed 427.1879.

7.26

Synthesis of (Z)-3-(1-(tert-butoxycarbonyl)-3,5-dimethyl-1H-pyrrol-2-yl)-2-(

2-nitrophenyl)acrylic acid 33
To a stirring solution of 32 (1.213 g, 2.845 mmol) and Pd(PPh3)4 (0.352 g, 0.305 mmol)
in dry THF (40 mL) under argon, morpholine (2.7 mL, 30 mmol) was added dropwise.
The reaction was monitored via TLC (30% acetone: 70% pet. spirit) and after complete
consumption of starting material, the solvent was removed under reduced pressure and
the reaction mixture redissolved in EtOAc (100 mL). The organic layer was extracted
with 1M HCl(aq) (3 × 100 mL) and saturated NaCl(aq) (1 × 100 mL), organic layer
collected, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude
product was purified by gradient silica gel column chromatography (100% pet. spirit to
40% acetone: 60% pet. spirit) to yield 33 as a red solid (0.749 g, 82%).
Rf = 0.56 (30% EtOAc: 70% pet. spirit). M.P. 83-84 °C; IR (solid, ν/cm-1):
2968, 1745, 1727, 1673, 1601, 1519, 1480, 1437, 1421, 1370, 1351, 1330,
1306, 1280, 1254, 1141, 1119, 1091, 1013, 997, 934, 883, 854, 804, 788,
761, 747, 720, 709, 694, 667, 620, 582, 542, 492, 456. 1H NMR (500
MHz, CDCl3) δ 8.13 (d, J = 8.1 Hz, 1H), 8.01 (s, 1H), 7.46 (t, J = 7.5 Hz,
1H), 7.40 (t, J = 7.6 Hz, 1H), 7.25 (d, J = 8.5 Hz, 1H), 5.62 (s, 1H), 2.39 (s, 3H), 1.63 (s,
9H), 1.27 (s, 3H).

13

C NMR (126 MHz, CDCl3) δ 171.3, 150.0, 148.5, 136.4, 135.4,

133.5, 133.4, 132.7, 128.8, 126.5, 125.5, 125.4, 125.0, 115.5, 84.9, 28.3, 16.3, 11.6.
HREI-MS: m/z calculated for C20H23N2O6 [M+H+] 387.1551; observed 387.1563.

7.27

Synthesis of tert-butyl (Z)-2-(3-(benzyloxy)-2-(2-nitrophenyl)-3-oxoprop-1-e

n-1-yl)-3,5-dimethyl-1H-pyrrole-1-carboxylate 34
A solution of 33 (0.018 g, 0.046 mmol) and PPh3 (0.025 g, 0.095 mmol) in dry THF (0.2
mL) was sonicated until fully dissolved. Benzyl alcohol (10 µL, 0.098 mmol) was added
dropwise to the reaction followed by diethyl azodicarboxylate (15 µL, 0.097 mmol). The
reaction was then sonicated for 60 minutes and monitored via TLC (30% EtOAc: 70%
pet. spirit). After complete consumption of starting material the reaction was diluted with
EtOAc (5 mL) and extracted with 1M HCl(aq) (1 × 5 mL) and saturated NaCl(aq) (1 × 5
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mL), organic layer collected and concentrated in vacuo yielding pure 34 as a red solid
(0.022 g, quantitative yield).
Rf = 0.69 (30% EtOAc: 70% pet. spirit). M.P. 74-78 °C; IR (solid,
ν/cm-1): 2926, 1707, 1608, 1523, 1455, 1369, 1344, 1324, 1307,
1270, 1222, 1174, 1139, 1089, 1018, 928, 881, 855, 790, 744, 697,
665, 618, 476. 1H NMR (500 MHz, CDCl3) δ 8.13 (dd, J = 8.1, 1.3
Hz, 1H), 7.91 (s, 1H), 7.44 (td, J = 7.5, 1.5 Hz, 1H), 7.39 (td, J =
7.7, 1.6 Hz, 1H), 7.34-7.27 (m, 5H), 7.24 (dd, J = 7.6, 1.5 Hz, 1H), 5.61 (s, 1H), 5.18 (s,
2H), 2.38 (s, 3H), 1.53 (s, 9H), 1.27 (s, 3H). 13C NMR (101 MHz, d6-DMSO) δ 165.0,
149.0, 147.7, 135.7, 134.2, 134.1, 134.0, 132.7, 132.0, 129.3, 128.4, 128.1, 128.0, 126.6,
124.8, 124.7, 123.6, 115.0, 84.3, 66.3, 27.4, 15.5, 11.0. HREI-MS: m/z calculated for
C27H28N2O6Na [M+Na+] 499.1840; observed 499.1839.

7.28

Synthesis of tert-butyl (Z)-2-(3-(benzylamino)-2-(2-nitrophenyl)-3-oxoprop-

1-en-1-yl)-3,5-dimethyl-1H-pyrrole-1-carboxylate 35
A solution of 33 (0.026 g, 0.068 mmol) and HATU (0.028 g, 0.075 mmol) in dry CH2Cl2
(5 mL) under argon was cooled to 0 °C. Benzyl amine (14 µL, 0.130 mmol) was added
dropwise to the reaction followed by DIPEA (28 µL, 0.162 mmol). The reaction was
allowed to warm to r.t. and stirred overnight. Upon consumption of the starting material,
the reaction was diluted with CH2Cl2 (20 mL) and extracted with 1M HCl(aq) (2 × 25 mL)
and saturated NaHCO3(aq) (2 × 25 mL). The organic layer was dried over anhydrous
MgSO4, filtered and concentrated in vacuo yielding pure 35 as a red solid (0.032 g,
quantitative yield).
Rf = 0.51 (30% EtOAc: 70% pet. spirit). M.P. 110-113 °C; IR (solid,
ν/cm-1): 3422, 2977, 2854, 2926, 1725, 1644, 1601, 1513, 1452, 1400,
1383, 1367, 1328, 1259, 1216, 1143, 1094, 1031, 1002, 916, 851, 809,
786, 768, 741, 699, 670, 626, 594, 579, 548, 482, 452, 409. 1H NMR
(400 MHz, CDCl3) δ 8.04 (dd, J = 8.1, 1.2 Hz, 1H), 7.62 (td, J = 7.5,
1.3 Hz, 1H), 7.53 (dd, J = 7.6, 1.4 Hz, 1H), 7.48 (td, J = 7.7, 1.5 Hz, 1H), 7.30-7.24 (m,
3H), 7.15-7.13 (m, 2H), 6.90 (s, 1H), 6.31 (t, J = 5.4 Hz, 1H), 5.80 (s, 1H), 4.41 (d, J =
5.8 Hz, 2H), 2.38 (s, 3H), 1.89 (s, 3H), 1.48 (s, 9H).

13

C NMR (101 MHz, CDCl3) δ

166.6, 149.9, 148.5, 138.2, 135.2, 134.7, 133.7, 133.3, 133.2, 128.9, 128.7, 128.0, 127.7,
127.4, 124.9, 124.6, 124.2, 115.0, 84.6, 44.1, 28.2, 16.3, 12.0. HREI-MS: m/z calculated
for C27H29N3O5Na [M+Na+] 498.1999; observed 498.2001.
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Allyl Esterification General Method 1

The appropriate fluorinated 2-(2-nitrophenyl)acetic acid was dissolved in 10 mL of
freshly distilled allyl alcohol, 2 drops of conc. H2SO4 (98%) was added and the reaction
refluxed under argon overnight. Upon complete consumption of the starting material, the
allyl alchol was reduced under vacuum and the reaction redissolved in ethyl acetate (100
mL). The organic layer was then extracted with NaHCO3(aq) (3 × 100 mL) and saturated
NaCl(aq) (1 × 100 mL), dried over anhydrous MgSO4, filtered and reduced under vacuum.
Crude products were purified by gradient column chromatography (0-10% acetone/pet.
spirit).

7.30

Synthesis of Allyl 2-(3-fluoro-2-nitrophenyl)acetate 36

Compound 36 was synthesised using General Method 1 with 2-(3-fluoro-2nitrophenyl)acetic acid (1.021 g, 5.129 mmol) to afford 36 (1.059 g, 86%) as a colourless
oil.
Rf = 0.75 (20% EtOAc: 80% pet. spirit). IR (oil, ν/cm-1): 3087, 3947,
2885, 1735, 1617, 1591, 1532, 1459, 1358, 1273, 1174, 982, 932, 854,
802, 771, 724, 555, 468, 417. 1H NMR (500 MHz, CDCl3) δ 7.49 (td,
J = 8.1, 5.2 Hz, 1H), 7.22 (ddd, J = 9.6, 8.5, 1.1 Hz, 1H), 7.17 (d, J = 7.7 Hz, 1H), 5.89
(ddt, J = 17.2, 10.5, 5.8 Hz, 1H), 5.30 (dq, J = 17.2, 1.4 Hz, 1H), 5.24 (dq, J = 10.4, 1.2
Hz, 1H), 4.61 (dt, J = 5.8, 1.3 Hz, 2H), 3.86 (s, 2H).

13

C NMR (126 MHz, CDCl3) δ

169.0, 154.8 (d, J = 260.8 Hz), 139.6 (d, J = 11.1 Hz), 132.7 (d, J = 8.2 Hz), 131.6, 129.8
(d, J = 1.4 Hz), 127.6 (d, J = 3.7 Hz), 119.0, 116.9 (d, J = 19.2 Hz), 66.3, 37.6 (d, J = 1.8
Hz). HREI-MS: m/z calculated for C11H11FNO4 [M+H+] 240.0667; observed 240.0672.

7.31

Synthesis of Allyl 2-(4-fluoro-2-nitrophenyl)acetate 37

Compound 37 was synthesised using General Method 1 with 2-(4-fluoro-2nitrophenyl)acetic acid (0.999 g, 5.017 mmol) to afford 37 (0.964 g, 80%) as a colourless
oil.
Rf = 0.86 (20% EtOAc: 80% Pet. Spirit). IR: (oil, ν/cm-1) 3084 ,
2945 , 2882 , 1734 , 1532 , 1499, 1423 , 1342 , 1238 , 1192 , 1159
, 986 , 928 , 878 ,817 , 800 , 722 , 684 , 543 , 506 , 361 . 1H NMR (500 MHz, CDCl3) δ
7.86 (dd, J = 8.4, 2.5 Hz, 1H), 7.38-7.31 (m, 2H), 5.90 (ddt, J = 17.2, 10.4, 5.8 Hz, 1H),
5.30 (dq, J = 17.2, 1.5 Hz, 1H), 5.24 (dq, J = 10.4, 1.2 Hz, 1H), 4.61 (dt, J = 5.8, 1.4 Hz,
2H), 4.03 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 169.6, 161.6 (d, J = 251.0 Hz), 149.2
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(d, J = 8.3 Hz), 134.9 (d, J = 8.3 Hz), 131.8, 125.86 (d, J = 4.1 Hz), 121.0 (d, J = 21.0
Hz), 118.9, 113.2 (d, J = 26.5 Hz), 66.1, 39.3. HREI-MS: m/z calculated for C11H11FNO4
[M+H+] 240.0667; observed 240.0672.

7.32

Synthesis of Allyl 2-(5-fluoro-2-nitrophenyl)acetate 38

Compound 38 was synthesised using General Method 1 with 2-(5-fluoro-2nitrophenyl)acetic acid (0.996 g, 5.003 mmol) to afford 38 (1.003 g, 84%) as a colourless
oil.
Rf = 0.81 (20% EtOAc: 80% Pet. Spirit). IR: (oil, ν/cm-1) 3086 ,
2944 , 2865 , 1734 , 1624 , 1590 , 1525 , 1484 , 1410 , 1343s, 1276
, 1251 , 1175 , 1154 , 1077 , 990 , 934 , 875 , 838 , 750 , 719 , 615 , 432 , 356. 1H NMR
(400 MHz, CDCl3) δ 8.19 (dd, J = 9.1, 5.2 Hz, 1H), 7.15 (ddd, J = 9.1, 7.2, 2.7 Hz, 1H),
7.07 (dd, J = 8.6, 2.7 Hz, 1H), 5.90 (ddt, J = 17.2, 10.4, 5.8 Hz, 1H), 5.30 (dq, J = 17.2,
1.5 Hz, 1H), 5.24 (dq, J = 10.4, 1.2 Hz, 1H), 4.62 (dt, J = 5.8, 1.3 Hz, 2H), 4.04 (s, 2H).
13

C NMR (101 MHz, CDCl3) δ 169.2, 164.9 (d, J = 257.6 Hz), 145.0, 133.3 (d, J = 9.3

Hz), 131.8, 128.3 (d, J = 10.2 Hz), 120.4 (d, J = 23.8 Hz), 118.9, 115.7 (d, J = 23.1 Hz),
66.2, 40.0 (d, J = 1.0 Hz). HREI-MS: m/z calculated for C11H11FNO4 [M+H+] 240.0667;
observed 240.0672.

7.33

Synthesis of Allyl 2-(2-fluoro-6-nitrophenyl)acetate 39

Compound 39 was synthesised using General Method 1 with 2-(3-fluoro-2nitrophenyl)acetic acid (0.979 g, 4.917 mmol) to afford 39 (0.938 g, 80%) as a colourless
oil.
Rf = 0.74 (20% EtOAc: 80% pet. spirit). IR (oil, ν/cm-1): 3098, 2948,
2882, 1737, 1530, 1469, 1417, 1342, 1252, 1208, 1170, 983, 931, 842,
796, 733, 681, 530, 366. 1H NMR (400 MHz, CDCl3) δ 7.91 (dt, J =
8.1, 1.3 Hz, 1H), 7.46 (td, J = 8.2, 5.7 Hz, 1H), 7.40 (td, J = 8.6, 1.4 Hz, 1H), 5.90 (ddt,
J = 17.2, 10.5, 5.7 Hz, 1H), 5.30 (dq, J = 17.2, 1.5 Hz, 1H), 5.23 (dq, J = 10.4, 1.3 Hz,
1H), 4.63 (dt, J = 5.7, 1.4 Hz, 2H), 4.09 (d, J = 1.2 Hz, 2H). 13C NMR (101 MHz, CDCl3)
δ 168.9 (d, J = 1.0 Hz), 161.3 (d, J = 250.0 Hz), 149.8 (d, J = 3.8 Hz), 131.8, 129.1 (d, J
= 9.5 Hz), 121.0 (d, J = 3.4 Hz), 120.8 (d, J = 24.0 Hz), 118.7, 118.4 (d, J = 19.1 Hz),
66.1, 30.9 (d, J = 5.0 Hz). HREI-MS: m/z calculated for C11H11FNO4 [M+H+] 240.0667;
observed 240.0672.
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Synthesis of Allyl 2-(2-nitro-4-(trifluoromethyl)phenyl)acetate 40

Compound 40 was synthesised using General Method 1 with 2-(3-fluoro-2nitrophenyl)acetic acid (1.011 g, 4.059 mmol) to afford 40 (0.835 g, 71%) as a colourless
oil.
Rf = 0.55 (20% acetone: 80% pet. spirit). IR (oil, ν/cm-1): 3087,
2947, 1736, 1633, 1540, 1506, 1425, 1407, 1352, 1323, 1217,
1130, 1088, 986, 906, 848, 821, 786, 732, 693. 1H NMR (500 MHz, CDCl3) δ 8.38 (d, J
= 1.2 Hz, 1H), 7.85 (dd, J = 8.0, 1.3 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 5.90 (ddt, J = 17.2,
10.4, 5.8 Hz, 1H), 5.31 (dq, J = 17.2, 1.5 Hz, 1H), 5.25 (dq, J = 10.4, 1.2 Hz, 1H), 4.63
(dt, J = 5.8, 1.3 Hz, 2H), 4.13 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 169.0, 149.0, 134.4,
133.7, 131.7, 131.6 (q, J = 34.3 Hz), 130.1 (q, J = 3.5 Hz), 122.9 (q, J = 272.7 Hz), 122.8
(q, J = 3.8 Hz), 119.1, 66.3, 39.7. HREI-MS: m/z calculated for C12H19F3NO4 [M−H+]
288.0489; observed 288.0490.

7.35

Synthesis of Allyl 2-(2-nitro-5-(trifluoromethyl)phenyl)acetate 41

Compound 41 was synthesised using General Method 1 with 2-(3-fluoro-2nitrophenyl)acetic acid (1.037 g, 4.163 mmol) to afford 41 (0.841 g, 70%) as a colourless
oil.
Rf = 0.65 (20% acetone: 80% pet. spirit). IR (oil, ν/cm-1): 3089,
2948, 1736, 1532, 1429, 1325, 1170, 1129, 1096, 1070, 987, 896,
836, 754, 702, 510, 419. 1H NMR (400 MHz, CDCl3) δ 8.20 (d, J = 8.5 Hz, 1H), 7.75
(dd, J = 8.5, 1.6 Hz, 1H), 7.65 (d, J = 1.3 Hz, 1H), 5.90 (ddt, J = 17.2, 10.4, 5.8 Hz, 1H),
5.31 (dq, J = 17.2, 1.5 Hz, 1H), 5.25 (dq, J = 10.4, 1.2 Hz, 1H), 4.63 (dt, J = 5.8, 1.3 Hz,
2H), 4.11 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 168.9, 150.9, 135.0 (q, J = 33.5 Hz),
131.6, 130.7, 130.5 (q, J = 3.7 Hz), 125.9, 125.9 (q, J = 3.6 Hz), 122.8 (q, J = 273.1 Hz),
119.0, 66.2, 39.5. HREI-MS: m/z calculated for C12H19F3NO4 [M−H+] 288.0489;
observed 288.0490.

7.36

Knoevenagel Condensation General Method 2

A mixture of K2CO3 and 18-Crown-6 were dissolved in dry THF (5 mL) under argon. A
solution of the appropriate allyl alcohol 36-41 in dry THF (5 mL) was added dropwise
and the reaction allowed to stir at room temperature. After 1 hour a solution of 7 in dry
THF (5 mL) was added dropwise to the reaction mixture and the reaction monitored via
TLC (20% acetone: 80% pet. spirit). After 18 hours if the reaction had not proceeded, the
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reaction was heated to 45 °C for a further 24 hours. Upon consumption of starting
material, the solvent was reduced under vacuum and the reaction mixture redissolved in
EtOAc (50 mL). The organic layer was extracted with saturated NaHCO3(aq) (2 × 50 mL).
The combined aqueous layers were further extracted with ethyl acetate (2 × 50 mL) and
the organic layers combined. The combined organic layers were extracted with saturated
NaCl(aq) (1 × 50 mL), dried over anhydrous MgSO4 and concentrated in vacuo. The crude
products and side products were then purified by gradient silica gel column
chromatography (100% pet. spirit to 30% EtOAc: 70% pet. spirit). Impure compounds
were then further purified by preparative TLC for characterisation and chemical testing.

7.37

Synthesis of Allyl 8-fluoro-1,3-dimethylpyrrolo[1,2-a]quinoline-5-carboxyla

te 48
Compound 48 was inadvertently synthesised using General Method 2 with allyl ester 37
(0.509 g, 2.128 mmol), 7 (0.418 g, 2.307 mmol), K2CO3 (0.585 g, 4.233 mmol) and
18-crown-6 (0.279 g, 1.056 mmol) reacted at 66 °C for 18 hours affording 48 (0.240 g,
38%) as a yellow highly fluorescent solid (blue in hexane under 365 nm UV light), (Z)43 (0.049 g, 7%) as an orange solid and (E)-43 (0.075 g, 10%) as a red solid.
Rf = 0.81 (20% Acetone: 80% Pet. Spirit). M.P. 79-81 °C. IR:
(solid, ν/cm-1) 2922, 2854, 2853, 1691, 1609, 1567, 1538, 1501,
1428, 1369, 1332, 1214, 1194, 1161, 1131, 1027, 993, 927, 906,
844, 827, 811, 768, 736, 715, 645, 598, 482, 442, 405, 367. 1H
NMR (400 MHz, CDCl3) δ 8.98 (dd, J = 9.2, 6.9 Hz, 1H), 8.12 (s, 1H), 7.91 (dd, J = 11.6,
2.6 Hz, 1H), 7.06 (ddd, J = 9.7, 7.2, 2.1 Hz, 1H), 6.43 (s, 1H), 6.10 (ddt, J = 17.2, 10.5,
5.7 Hz, 1H), 5.45 (dq, J = 17.2, 1.5 Hz, 1H), 5.32 (dq, J = 10.4, 1.3 Hz, 1H), 4.85 (dt, J
= 5.7, 1.4 Hz, 2H), 2.88 (s, 3H), 2.37 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 166.1, 160.9
(d, J = 245.0 Hz), 136.2 (d, J = 9.8 Hz), 132.7, 128.9 (d, J = 9.2 Hz), 128.6, 127.6, 123.4
(d, J = 2.0 Hz), 119.1 (d, J = 2.6 Hz), 118.2, 118.2, 117.7, 112.8 (d, J = 1.3 Hz), 111.1 (d,
J = 21.5 Hz), 102.8 (d, J = 27.3 Hz), 65.3, 18.2, 10.7. HREI-MS: Adduct could not be
detected by high resolution mass spectrometry.

7.38

Synthesis of Allyl (Z)-3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(3-fluoro-2-nitroph

enyl)acrylate (Z)-42
Compound (Z)-42 was synthesised using General Method 2 with allyl ester 36 (0.369 g,
1.541 mmol), 7 (0.297 g, 1.639 mmol), K2CO3 (0.422 g, 3.056 mmol) and 18-crown-6
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(0.200 g, 0.757 mmol) reacted at room temperature for 18 hours affording (Z)-42 (0.147
g, 28%) as a red solid and (E)-42 (0.137 g, 26%) as a red solid.
Rf = 0.78 (20% EtOAc: 80% pet. spirit). M.P. 64-68 °C; IR (solid,
ν/cm-1): 3276, 2918, 2869, 1686, 1650, 1604, 1570, 1526, 1463, 1395,
1351, 1317, 1256, 1240, 1188, 1153, 1071, 974, 929, 907, 854, 823,
805, 791, 769, 725, 708, 662, 615, 554, 472, 427. 1H NMR (500 MHz,
CDCl3) δ 11.82 (br s, 1H), 7.47 (td, J = 8.1, 5.4 Hz, 1H), 7.21-7.17 (m, 2H), 6.81 (s, 1H),
5.91 (d, J = 2.0 Hz, 1H), 5.85 (ddt, J = 16.7, 11.1, 5.6 Hz, 1H), 5.19-5.15 (m, 2H), 4.60
(dt, J = 5.5, 1.3 Hz, 2H), 2.33 (s, 3H), 2.15 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 166.8,
154.1 (d, J = 259.0 Hz), 139.4 (d, J = 11.7 Hz), 137.7, 135.3, 133.2, 132.7, 131.9 (d, J =
2.7 Hz), 131.8, 127.6 (d, J = 3.7 Hz), 124.3, 118.0, 115.7 (d, J = 19.9 Hz), 111.8, 110.0
(d, J = 1.8 Hz), 65.6, 13.7, 11.5. HREI-MS: m/z calculated for C18H18FN2O4 [M+H+]
345.1245; observed 345.1246.
Rf = 0.55 (20% EtOAc: 80% pet. spirit). M.P. 80-84 °C; IR (solid,
ν/cm-1): 3460, 3381, 3082, 2923, 2881, 1689, 1599, 1554, 1531,
1472, 1446, 1356, 1262, 1230, 1198, 1150, 1065, 973, 923, 853,
804, 762, 733, 703, 671, 637, 541. 1H NMR (500 MHz, CDCl3) δ
7.81 (s, 1H), 7.58 (td, J = 8.1, 5.2 Hz, 1H), 7.35 (t, J = 8.9 Hz, 1H), 7.25 (d, J = 7.7 Hz,
1H), 6.93 (s, 1H), 5.89 (ddt, J = 16.8, 11.1, 5.7 Hz, 1H), 5.78 (d, J = 1.7 Hz, 1H), 5.22
(dq, J = 17.2, 1.4 Hz, 1H), 5.18 (dq, J = 10.5, 1.2 Hz, 1H), 4.63 (dt, J = 5.5, 1.3 Hz, 2H),
2.19 (s, 3H), 2.02 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 166.0, 154.5 (d, J = 260.9 Hz),
139.9 (d, J = 11.9 Hz), 135.2, 133.4, 132.7 (d, J = 8.5 Hz), 132.3, 131.7, 129.8, 127.8 (d,
J = 3.3 Hz), 123.3, 117.7, 117.3 (d, J = 19.5 Hz), 112.5 (d, J = 1.7 Hz), 111.2, 65.6, 13.4,
11.4. HREI-MS: m/z calculated for C18H18FN2O4 [M+H+] 345.1245; observed 345.1246.

7.39

Synthesis of Allyl (Z)-3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(4-fluoro-2-nitroph

enyl)acrylate (Z)-43
Compound (Z)-43 was synthesised using General Method 2 with allyl ester 37 (0.509 g,
2.128 mmol), 7 (0.418 g, 2.307 mmol), K2CO3 (0.585 g, 4.233 mmol) and 18-crown-6
(0.279 g, 1.056 mmol) reacted at room temperature for 18 hours affording (Z)-43 (0.098
g, 13% yield) as an orange solid and (E)-43 (0.142 g, 19%) as a red solid.
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Rf = 0.76 (20% Acetone: 80% Pet. Spirit). M.P. 88-90 °C. IR:
(solid, ν/cm-1) 3275, 2920, 1689, 1571, 1527, 1462, 1406, 1363,
1343, 1314, 1269, 1177, 1147, 987, 969, 939, 871, 838, 818, 795,
731, 686, 672, 602, 554, 466, 420, 374. 1H NMR (500 MHz,
CDCl3) δ 11.82 (br s, 1H), 7.79 (dd, J = 8.4, 2.7 Hz, 1H), 7.42 (dd, J = 8.5, 5.6 Hz, 1H),
7.36 (ddd, J = 8.5, 7.4, 2.7 Hz, 1H), 6.78 (s, 1H), 5.91 (d, J = 2.6 Hz, 1H), 5.79 (ddt, J =
17.1, 10.5, 5.7 Hz, 1H), 5.16-5.10 (m, 2H), 4.55 (dt, J = 5.6, 1.4 Hz, 2H), 2.35 (s, 3H),
2.17 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 167.0, 160.9 (d, J = 251.1 Hz), 148.8 (d, J
= 8.2 Hz), 134.6, 134.1 (d, J = 7.7 Hz), 133.3 (d, J = 4.0 Hz), 131.7, 131.6, 131.6, 124.3,
120.6 (d, J = 20.6 Hz), 118.2, 112.7, 112.1 (d, J = 26.0 Hz), 111.5, 65.6, 13.7, 11.6.
HREI-MS: m/z calculated C18H17FN2O4Na [M+Na+] 367.1065; observed 367.1070.
Rf = 0.46 (20% Acetone: 80% Pet. Spirit). M.P. 132-135 °C. IR:
(solid, ν/cm-1) 3465, 3370, 3091, 2923, 2854, 1742, 1691, 1648,
1602, 1557, 1531, 1497, 1441, 1344, 1263, 1229, 1204, 1166, 1147,
1065, 1024, 992, 970, 924, 877, 838, 810, 763, 718, 675, 657, 636,
605, 583, 516, 434, 375. 1H NMR (400 MHz, CDCl3) δ 7.94 (dd, J = 8.2, 2.6 Hz, 1H),
7.79 (s, 1H), 7.49 (dd, J = 8.5, 5.6 Hz, 1H), 7.41 (ddd, J = 8.5, 7.3, 2.7 Hz, 1H), 6.80 (br
s, 1H), 5.87 (ddt, J = 17.2, 10.5, 5.5 Hz, 1H), 5.77 (d, J = 2.5 Hz, 1H), 5.23-5.16 (m, 2H),
4.67-4.57 (m, 2H), 2.20 (s, 3H), 2.01 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 166.3, 161.8
(d, J = 252.3 Hz), 149.8 (d, J = 8.7 Hz), 134.8 (d, J = 7.2 Hz), 134.4, 132.3, 130.9, 128.5
(d, J = 4.6 Hz), 127.9, 123.4, 120.9 (d, J = 21.0 Hz), 117.8, 115.1, 113.1 (d, J = 26.3 Hz),
111.1, 65.6, 13.4, 11.4. HREI-MS: m/z calculated C18H17FN2O4Na [M+Na+] 367.1065;
observed 367.1070.

7.40

Synthesis of Allyl (Z)-3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(5-fluoro-2-nitroph

enyl)acrylate (Z)-44
Compound (Z)-44 was synthesised using General Method 2 with allyl ester 38 (0.506 g,
2.115 mmol), 7 (0.421 g, 2.324 mmol), K2CO3 (0.587 g, 4.247 mmol) and 18-crown-6
(0.276 g, 1.044 mmol) reacted at room temperature for 20 hours followed by a further 24
hours of heating at 45 °C to afford (Z)-44 (0.161 g, 22%) as an orange solid and (E)-44
(0.151 g, 21%) as a red solid.
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Rf = 0.62 (20% Acetone: Pet. Spirit). M.P. 91-93 °C. IR: (solid,
ν/cm-1) 3283, 3068, 2922, 2853, 1730, 1679, 1615, 1570, 1540,
1520, 1461, 1412, 1389, 1343, 1309, 1269, 1252, 1236, 1198, 1178,
1151, 1087, 1029, 999, 974, 940, 910, 888, 849, 834, 821, 795, 779,
762, 725, 708, 684, 670, 634, 614, 584, 551, 491, 468, 439, 419, 382, 368. 1H NMR (500
MHz, CDCl3) δ 11.81 (br s, 1H), 8.12-8.09 (m, 1H), 7.12-7.08 (m, 2H), 6.80 (s, 1H), 5.91
(d, J = 2.6 Hz, 1H), 5.79 (ddt, J = 17.1, 10.6, 5.7 Hz, 1H), 5.15 (dq, J = 6.4, 1.4 Hz, 1H),
5.12 (dq, J = 13.0, 1.5 Hz, 1H), 4.56 (dt, J = 5.7, 1.4 Hz, 2H), 2.35 (s, 3H), 2.18 (s, 3H).
13

C NMR (126 MHz, CDCl3) δ 166.8, 164.7 (d, J = 256.8 Hz), 144.9, 140.5 (d, J = 9.3

Hz), 134.9, 132.1, 131.7, 131.5, 127.2 (d, J = 10.1 Hz), 124.3, 119.4 (d, J = 23.1 Hz),
118.2, 114.5 (d, J = 23.1 Hz), 113.0, 111.6, 65.6, 13.7, 11.6. HREI-MS: m/z calculated
for C18H17FN2O4 [M+H+] 345.1245; observed 345.1329, m/z calculated C18H17FN2O4
[M+Na+] 367.1065; observed 367.1148.
Rf = 0.56 (20% Acetone: Pet. Spirit). M.P. 138-140 °C. IR: (solid,
ν/cm-1) 3457, 3074, 2922, 2852, 1684, 1612, 1582, 1557, 1522,
1439, 1363, 1335, 1218, 1149, 1082, 1031, 983, 962, 935, 911, 889,
844, 802, 763, 748, 726, 666, 639, 622, 604, 553, 522, 452, 419,
380. 1H NMR (400 MHz, CDCl3) δ 8.26 (dd, J = 9.1, 5.1 Hz, 1H), 7.77 (s, 1H), 7.27
(ddd, J = 9.5, 6.7, 2.4 Hz, 1H), 7.19 (dd, J = 8.4, 2.8 Hz, 1H), 6.85 (br s, 1H), 5.86 (ddt,
J = 17.2, 10.5, 5.5 Hz, 1H), 5.78 (d, J = 2.4 Hz, 1H), 5.23-5.16 (m, 2H), 4.68-4.57 (m,
2H), 2.20 (s, 3H), 2.02 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 166.0, 164.7 (d, J = 254.8
Hz), 145.5 (d, J = 3.0 Hz), 135.8 (d, J = 9.7 Hz), 134.7, 132.3, 131.2, 128.1 (d, J = 10.1
Hz), 127.7, 123.2, 120.0 (d, J = 22.8 Hz), 117.8, 116.3 (d, J = 23.3 Hz), 115.2, 111.2,
65.6, 13.4, 11.4. HREI-MS: m/z calculated for C18H17FN2O4 [M+H+] 345.1245;
observed 345.1251.

7.41

Synthesis of Allyl 1,3-dimethyl-6-nitropyrrolo[1,2-a]quinoline-5-carboxylate

49
Compound 49 was inadvertently synthesised using General Method 2 with allyl ester 39
(0.360 g, 1.506 mmol), 7 (0.296 g, 1.634 mmol), K2CO3 (0.426 g, 3.082 mmol) and
18-crown-6 (0.204 g, 0.770 mmol) reacted at room temperature for 18 hours affording 49
(0.055 g, 11%) as an intensely red solid.
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Rf = 0.22 (10% acetone: 90% pet. spirit). M.P. 70-74 °C; IR (solid,
ν/cm-1): 2960, 2923, 2855, 1701, 1650, 1620, 1592, 1541, 1514,
1475, 1441, 1420, 1387, 1362, 1345, 1322, 1290, 1261, 1234, 1179,
1096, 1008, 992, 965, 935, 918, 874, 832, 805, 772, 759, 735, 715,
649, 622, 589, 560, 511, 467, 433. 1H NMR (500 MHz, CDCl3) δ 8.45 (dd, J = 8.6, 0.5
Hz, 1H), 8.06 (s, 1H), 7.84 (dd, J = 7.9, 0.9 Hz, 1H), 7.50 (t, J = 8.3 Hz, 1H), 6.52 (s,
1H), 6.02 (ddt, J = 17.1, 10.4, 6.0 Hz, 1H), 5.38 (dq, J = 17.2, 1.4 Hz, 1H), 5.28 (dq, J =
10.4, 1.2 Hz, 1H), 4.75 (dt, J = 6.0, 1.2 Hz, 2H), 2.91 (s, 3H), 2.39 (s, 3H).

13

C NMR

(126 MHz, CDCl3) δ 166.4, 148.4, 136.9, 132.1, 129.3, 127.5, 125.8, 125.5, 120.1, 120.1,
119.0, 118.9, 118.8, 116.2, 113.4, 65.8, 18.6, 10.7. HREI-MS: Adduct not detected by
high resolution mass spectrometry.

7.42

Synthesis of Allyl (Z)-3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitro-4-(trifluoro

methyl)phenyl)acrylate (Z)-46
Compound (Z)-46 was synthesised using General Method 2 with allyl ester 40 (0.436 g,
1.509 mmol), 7 (0.300 g, 1.656 mmol), K2CO3 (0.423 g, 3.057 mmol) and 18-crown-6
(0.205 g, 0.776 mmol) reacted at room temperature for 20 hours followed by a further 24
hours of heating at 45 °C to afford (Z)-46 (0.052 g, 9%) as an red solid, (E)-46 (0.034 g,
6%) as a red solid, 50 (0.076 g, 14%) as a yellow highly fluorescent solid (blue in hexane
under 365 nm UV light) and 51 (0.023 g, 4%) as a yellow tinged oil.
Rf = 0.55 (10% acetone: 90% pet. spirit). M.P. 90-93 °C; IR (solid,
ν/cm-1): 3531, 3395, 3286, 3089, 2922, 2878, 1692, 1650, 1626,
1572, 1535, 1500, 1431, 1391, 1320, 1264, 1244, 1223, 1175,
1114, 1087, 1028, 983, 919, 824, 803, 780, 728, 705, 666, 615,
551, 453. 1H NMR (500 MHz, CDCl3) δ 11.85 (br s, 1H), 8.29 (d, J = 0.9 Hz, 1H), 7.86
(dd, J = 8.0, 1.3 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 6.83 (s, 1H), 5.93 (d, J = 2.4 Hz, 1H),
5.79 (ddt, J = 17.1, 10.6, 5.8 Hz, 1H), 5.16 (dq, J = 10.4, 1.2 Hz, 1H), 5.14 (dq, J = 17.1,
1.4 Hz, 1H), 4.56 (dt, J = 5.8, 1.3 Hz, 2H), 2.36 (s, 3H), 2.18 (s, 3H). 13C NMR (126
MHz, CDCl3) δ 166.5, 148.7, 140.7, 135.4, 133.5, 132.6, 132.1, 131.6, 130.1 (q, J = 33.9
Hz), 129.7 (q, J = 3.3 Hz), 124.5, 123.0 (q, J = 272.4 Hz), 121.8 (q, J = 3.8 Hz), 118.6,
112.2, 111.9, 65.8, 13.7, 11.6. HREI-MS: m/z calculated for C19H18F3N2O4 [M+H+]
395.1213; observed 395.1201.
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Rf = 0.33 (10% acetone: 90% pet. spirit). M.P. 110-115 °C; IR
(solid, ν/cm-1): 3526, 3398, 2922, 2853, 1688, 1604, 1539, 1502,
1458, 1354, 1323, 1222, 1173, 1110, 1075, 970, 929, 797, 666,
601, 439. 1H NMR (500 MHz, CDCl3) δ 8.45 (d, J = 1.0 Hz, 1H),
7.90 (dd, J = 7.9, 1.1 Hz, 1H), 7.83 (s, 1H), 7.67 (d, J = 7.9 Hz, 1H), 6.80 (br s, 1H), 5.87
(ddt, J = 17.1, 10.8, 8.2 Hz, 1H), 5.79 (d, J = 1.8 Hz, 1H), 5.24-5.17 (m, 2H), 4.67-4.58
(m, 2H), 2.20 (s, 3H), 2.01 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 165.7, 149.5, 136.3,
135.0, 134.3, 132.1, 131.7 (q, J = 34.3 Hz), 131.7, 129.7 (q, J = 3.3 Hz), 128.3, 123.1,
122.7 (q, J = 272.9 Hz), 122.6 (q, J = 3.8 Hz), 118.1, 114.6, 111.4, 65.8, 13.4, 11.5.
HREI-MS: m/z calculated for C19H18F3N2O4 [M+H+] 395.1213; observed 395.1195.
Rf = 0.76 (10% acetone: 90% pet. spirit). M.P. 110-114 °C; IR
(solid, ν/cm-1): 2959, 2924, 2855, 1730, 1692, 1651, 1629, 1601,
1535, 1507, 1456, 1428, 1391, 1321, 1274, 1244, 1220, 1161,
1134, 1112, 1087, 1025, 920, 863, 824, 769, 736, 658, 648, 616,
575, 549, 437. 1H NMR (400 MHz, CDCl3) δ 9.12 (d, J = 8.6 Hz, 1H), 8.47 (s, 1H), 8.27
(s, 1H), 7.56 (dd, J = 8.7, 1.1 Hz, 1H), 6.51 (s, 1H), 6.12 (ddt, J = 17.2, 10.5, 5.7 Hz, 1H),
5.46 (dq, J = 17.2, 1.5 Hz, 1H), 5.33 (dq, J = 10.4, 1.3 Hz, 1H), 4.88 (dt, J = 5.7, 1.4 Hz,
2H), 2.93 (s, 3H), 2.40 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 166.0, 134.9, 132.7, 129.8,
127.9 (q, J = 32.5 Hz), 127.8, 126.1, 125.8, 125.8, 124.3 (q, J = 272.1 Hz), 120.0 (q, J =
3.5 Hz), 119.2, 118.7, 118.4, 113.1 (q, J = 4.3 Hz), 112.3, 65.5, 18.4, 10.8. HREI-MS:
m/z calculated for C19H17F3NO2 [M+H+] 348.1206; observed 348.1208.
Rf = 0.31 (10% acetone: 90% pet. spirit). IR (oil, ν/cm-1): 3089,
2958, 1737, 1632, 1580, 1541, 1507, 1438, 1413, 1354, 1325,
1274, 1225, 1131, 1088, 988, 906, 843, 787, 747, 705, 685, 643,
551, 511, 434. 1H NMR (400 MHz, CDCl3) δ 8.33 (d, J = 1.2 Hz, 1H), 7.91 (dd, J = 8.2,
1.5 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 5.90 (ddt, J = 17.2, 10.5, 5.8 Hz, 1H), 5.40 (s, 1H),
5.33 (dq, J = 17.2, 1.4 Hz, 1H), 5.28 (dq, J = 10.4, 1.2 Hz, 1H), 4.71 (dt, J = 5.8, 1.3 Hz,
2H), 3.82 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 167.1, 166.3, 149.0, 132.8, 132.2 (q, J
= 34.6 Hz), 131.7, 131.0, 130.1 (q, J = 3.4 Hz), 122.7 (q, J = 272.9 Hz), 122.7 (q, J = 3.9
Hz), 119.6, 67.2, 54.1, 53.6. HREI-MS: m/z calculated for C14H13F3NO6 [M+H+]
348.0689; observed 348.0689.
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Synthesis of Allyl 1,3-dimethyl-7-(trifluoromethyl)pyrrolo[1,2-a]quinoline-5

-carboxylate 52
Compound 52 was synthesised using General Method 2 with allyl ester 41 (0.438 g, 1.514
mmol), 7 (0.301 g, 1.661 mmol), K2CO3 (0.423 g, 3.124 mmol) and 18-crown-6 (0.201
g, 0.760 mmol) reacted at room temperature for 20 hours followed by a further 24 hours
of heating at 45 °C affording 52 (0.180 g, 34%) as a yellow highly fluorescent solid (blue
in hexane under 365 nm UV light).
Rf = 0.68 (20% acetone: 80% pet. spirit). M.P. 106-110 °C; IR (solid,
ν/cm-1): 2923, 2883, 2856, 1683, 1623, 1541, 1494, 1447, 1372,
1336, 1320, 1288, 1254, 1221, 1156, 1111, 1084, 1030, 992, 934,
919, 864, 811, 774, 747, 733, 687, 665, 617, 498, 426. 1H NMR
(500 MHz, CDCl3) δ 9.38 (d, J = 0.9 Hz, 1H), 8.31 (d, J = 8.9 Hz, 1H), 8.27 (s, 1H), 7.64
(dd, J = 8.9, 1.7 Hz, 1H), 6.51 (s, 1H), 6.13 (ddt, J = 17.1, 10.6, 8.5 Hz, 1H), 5.47 (dq, J
= 17.2, 1.4 Hz, 1H), 5.34 (dq, J = 10.6, 1.2 Hz, 1H), 4.88 (dt, J = 5.6, 1.2 Hz, 2H), 2.93
(s, 3H), 2.40 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 165.9, 137.2, 132.6, 129.7, 129.5,
128.0, 125.6 (q, J = 32.8 Hz), 125.5, 124.7 (q, J = 3.9 Hz), 124.5 (q, J = 271.6 Hz), 123.0
(q, J = 3.5 Hz), 119.0, 118.9, 118.5, 116.3, 112.6, 65.6, 18.7, 10.8. HREI-MS: m/z
calculated for C19H17F3NO2 [M+H+] 348.1206; observed 348.1207.

7.44

Fe/CH3COOH Reduction General Method 3

A mixture of the appropriate cis allyl ester and Fe(0) were dissolved in 6 mL
CH3COOH:EtOH:H2O (1:1:1) and sonicated for 1 hour at 40 °C. After consumption of
starting material (TLC analysis), the reaction was filtered through celite and washed with
Et2O (50 mL). The organic layer was extracted with H2O (3 × 50 mL). The organic layer
was dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude products
were purified by preparative TLC (5% acetone: 95% pet. spirit) yielding 53, 54 and 3.

7.45

Synthesis of (Z)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-6-fluoroindolin

-2-one 53
Compound 53 was synthesised using General Method 3 with (Z)-43 (0.030 g, 0.088
mmol) and Fe(0) (0.049 g, 0.877 mmol) yielding 53 (0.017 g, 75%) as a yellow solid.
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Rf = 0.39 (20% Acetone: 80% Pet. spirit). 1H NMR (500 MHz, d6Acetone) δ 13.28 (br s, 1H), 9.88 (br s, 1H), 7.64 (dd, J = 8.1, 5.2
Hz, 1H), 7.57 (s, 1H), 6.77-6.72 (m, 2H), 5.99 (d, J = 2.5 Hz, 1H),
2.34 (s, 3H), 2.31 (s, 3H). 13C NMR (126 MHz, d6-Acetone) δ 170.9,
162.6 (d, J = 240.5 Hz, 1C), 140.1 (d, J = 12.3 Hz), 136.7, 132.9, 128.0, 124.1 (d, J = 1.8
Hz), 123.5 (d, J = 2.1 Hz), 119.6 (d, J = 9.6 Hz), 113.3, 112.7, 108.3 (d, J = 22.8 Hz),
98.1 (d, J = 27.1 Hz), 13.7, 11.5. HREI-MS: m/z calculated C15H13FN2O [M+Na+]
279.0904; observed 279.0909.

7.46

Synthesis of (Z)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-5-fluoroindolin

-2-one 54
Compound 54 was synthesised using General Method 3 with (Z)-44 (0.030 g, 0.88 mmol)
and Fe(0) (0.051 g, 0.906 mmol) yielding 54 (0.018 g, 80%) as a yellow solid.
Rf = 0.38 (20% Acetone: 80% Pet. spirit). 1H NMR (400 MHz, d6Acetone) δ 13.49 (br s, 1H), 9.75 (br s, 1H), 7.65 (s, 1H), 7.48 (dd,
J = 9.3, 2.5 Hz, 1H), 6.91 (dd, J = 8.4, 4.6 Hz, 1H), 6.84 (ddd, J =
9.5, 8.5, 2.5 Hz, 1H), 6.02 (d, J = 2.5 Hz, 1H), 2.35 (s, 3H), 2.34 (s,
3H). 13C NMR (101 MHz, d6-Acetone) δ 170.8, 159.8 (d, J = 234.6 Hz), 137.7, 135.6 (d,
J = 3.5 Hz), 133.9, 131.5, 129.5, 128.1, 125.3, 113.7, 112.4 (d, J = 24.3 Hz), 110.7 (d, J
= 8.7 Hz), 105.7 (d, J = 25.7 Hz), 13.8, 11.6. HREI-MS: m/z calculated for C15H13FN2O
[M+H+] 257.1085; observed 257.1090, m/z calculated C15H13FN2O [M+Na+] 279.0904;
observed 279.0910.

7.47

Synthesis of (Z)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one 3

Compound 3 was synthesised using General Method 3 with (Z)-31 (0.030 g, 0.092 mmol)
and Fe(0) (0.053 g, 0.949 mmol) yielding 3 (0.017 g, 78%) as a yellow solid (NMR data
matched the literature).192
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Appendix 1: X-ray Crystallographic Data for 48
Empirical formula

C18H16FNO2

Formula weight

297.32

Temperature/K

294

Crystal system

triclinic

Space group

P-1

a/Å

8.0663(4)

b/Å

8.5923(5)

c/Å

11.8061(6)

α/°

111.046(5)

β/°

101.373(4)

γ/°

90.074(5)

Volume/Å3

746.35(8)

Z

2

ρcalcg/cm3

1.323

μ/mm-1

0.095

F(000)

312.0

Crystal size/mm3

0.4 × 0.16 × 0.1

Radiation

MoKα (λ = 0.71073)

2Θ range for data collection/°

3.782 to 61.242

Index ranges

-11 ≤ h ≤ 11, -12 ≤ k ≤ 12, -16 ≤ l ≤ 16

Reflections collected

18232

Independent relfections

4383 [R int = 0.0293, R sigma = 0.0325]

Data/restraints/parameters

4383/2/215

Goodness-of-fit on F2

1.023

Final R indexes [I>=2σ (I)]

R1 = 0.0538, wR2 = 0.1463

Final R indexes [all data]

R1 = 0.1049, wR2 = 0.1743

Largest diff. peak/hole / e Å-3

0.21/-0.19
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Appendix 2: NMR Spectra
1

H (500 MHz, d6-DMSO) and 13C Carbon (126 MHz, d6-DMSO) NMR spectra of 4
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H (500 MHz, d6-DMSO) and 13C Carbon (126 MHz, d6-DMSO) NMR spectra of 5
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H (500 MHz, d6-DMSO) and 13C APT (126 MHz, CDCl3) NMR spectra of 6
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 7
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of (Z)-8
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 9
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 1
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 14
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 20
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 21
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 22
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of (Z)-23
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of (E)-23
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 25
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 24
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 2
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 26
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 27

-190-

Appendix

1

Geraud N. Sansom

H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 28
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H (400 MHz, CDCl3) and 13C APT (101 MHz, CDCl3) NMR spectra of 30
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of (Z)-31
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of (E)-31
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 32
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 33
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H (500 MHz, CDCl3) and 13C APT (101 MHz, d6-DMSO) NMR spectra of 34
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H (500 MHz, CDCl3) and 13C APT (CDCl3) NMR spectra of 35
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 36

-199-

Appendix

1

Geraud N. Sansom

H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 37

-200-

Appendix

1

Geraud N. Sansom

H (400 MHz, CDCl3) and 13C APT (101 MHz, CDCl3) NMR spectra of 38
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H (400 MHz, CDCl3) and 13C APT (101 MHz, CDCl3) NMR spectra of 39
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 40
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H (400 MHz, CDCl3) and 13C APT (101 MHz, CDCl3) NMR spectra of 41
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H (400 MHz, CDCl3) and 13C APT (101 MHz, CDCl3) NMR spectra of 48
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of (Z)-42
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of (E)-42
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of (Z)-43
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H (400 MHz, CDCl3) and 13C APT (101 MHz, CDCl3) NMR spectra of (E)-43
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of (Z)-44
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H (400 MHz, CDCl3) and 13C APT (101 MHz, CDCl3) NMR spectra of (E)-44
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 49
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of (Z)-46
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of (E)-46
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H (400 MHz, CDCl3) and 13C APT (101 MHz, CDCl3) NMR spectra of 50
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H (400 MHz, CDCl3) and 13C APT (101 MHz, CDCl3) NMR spectra of 51
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H (500 MHz, CDCl3) and 13C APT (126 MHz, CDCl3) NMR spectra of 52
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H (500 MHz, d6-Acetone) and 13C APT (126 MHz, d6-Acetone) NMR spectra of 53
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H (400 MHz, d6-Acetone) and 13C APT (101 MHz, d6-Acetone) NMR spectra of 54

-219-

